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Tissue engineering is a rapidly evolving multidisciplinary field that develops biological 
substitutes to restore, maintain, or improve damaged tissues. Biodegradable tissue engi-
neering applications are often complex, multi-component composite structures that com-
bine a biodegradable medical device with cells, tissues, or other biological factors. Mate-
rials used in tissue engineering applications are often sensitive and cannot withstand high 
temperatures, humidity, irradiation, and/or chemicals. These qualities pose special chal-
lenges to sterilization process and packaging design. The heavy legislation and regula-
tions that apply to tissue engineering products affect the packaging solution from choos-
ing the sterilization method to the design and testing of the final package. The stringent 
and ever evolving regulations also slow down the adoption of new manufacturing and 
packaging technologies in the healthcare industry. 
This thesis is a literature review. The scope of this thesis was to examine suitable pack-
aging solutions for biodegradable tissue engineering products. For background, the cur-
rent relevant legislation and regulations in the European Union and in the United States 
were reviewed, and different aspects of packaging of medical devices were discussed. 
Also several traditional and novel sterilization methods, as well as aseptic processing 
were reviewed, and multiple packaging solutions that are or could be suitable for sterile 
biodegradable implantable medical devices were presented. 
Due to the diverse nature of biodegradable tissue engineering products, it is impossible 
to suggest one universal packaging solution. Some general guidelines, however, can be 
suggested based on the common features of biodegradable tissue engineering products, 
usability studies, and sustainability considerations. An ideal packaging would be a double 
sterile barrier system consisting of a rigid tray in a flexible, clear pouch that would also 
serve as a moisture barrier. All the packaging components should be easy to open quickly 
in an operating room environment. The outer carton should be as small as possible, while 
still providing sufficient protection and information. The final materials for the packaging 
should be chosen based on whether the product will be sterilized in the final package or 
whether it will be aseptically processed.  
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Kudosteknologia on nopeasti kasvava monitieteellinen ala, jonka puitteissa kehitetään 
vahingoittuneiden kudosten korjaamiseen ja ylläpitoon tarvittavia biologisia korvikkeita. 
Biohajoavat kudosteknologiset tuotteet ovat usein monikomponenttisia komposiittiraken-
teita, joissa yhdistetään lääkinnällinen laite ja soluja, kudoksia tai muita biologisia teki-
jöitä. Kudosteknologisten tuotteiden materiaalit ovat yleensä herkkiä, eivätkä ne kestä 
esimerkiksi korkeita lämpötiloja tai kosteutta. Nämä ominaisuudet asettavat erityisiä vaa-
timuksia myös tuotteiden pakkauksille, ja esimerkiksi sopivan sterilointimenetelmän löy-
täminen voi olla haastavaa. Kudosteknologia on voimakkaasti säädelty ja valvottu ala, ja 
kaikkien tuotteeseen, tuotantoon ja pakkaukseen liittyvien toimien ja materiaalien tulee 
täyttää kyseistä tuotetta koskevat viranomaisvaatimukset. Voimakkaasta säätelystä joh-
tuen myös uusien teknologioiden käyttöönotto on yleisesti hidasta terveysteknologiayri-
tyksissä.  
 
Tämä diplomityö on kirjallisuuskatsaus. Työn tarkoituksena oli tutkia mahdollisia pak-
kausratkaisuja biohajoaville kudosteknologia tuotteille. Taustatiedoiksi käsiteltiin ajanta-
saista lääkinnällisten laitteiden ja kudosteknologiasovellusten lainsäädäntöä Euroopan 
Unionissa ja Yhdysvalloissa, sekä käytiin läpi erilaisia lääkinnällisten laitteiden pakkaa-
miseen liittyviä yleisiä seikkoja. Työssä esiteltiin useita steriileille biohajoaville kudos-
teknologisille tuotteille soveltuvia pakkausratkaisuja. Myös perinteisiä ja uusia steri-
lointi- ja desinfiointimenetelmiä käytiin läpi, sekä käsiteltiin aseptista pakkausta.  
 
Johtuen biohajoavien kudosteknologisten tuotteiden erilaisista ominaisuuksista on mah-
dotonta ehdottaa yleistä pakkausratkaisua joka sopisi kaikille tuotteille. Joitakin yleisiä 
johtopäätöksiä voidaan kuitenkin vetää perustuen biohajoavien kudosteknologiasovellus-
ten yleisiin piirteisiin, käyttäjätutkimuksiin, sekä huomioiden ekologiset näkökohdat. Ide-
aali pakkaus olisi kaksinkertainen steriilipakkaus, jossa läpinäkyvään pussiin on pakattu 
jäykkä tarjotin joka sisältää tuotteen. Pussi toimisi myös tuotteen kosteussuojana. Kaikki 
pakkauksen osat olisi helppo avata leikkaussaliolosuhteissa ja etiketit olisivat selkeitä ja 
helppolukuisia. Pakkauskartongin tulisi olla mahdollisimman pieni, mutta kuitenkin suo-
jattava tuotetta riittävästi ja tarjottava tarpeellinen informaatio. Lopulliset pakkausmate-
riaalit tulisi valita sen perusteella steriloidaanko tuote lopullisessa pakkauksessaan, vai 
pakataanko se aseptisesti.  
 
iii 
PREFACE 
This thesis was written at Tampere University of Technology, the Department of Elec-
tronics and Communications Engineering, as part of my Master of Science Degree in 
Materials Science. It is a literature review, concentrating on the biodegradable tissue en-
gineering products and the challenges regarding their packaging solutions.  
I would like to thank Professor Minna Kellomäki and DrTech Anne-Marie Haaparanta 
for offering me the opportunity to write this thesis, and for acting as examiners of this 
work. I am especially grateful to Dr Haaparanta for instructions, valuable comments and 
overall support during this project. I would also like to thank my family and friends for 
support and understanding, and for always believing in me. A big thank you also for my 
fellow students who offered comments and suggestions along the way. 
In Tampere March 20, 2016 
Taru Lindell 
iv 
TABLE OF CONTENTS 
1. INTRODUCTION ................................................................................................ 1 
2. TISSUE ENGINEERING ..................................................................................... 3 
 Scaffolds in tissue engineering .................................................................... 3 
 Cells in tissue engineering .......................................................................... 6 
3. MEDICAL DEVICES ........................................................................................... 9 
 Medical devices regulation ......................................................................... 9 
 Medical devices regulation in the European Union.................................... 11 
 Medical devices regulation in the United States ........................................ 15 
4. CELL- AND TISSUE THERAPY PRODUCTS .................................................. 22 
 Cell- and tissue therapy products regulation .............................................. 22 
 Cell- and tissue therapy products regulation in the European Union .......... 22 
 Cell- and tissue therapy products regulation in the United States ............... 26 
5. PACKAGING OF MEDICAL DEVICES ........................................................... 30 
 Packaging of sterile implantable medical devices ...................................... 33 
 Packaging of sterile biodegradable implantable medical devices ............... 35 
 Packaging of advanced tissue engineering products .................................. 37 
6. PACKAGING SOLUTIONS FOR STERILE BIODEGRADABLE 
IMPLANTABLE MEDICAL DEVICES .................................................................... 39 
 Bags and pouches ..................................................................................... 41 
 Blisters and strip packs ............................................................................. 43 
 Tubes and vials ......................................................................................... 45 
 Trays and lids ........................................................................................... 46 
 Applicators ............................................................................................... 48 
 Double packaging ..................................................................................... 49 
 Cartons and boxes ..................................................................................... 50 
 Packaging systems .................................................................................... 52 
7. STERILIZATION AND ASEPTIC PROCESSING ............................................. 54 
 Heat sterilization ....................................................................................... 56 
 Ionizing radiation sterilization................................................................... 57 
 Chemical sterilization ............................................................................... 62 
 Disinfectants ............................................................................................. 67 
 Aseptic processing .................................................................................... 72 
8. CONCLUSIONS ................................................................................................. 76 
REFERENCES ........................................................................................................... 78 
APPENDIX A: Classification of medical devices according to the directive 93/42/EEC 
APPENDIX B: Standards and guidance documents relevant to sterile barrier systems 
APPENDIX C: Summary of the sterilization and disinfection methods 
 
v 
ABBREVIATIONS AND SYMBOLS 
 
1D 1-dimensional 
2D 2-dimensional 
3D 3-dimensional 
60Co Cobalt 60 isotope 
137Cs Cesium 137 isotope 
192Ir Iridium 192 isotope 
λ Wavelength 
ABS Acrylonitrile butadiene styrene 
ADSC Adipose-derived stem cell 
AIMDD Active Implantable Medical Devices Directive 90/385/EEC 
AOS Active oxygen species 
ATMP Advanced-therapy medicinal product 
bFGF Basic fibroblast growth factor 
BFS Blow-fill-seal technology 
BLA Biologics License Application 
BMP Bone morphogenetic protein 
C Coulomb, electric charge unit 
CAD Computer-aided design 
CBER Center for Biologics Evaluation and Research 
CDRH Center for Devices and Radiological Health 
CE-mark Conformiteé Européenne mark 
CEN European Committee for Standardization 
CENELEC European Committee for Electrotechnical Standardization 
CFR Code of Federal Regulations 
ClO- Hypochlorite ion 
ClO2 Chlorine dioxide  
CO2 Carbon dioxide 
COCIR European Coordination Committee of the Radiological, Electromed-
ical, and Healthcare IT Industry 
CTT Cell- and tissue therapy product 
DNA Deoxyribonucleic acid 
e-Beam High energy electrons 
eCFR Electronic Code of Federal Regulations 
ECM Extra cellular matrix 
EDMA  European Diagnostic Manufacturers Association 
EEC European Economic Area 
EFTA European Free Trade Association 
EGF Epidermal growth factor 
eMDR Electronic Medical Device Reporting 
ES Embryotic stem cell 
EtO Ethylene oxide 
ETSI European Telecommuni8cations Standards Institute 
EU   European Union 
eV Electron volt, energy unit 
FD&C Act Federal Food Drug & Cosmetic Act 
FDA U.S. Food and Drug Administration 
FDAMA Food and Drug Administration Modernization Act of 1997 
vi 
FDASIA The FDA Safety and Innovation Act 
FEP Fluorinated ethylene propylene 
FFS Form-fill-seal technology 
FIHTA Finnish Health Technology Federation (Terveysteknologian liitto ry) 
Fimea Finnish Medicines Agency 
FR Federal Register 
GCP Good Clinical Practice 
GMP Good Manufacturing Practices 
GTP  Good Tissue Practice 
Gy Grey, absorbed radiation dose unit 
H2O2 Hydrogen peroxide 
HA Hydroxyapatite 
HCT/P Human cells, tissues, and cellular and tissue-based product 
HDPE High density polyethylene 
HEPA High efficiency particulate air 
HOCl Hypochlorus acid 
Hz Herz, frequency unit 
IDE Investigational Device Exemption 
IGF Insulin-like growth factor 
IMDRF International Medical Device Regulation Forum 
iPS Induced pluripotent stem cell 
IR Infrared radiation 
ISO The International Organization for Standardization 
IVD In Vitro Diagnostics 
IVDMD In Vitro Diagnostics Medical Devices Directive 98/79/EC 
J Joule, energy unit 
MDD Medical Devices Directive 93/42/EEC 
MDR Medical Device Reporting 
MDSC Muscle-derived stem cell 
MSC Mesenchymal stem cell 
NB Notified Body 
NO2 Nitrogen dioxide 
O2 Oxygen 
O3 Ozone 
OCP Office of Combination Products 
OCTGT Office of Cellular, Tissue, and Gene Therapies 
OPA Ortho-phthalaldehyde 
PCL Poly(capro lactone) 
PDGF  Platelet-derived growth factor 
PDMS Poly(dimethylsiloxane) 
PDO Polydioxanone 
PE Polyethylene 
PEEK™ Polyether ether ketone 
PEI Polyetherimide 
PET Polyethylene terephthalate 
PETG Polyethylene terephthalate glykol 
PGA Poly(glycolic acid) 
PHA Polyhydroxyalkanoate 
PHB Polyhydroxybutyrate 
PHS Act Public Health Services Act 
vii 
PHV Polyhydroxyvalerate 
PI Polyimide 
PLA Polylactide 
PLGA Poly(lactide-co-glycolide) 
PMA Premarket Approval 
PMMA Poly(methylmetacrylate) 
PP Polypropylene 
ppm Parts per million 
PS Polystyrene 
PTFE Polytetrafluoroethylene 
PVC Poly(vinyl chloride) 
PVDF Polyvinylidene fluoride 
QSR Quality System Regulation 
RABS Restricted access barrier system 
RDF Request for Designation 
RNA Ribonucleic acid 
rPET Recycled polyethylene terephthalate 
SAL Sterility Assurance Level 
scCO2 Supercritical carbon dioxide 
TCP Tricalsiumphosphate 
TGF Transforming growth factor 
TiO2 Titanium dioxide 
US United States 
UV Ultraviolet radiation 
 
1 
1. INTRODUCTION 
Tissue engineering is a multidisciplinary field that develops biological substitutes to re-
store, maintain, or improve tissue functions (Czernuszka et al, 2002). The most common 
tissue engineering strategy is to place cells on or within an implantable biodegradable 
matrix – a scaffold - that degrades at a controlled rate and is replaced in the body by the 
regenerating tissue (Dhandayuthapani et al, 2011). Scaffolds are classified and regulated 
as medical devices, and tissue engineering products containing, or consisting of, engi-
neered cells or tissues are classified as advanced therapy medicinal products. The ad-
vanced therapies that include gene-, cellular-, and tissue therapies, as well as drug-device, 
biologic-device, or drug-biologic combination products, are most recent additions to the 
larger biopharmaceuticals group. Biopharmaceuticals are considered to be the key to the 
future pharmaceutical treatments, and currently as many as half of all medicinal products 
in development are biopharmaceuticals. (Fimea, 2014)   
Due to the rapid evolving of the field at the moment, the regulations regarding advanced 
therapies are at different stages of development in different countries. Harmonized termi-
nology and technical requirements are yet to be established, and the regulatory agencies 
across the globe are working to create a risk-based regulation system with some common 
features. (Kellathur & Lou, 2012) Advanced therapy products are often complex compo-
site structures, thus they impose new challenges on packaging and sterilization technol-
ogy (Crosby, 2008). The correct selection of a package is crucial: estimated 10% of all 
medical device recalls are due to packaging failures (Cleanroom Technology, 2014).  
The packaging of a device generally has three main functions: protection, utility and com-
munication. Protection is necessary for maintaining the package integrity for its lifespan 
from sterilization to shipping, storage, handling and use. (Bix & De La Fuente, 2009) All 
implantable medical devices must be sterilized prior to their surgical placement (Athana-
siou et al, 1996). Sterility and its maintenance, as well as prevention of cross-infection, 
are the most critical factors in patient care. The packaging around a medical device allows 
the device to be sterilized, provides a microbial barrier, and maintains the sterility of the 
device. (Sterile Barrier Association, 2006) Biodegradable implantable devices also need 
to be protected from moisture due to their hydrolytically unstable nature (Bernkopf, 
2007). A package may also have additional functions beside protection, such as serving 
as a measuring device, dispenser, stabilizing stand or a disposal bin. Utility has to do with 
the usability of a product: in many cases medical professionals base their decision on 
superior medical technology, but in case of two or more similar products, other factors 
emerge, usability of the package being one of them. Device packages are also a means to 
2 
communicate information through materials, graphics and shape. Communication in-
volves passing important information for the safe and effective use of the device. Clear 
and easy product identification is especially crucial for medical devices that are used in 
hospital settings. (Bix & De La Fuente, 2009) The visual appearance of the package also 
has to reflect the requirement of cleanliness associated with medical devices (Cleanroom 
Technology, 2014). The device manufacturer also has to make sure that components of 
the package, like adhesives and inks, do not interfere with the product’s safety and effi-
cacy (Bix & De La Fuente, 2009). For sterile medical devices, the packaging materials 
need to be compatible with the chosen method of sterilization (Teixeira, 2014). 
Sterilization process can affect the physical and mechanical properties of the device, thus 
affecting its performance in vivo (Athanasiou et al, 1996). Some materials may not with-
stand the initial sterilization process, and some are known to degrade with time after ster-
ilization, which poses a significant risk to the sterility and integrity of the device (Sim-
mons, 2012). The traditional end sterilization methods are often not suitable for heat and 
moisture sensitive biodegradable scaffolds and complex advanced therapy products. 
More gentle sterilization methods have been or are being developed, but many of them 
still lack the approval of authorities in the European Union or in the United States. There-
fore, a wide variety of biodegradable medical devices and combination products are asep-
tically processed, although it is usually the last option due to the high manufacturing costs 
and less robust process control. (Lambert et al, 2011; ISO 13408-7, 2012) 
This thesis is a literature review. The purpose of this work is to examine possible pack-
aging solutions for sterile biodegradable tissue engineering products. For background, 
current regulations regarding medical devices and advanced therapies in the two largest 
markets, European Union and the United States are reviewed, and general aspects of med-
ical device packaging are discussed. Also multiple existing packaging solutions that are 
suitable for sterile biodegradable implantable medical devices are presented, and several 
traditional and novel sterilization methods are reviewed.  
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2. TISSUE ENGINEERING  
Injuries and different pathological conditions can result to a tissue or organ failure.  Tra-
ditionally damaged tissues and organs have been repaired by transplantation, surgical 
methods, artificial prostheses or mechanical devices, or by drug therapy. These methods, 
however, do not offer satisfactory results neither in repair nor long-term recovery, espe-
cially in the case of major damages. Tissue engineering provides an alternative solution 
to the issue.  (Nature Biotechnology, 2000) Tissue engineering is a multidisciplinary field 
that develops biological substitutes to restore, maintain, or improve tissue functions 
(Czernuszka et al, 2002). The general tissue engineering strategies can be divided into 
three groups (Dhandayuthapani et al, 2011):  
1) Implantation of isolated cells or cell substitutes into the organism. 
2) Delivering of tissue-inducing substances, such as growth factors. 
3) Placing cells on or within different, natural or synthetic, implantable matrices. 
The third strategy is most commonly associated with the concept of tissue engineering 
(Dhandayuthapani et al, 2011). Natural, synthetic, or semisynthetic functional constructs 
are implanted into the damaged site, where they are either fully functional from the mo-
ment of implantation, or they will grow into the required functionality. Relevant cells are 
grown in the laboratory, and supportive structures, scaffolds, are needed to act as sub-
strates for cellular attachment and to guide the cell growth in favored orientations. (Czer-
nuszka et al, 2002; Nature Biotechnology, 2000) In addition to medical applications, there 
are also non-therapeutic tissue engineering applications, including biosensors for detect-
ing biological or chemical agents and tissue chips for toxicity testing in drug develop-
ment. (National Institute of Biomedical Imaging and Bioengineering, 2015) The tissue 
engineering market is growing fast: the total global market for tissue engineering products 
is estimated to be $23 billion in 2015, expected to reach a 23% yearly rise, and reach $94 
billion in 2022 (Industry Experts, 2015).  
 Scaffolds in tissue engineering 
Tissues consist of cells, and usually a group of cells make and secrete their own support 
structure, which is called the extra-cellular matric (ECM). The matrix supports the cells 
and acts as a relay station for various signaling molecules. (National Institute of Biomed-
ical Imaging and Bioengineering, 2015) In tissue engineering the necessary support struc-
tures are provided by scaffolds, that are commonly defined as three-dimensional (3D), 
solid and porous biomaterial structures that are designed to perform some or all of the 
following functions (Dhandayuthapani et al, 2011):  
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(a) Promote interactions between cells and the biomaterial, cell adhesion and ECM   
deposition. 
(b) Permit sufficient transport of nutrients, gasses, and regulatory factors that enable 
cell survival, proliferation and differentiation. 
(c) Degrade at a controllable rate that matches the regeneration rate of the tissue at 
the implantation site.  
(d) Be biocompatible; provoke minimal inflammation and toxicity in vivo. 
Tissue engineering scaffolds have been used to regenerate bone-, cartilage-, ligament-, 
skin-, vascular- and neural tissues, and skeletal muscles (Dhandayuthapani et al, 2011). 
By the definition of the European Council Directive 92/43/EEC, scaffolds are classified 
as medical devices. The regulations regarding medical devices in the European Union and 
in the United States are discussed in more detail in chapter 3, and packaging of medical 
devices is discussed in chapter 5. 
The scaffold’s architecture defines the ultimate shape of the engineered tissue, thus the 
scaffold microstructure is a crucial factor in a tissue engineering construct (Hutmacher, 
2000). Typical scaffold designs include meshes, fibers, sponges, and foams 
(Dhandayuthapani et al, 2011). Since most tissues in the body are 3D structures, also most 
tissue engineering scaffolds are 3D constructs; 3D nanoporous hydrogels, or 3D mi-
croporous structures. Scaffold microstructure can also be a one-dimensional (1D) fiber 
structure or a 2-dimensional (2D) substrate. Generally, 2D structures, such as well plates 
and Petri dishes, are used for cell culture studies. (Haaparanta, 2015) High, typically over 
90% porosity, optimal pore size that depends on the type of cells used, and pore intercon-
nectivity are important factors in the migration of cells, nutrition and waste exchange 
inside the scaffold (Hutmacher, 2000; Haaparanta, 2015). The advantages and disad-
vantages of different scaffold microstructures are presented in table 1. 
Table 1. Scaffold microstructures and their respective advantages and disadvantages. 
(Modified from Haaparanta, 2015) 
Scaffold microstructure Advantages/disadvantages 
1D fibers Cells cultured on individual fibers. / Length and di-
ameter of the fibers may vary. 
2D substrates Assessment of material chemistry, mechanics and 
micro-scale patterns. / Impermeable. 
3D nanoporous hydrogel Cells on top of hydrogel. / Interacting with 2D sub-
strate in nanoscale. 
 Cells encapsulated inside 3D structure. / Have to 
degrade the surrounding structure to extend pro-
cess.  
3D microporous structures Highly porous, cells are able to spread in three di-
mensions. Depending on the pore size cells can be 
aligned in 1D, or attach to multiple struts and 
spread in 3D. 
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In addition to an appropriate microstructure, the scaffold material should be biocompati-
ble. In biodegradable applications, the scaffold should degrade at a controllable degrada-
tion rate, to allow the healing tissue to eventually replace the scaffold. Appropriate sur-
face chemistry is important for cell attachment, proliferation, and differentiation, and the 
scaffold’s mechanical properties have to match those of the tissue at the site of implanta-
tion. Tissue engineering scaffolds should also be easily manufactured into different 
shapes and sizes. (Hutmacher, 2000; Czernuszka et al, 2002)  
The choice of the scaffold material depends on the intended use. The material can be 
ceramic, glass, natural polymer, synthetic biodegradable polymer and in some cases, syn-
thetic, non-biodegradable polymer. Examples of different scaffold materials are listed in 
table 2. (Dhandayuthapani et al, 2011; Shastri, 2003) 
Table 2. Examples of different materials used in tissue engineering scaffolds. 
(Dhandayuthapani et al, 2011; Shastri, 2003; Amini et al, 2011) 
Natural polymers  
Proteins Silk, collagen, gelatin, fibrinogen, elastin, keratin, 
actin, myosin 
Polysaccharides Cellulose, amylose, starch, chitin, dextran, gly-
cosaminoglycans, hyaluronic acid 
Polynucleotides Deooxyribonucleic acid (DNA), ribonucleic acid 
(RNA) 
Synthetic polymers  
Biodegradable polymers Polylactides (PLAs), Polyglycolic acid (PGA), 
poly(lactic-co-glycolic acid) (PLGA) copolymer, 
Polycaprolactone (PCL), polyhydroxyalkanoates 
(PHAs), Polydioxanone (PDO), Polyhydroxy-
butyrate (PHB), Polyhydroxyvalerate (PHV)  
Non-degradable polymers Polytetrafluoroethylene (PTFE, teflon), extended-
PTFE (Gore-Tex®), Polyethylene (PE), Polypro-
pylene (PP), Poly(methylmetacrylate) (PMMA), 
Poly(dimethylsiloxane) (PDMS). 
Ceramics  
Natural Hydroxyapatite (HA), Tricalsiumphosphate (TCP) 
Composition glasses Bioactive glass 
Glass ceramics Apatite-wollastonite glass ceramic 
 
Synthetic polymers are often cheaper than natural ones; they can be fabricated in large 
uniform quantities in controlled conditions, and they have a long shelf life. Due to their 
processability to different shapes and sizes and the possibility to control the degradation 
rate, porosity, microstructure, and mechanical properties, biodegradable synthetic poly-
mers are a popular choice of material for tissue engineering scaffolds. (Dhandayuthapani 
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et al, 2011). There is also a growing demand for composite scaffolds. A major advantage 
of composite structures is that they can be tailored to meet the required conditions. 
(Haaparanta, 2015) A composite is a structure that consists of two or more distinctly dif-
ferent materials, each of which contributes to enhance the properties of the final product. 
The major component in the structure is usually a matrix, and another component acts as 
a reinforcing filler. (Hull & Clyne, 1996) In tissue engineering scaffolds, the matrix ma-
terial is usually a polymer or a ceramic. The filler material can be in various forms; par-
ticles, fibres, or textiles. In tissue engineering, the most common composites are polymer-
polymer compositions, and polymer-ceramic-, or polymer-bioactive glass constructions. 
A specific composite structure, a hybrid, combines the advantages of both natural and 
synthetic biomaterials. (Hull & Clyne, 1996; Haaparanta, 2015) An example of a hybrid 
structure is a collagen rich acellular matrix that is prepared by removing cellular compo-
nents from a tissue via mechanical or chemical manipulation, and coated with a biode-
gradable polymer to improve mechanical stability and to enhance hemocompatibility of 
the protein matrix. (Dhandayuthapani et al, 2011) 
The chosen scaffold material or materials, and the intended use of the scaffold, define the 
suitable scaffold fabrication method. Most fabrication methods involve heat and/or pres-
sure applied to the material, or dissolving it into an organic solvent and molding the ma-
terial into its shape. The scaffold structure development is affected by the fabrication 
method, thus the requirements of the specific tissue must be considered when selecting 
the appropriate fabrication technique. For example solvent casting and freeze drying pro-
duce porous scaffold structures; micromolding and emulsification produce microgels; and 
nanofibre electrospinning and microfiber wetspinning produce biocompatible fibres with 
good mechanical properties. Complex tissues that are composed of multiple cell types, as 
well as patient specific scaffolds, can be manufactured by inkjet-printing or computer-
aided design (CAD) data manipulation techniques. (Dhandayuthapani et al, 2011)  
 Cells in tissue engineering 
Cells that are used in tissue engineering applications can be from three different sources: 
autologous cells from the patient; allogeneic cells from another human donor, who is not 
immunologically identical to the patient; and xenogeneic cells that are from a different 
species. The use of xenogeneic cells in tissue engineering is controversial due to potential 
animal pathogen transfer. However, there has been studies whether xenogeneic cells 
could be used to temporarily support a failing tissue until a donor organ becomes availa-
ble, or the tissue repairs itself. Each of these source categories can be further defined by 
whether the cells are adult stem cells, embryotic stem cells that are able to both self renew 
and differentiate to different cell types, or a mixture of differentiated cells at different 
stages of maturation. (Griffith & Naughton, 2002) In tissue engineering applications, cells 
are generally loaded into scaffolds in vitro, incubated to ensure attachment to the scaffold, 
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and implanted into the target tissue site (Caplan, 2007). By the definition of the Regula-
tion (EC) No 1394/2007 tissue engineering products containing, or consisting of, engi-
neered cells or tissues are classified as advanced therapy medicinal products (ATMPs). 
The regulations regarding ATMPs and packaging options for ATMPs are discussed in 
chapter 4.  
Adult bone marrow contains multipotent progenitor cells, referred to as mesenchymal 
stem cells (MSCs) or adult stem cells. MSCs are able to differentiate into specific end-
stage cell types, thus MSCs can be used in tissue engineering for reforming mesenchymal 
tissues, such as bone, cartilage, muscle, bone marrow stroma, and dermis, as well as other 
connective tissues, when implanted into different tissue sites. MSCs also secrete a variety 
of bioactive macromolecules that are part of immune response, as well as structure regen-
erative microenvironments at tissue damage sites. MSC-like cells have also been isolated 
from adipose tissue (adipose-derived stem cells, ADSC) and muscle tissue (muscle-de-
rived stem cells, MDSC), and they exhibit MSC-like differentiation properties and spe-
cific cell surface markers. The differentiation characteristics, yield, and purity, however, 
are different for stem cell preparations from different tissues. (Caplan, 2007) 
Embryonic stem cells (ES) have the ability to grow indefinitely and maintain their plu-
ripotency at the same time, thus lot of expectations were loaded on human ES cells to 
gain knowledge on decease mechanisms, to screen new drug substances, and to treat var-
ious diseases and injuries. However, ESs are derived from the inner cell mass of mam-
malian blastocysts, and the use of human embryos faces numerous ethical questions and 
concerns. Also, an effective use of ESs would require generation of disease specific or 
patient specific ES cells, which has proven to be difficult to obtain. To circumvent these 
issues, induced pluripotent stem cells (iPSs) have been introduced. (Takahashi et al, 2007) 
The iPSs are adult somatic cells, such as skin fibroblasts, that have been reprogrammed 
by the activation of a certain number of genes (transgenes). The iPSs enable bypassing of 
immune rejection issues and ethical concerns related to the use of ESs, thus making pa-
tient-specific cell therapies possible. The unlimited expansion potential makes the iPSs a 
valuable cell source for tissue engineering applications, although there are still issues to 
be addressed, for instance, the efficiency of deriving specific cells from iPSs varies for 
each cell line. (Wang et al, 2011) 
The term “growth factor” is often broadly used to describe proteins that affect cell migra-
tion, proliferation, and differentiation, in other words, the critical signaling molecules that 
instruct cells during their development. Growth factors can be grouped into three over-
lapping categories: mitogens that stimulate cell division, growth factors that induce pro-
liferation but have also other functions, and morphogens that control the generation of 
tissue form. (Lee et al, 2010) In tissue engineering growth factors can be used to induce 
differentiation and tissue growth in vitro, or cell migration into the damage site in vivo. 
Growth factors can also be used to modulate the interactions between cells. (Griffith & 
Naughton, 2002) In tissue engineering applications growth factors are either chemically 
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immobilized into or onto the scaffold, or physically encapsulated in the delivery system. 
Popular growth factors used in tissue engineering applications are for instance: bone mor-
phogenetic protein (BMP), epidermal growth factor (EGF), basic fibroblast growth factor 
(bFGF), insulin-like growth factor (IGF), platelet-derived growth factor (PDGF), and 
transforming growth factor (TGF). (Lee et al, 2010)  
Cell expansion and tissue reconstruction through ex vivo cultures are key processes when 
producing engineered tissues with sufficient functionality and structural integrity. Figure 
1 presents a typical cycle of autograph and allograph cell- and tissue processing for ther-
apeutic applications. (Kino-oka & Taya, 2009) 
 
Figure 1. A schematic illustration of a typical cell- and tissue processing for therapeutic 
applications. (Kino-oka & Taya, 2009) 
In typical cell- and tissue processing, cells are harvested by biopsy to prepare a starting 
cell population. The isolated cells are provided to a primary culture for acclimation, and 
following subcultures are repeated until a sufficient quantity of cells is obtained. Then, 
depending on the application, the cultured cells are either administered to the patient, or 
to tissue cultures for a reconstruction process to form biologically functional substitutes 
as final products. This kind of cell- and tissue processing can be defined as a low repro-
ducibility tailor-made process that involves a number of manual procedures. Due to the 
direct use of un-sterilable products and the arduous culture operations, strict management 
against contamination and human error during manufacturing is essential. Innovative cell- 
and tissue processing techniques have been developed, but the major challenge is to up-
scale laboratory-scale designs into production-scale designs. (Kino-oka & Taya, 2009) 
The manufacturing of cultured tissues is still burdened by instability due to the qualitative 
fluctuation of cell sources as raw materials and the risk of biological contamination (Kino-
oka, 2014). 
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3. MEDICAL DEVICES 
Medical devices are devices that achieve their therapeutic effect via physical means, in-
stead of a metabolic, pharmaceutical or immunological process, although the effect may 
be assisted by those processes. The technical revision on the European Council Directive 
92/43/EEC on Medical Devices (MDD), Directive 2007/47/EC, defines a general medical 
device as any instrument, apparatus, appliance, software, material or other article, that is 
intended by its manufacturer to be used, alone or in combination or together with any 
accessories, for human beings for the purpose of diagnosis, prevention, monitoring, treat-
ment, alleviation or compensation of a disease, injury or handicap; investigation, replace-
ment, modification of the anatomy or a physiological process; or control of conception. 
(European Commission, 2015) 
Medical devices can be classified in many different ways, but the classification based on 
the risk associated with misuse or failure is the most common one. The specific classifi-
cation and regulatory requirements vary from country to country, but risk-based classifi-
cation guides the appropriate level of manufacturing control and regulatory actions 
needed to ensure safe and effective products. (Bix & De La Fuente, 2009) The classifica-
tion according to the European Council is discussed in chapter 3.2 and the classification 
according to the U.S. Food and Drug Administration (FDA) in chapter 3.3. The Interna-
tional Medical Device Regulators Forum (IMDRF) was established in 2011 on the 
grounds of former Global Harmonization Task Force to accelerate international harmo-
nization of medical device regulatory convergence. It consists of a voluntary group of 
medical device regulators from different countries, and it provides a forum to discuss 
future directions in medical device regulatory harmonization. (IMDRF, 2015) 
Medical devices is an extremely diverse group of devices. They vary greatly in size and 
complexity; from simple tongue depressors to Magnetic Resonance Imaging tunnels. 
Some medical devices are meant for mass markets, some are specialty items. Some are 
packed individually, and some in boxes of 1000s. Some medical devices are reprocessed, 
whereas others are disposable, and some are used for a lifetime. Risks regarding misuse 
and failure of the device are equally diverse, ranging from inconvenience to death. Med-
ical devices field is constantly evolving which results in short life span of many products. 
(Bix & De La Fuente, 2009)  
 Medical devices regulation 
Health-care related infections are a major concern in patient safety, even in well devel-
oped countries. Therefore manufacturing of medical devices and their sterile barrier sys-
tems are a highly regulated area, and traceability throughout the life cycle of the device 
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is essential. (Sterile Barrier Association, 2006) Figure 2 illustrates the life-span diagram 
of common stages of medical devices regulatory control.   
 
Figure 2. Common stages of government regulations on medical devices. (WHO, 2003) 
Authorities in different countries have different systems for pre-market review, but they 
all apply risk management: medical devices must meet the safety and performance, qual-
ity system, and labeling requirements and the degree of regulatory requirements increase 
with the potential risks of the device. The evaluation of safety and effectiveness of med-
ical devices is continued when they are placed in the market, for possible device failures 
or incidents related to misuse of the device. The actual terms of post market surveillance 
are also varying from country to country, but the two main activities are post-market sur-
veillance studies and adverse event reporting. (WHO, 2003)  
Quality system requirements can influence all phases in the life-span of a medical device. 
Applicable quality system requirements depend on the regulatory system of the country 
and the risk class of the device. International quality system standards are issued by the 
International Organization for Standardization (ISO). Quality system standards are ge-
neric management standards, therefore they are applicable to any organization. The two 
best known series of generic management system standards are ISO 9000: Quality man-
agement, for managing quality systems, and ISO 14000: Environmental management, for 
environmental management systems. The specific quality system standard for medical 
devices is ISO 13485: Medical devices – Quality management systems – Requirements 
for regulatory purposes. (WHO, 2003) According to ISO 13485, the manufacturer has to 
determine the applicable legal requirements, that is, to find out which acts, statutes, and 
regulations – current and the ones that are in preparation - are concerning their products 
and operations (Stålhberg, 2015). Although the ISO standards are widely recognized 
across the world, not all of them are recognized for example by the United States regula-
tory authorities. Medical devices regulation in the European Union (EU) and in the United 
States (US) are further discussed in the chapters 3.2 and 3.3. 
Keeping up with legislation and regulation updates can be a major challenge to a medical 
device manufacturer. To find help with that task, many manufacturers participate in dif-
ferent medical devices societies, for example Eucomed Medical Technology, European 
Coordination Committee of the Radiological, Electromedical, and Healthcare IT Industry 
(COCIR), European Diagnostic Manufacturers Association (EDMA), and in Finland, the 
Finnish Health Technology Federation (Terveysteknologian liitto ry, FIHTA). Also Con-
forlex, a web service provided by FIHTA and Conforman Oy, offer information about 
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medical devices legislation internationally. Regarding regulations in the EU, the EU Law 
and Publications has a so called Bookshop –service, where it is possible to subscribe to a 
newsletter about new publications on medical devices. The most important source of in-
formation on the EU legislation, however, is the Official Journal of the European Union, 
the official publication channel for all documents regarding legislation in the EU. (Ståhl-
berg, 2015) 
 Medical devices regulation in the European Union 
The core legal framework regarding medical devices in the EU consists of three directives 
(European Commission, 2015):  
 Council Directive 93/42/EEC on Medical Devices (MDD) (1993) 
 Council Directive 90/385/EEC on Active Implantable Medical Devices Directive 
(AIMDD) (1990)  
 Council Directive 98/79/EC on In vitro Diagnostics Medical Devices (IVDMD) 
(1998) 
European Council Directives are developed by the EU member states, and the member 
states are obligated to introduce them into their own laws. The directives replace individ-
ual national regulations. (Nolan, 2004) The directives also bind the countries that are not 
yet EU member states, but are applying to become a member, as well as potential future 
member states. The current EU member states in 2015, and the countries currently apply-
ing to become a member, are shown in table 3. Because a uniform legislation has been a 
prerequisite for extending the EU internal market area to all European Free Trade Asso-
ciation (EFTA) countries, the EU legislation also applies in the three countries that are 
not EU member states, but are part of the European Economic Area (EEC): Iceland, Lich-
tenstein, and Norway. (Ståhlberg, 2015)  
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Table 3. The current European Union member states (joining year in parenthesis) and 
countries that are currently applying to become a European Union member state (Ståhl-
berg, 2015). 
Current European Union member states 
Austria (1995) Estonia (2004) Italy (1952) Poland (2004) 
Belgium (1952) Finland (1995) Latvia (2004) Romania (2007) 
Bulgaria (2007) France (1952) Lithuania (2004) Slovakia (2004) 
Croatia (2013) Germany (1952) Luxembourg (1952) Slovenia (2004) 
Cyprus (2004) Greece (1981) Malta (2004) Spain (1986) 
Czech Republic (2004) Hungary (2004) Netherlands (1952) Sweden (1995) 
Denmark (1973) Ireland (1973) Portugal (1986) 
United Kingdom 
(1973) 
Countries that are applying to become a European Union member state 
Albania Iceland Serbia 
Former Yugoslav Republic of 
Macedonia 
Montenegro Turkey 
The original directives have been amended several times, including the last technical re-
vision brought about by the Directive 2007/47/EC. The latest consolidated versions of the 
directives are available at the European Commission website. In 2012 the European Com-
mission adopted a Proposal for a Regulation of the European Parliament and of the 
Council on medical devices and in vitro diagnostic medical devices. When these regula-
tions are officially adopted, they will replace the current medical devices directives. (Eu-
ropean Commission, 2015) Changes to the directives have to be approved by the Council 
of Ministers and the European Parliament and thus, the process may take several years, 
especially if the proposed legislation is intended to create a more coordinated and cen-
trally-acting body. (Kramer et al, 2014)  
In addition to the legally binding European Council Directives there are non-binding 
guidance documents: MEDDEVs, Consensus Statements, and Informative Documents. 
The purpose of the guidance documents is to provide guidance in implementing the di-
rectives, and ensure a uniform application of the directives within the EU. Therefore the 
guidance documents are also expected to be followed, even though they are not legally 
binding. The three medical devices directives list the essential requirements for devices 
and their packaging that all medical devices sold in the EU must meet (European Com-
mission, 2015). The AIMDD and IVDMD are not relevant to the subject of this thesis, 
thus they will not be further discussed.  
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It is the responsibility of the manufacturer of a device to conform to all of the sections of 
the essential requirements. Conformity assessment includes testing, inspection and certi-
fication; the procedure for each product is specified in the applicable legislation. The as-
sessment is conducted by the manufacturer, unless the applicable legislation requires in-
volvement of a Notified Body (NB); a non-profit organization legally designated by an 
EU country. In that case, manufacturers are free to choose any NB from the list published 
and updated by the European Commission. (European Commission, 2015b) Each EU 
member state has a governmental Competent Authority that supervises the NBs and is 
responsible for the post-approval surveillance. The structure, personnel, functions, and 
funding of the Competent Authority varies between individual countries. (Kramer et al, 
2014) The manufacturer, or an authorized representative, must compile a Declaration of 
Conformity, which should identify the product, the legislation according to which it is 
issued, the manufacturer, the NB, and reference to harmonized standards or other norma-
tive documents. Harmonized standards are European standards developed by a recog-
nized European Standards Organization: the European Committee for Standardization 
(CEN), European Committee for Electrotechnical Standardization (CENELEC), or Euro-
pean Telecommunications Standards Institute (ETSI). They can be used to demonstrate 
that products, services, or processes comply with the relevant EU legislation. The list of 
current harmonized standards is published in the Official Journal of the European Union, 
and it is also available at the European Commission webpage. When a medical device 
complies with the essential requirements stated in the directives, it is marked with a Con-
formité Européenne (CE) mark, and can be legally placed into the market in any EU 
member country. (European Commission, 2015b) A flow chart of a general path for ob-
taining a CE mark is presented in figure 3. 
 
Figure 3. General steps that the manufacturer of a medical device has to take in order to 
obtain a CE mark. (Ståhlberg, 2015) 
1. Define marketing -
and regulation strategy 
for the device
2. Define intended use 
of the device
3. Find out what 
legislation applies
4. Define classification 
of the device
5. Recognize applicable 
essential requirements
6. Proof of conformity 
to the essential 
requirements
7. Declaration of 
conformity and CE 
mark
8. Registration of the 
device
9. Post-market 
surveillance during life-
span of the device
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The MDD categorizes general medical devices in four classes: I, IIa, IIb and III. The 
classification is based on the duration of the use, invasiveness of the device, whether the 
device is reusable or intended for single use, whether it needs an outer power source to 
operate, and whether it is in contact with the central circulatory system or the central 
nervous system. Guidance document MEDDEV 2.4/1 rev. 9 contains guidelines relating 
to the application of the MDD. Summary of the classification criteria of general medical 
devices is presented in appendix A. The duration of the use of a medical device is divided 
in three categories: transient, short term and long term. According to the MDD transient 
use is intended to continue less than 60 minutes, short term use for maximum of 30 days, 
and long term use for more than 30 days. 
As mentioned previously, all EU member states have a Competent Authority that super-
vises medical devices’ compliance with the legislation and regulations. For example in 
Finland the Competent Authority is Valvira – the National Supervisory Authority for 
Welfare and Health. Valvira is the central ministry of Ministry of Social affairs and 
Health, and it is responsible for general guidance and supervision of functions under the 
629/2010 Medical Devices Act, as well as other duties designated for Competent Author-
ities specified in the EU legislation. (Ståhlberg, 2015) Medical device legislation in Fin-
land is listed in table 4.  
Table 4. Legislation and regulations in Finland that conform to the Council Directive 
93/42/EEC on Medical Devices. (Valvira, 2015) 
629/2010 Medical Devices Act 
Valvira 1/2010 Manufacturer's Incident report 
Valvira 2/2010 Registration of Medical Devices 
Valvira 3/2010 Clinical Investigations of Medical Devices 
Valvira 4/2010 Healthcare professionals Incident Report 
Valvira 1/2011 Conformity Assessment of Medical Devices 
Valvira 2/2011 CE-marking of Medical Devices 
As part of Finnish Government, the Ministry of Social affairs and Health can legislate 
acts regarding medical devices and provide guidance in their implementation. It also su-
pervises medical devices sector in Finland, prepares and defines Finland’s statements re-
garding medical devices sector in the EU, and is responsible for preparation and imple-
mentation of EU legislation in Finland. The Competent Authority also appoints and su-
pervise NBs. Although manufacturers are free to choose any legally designated NB in the 
EU, it is often the easiest to choose one from the same EU member state where the man-
ufacturer is located. In Finland, there are two NBs with wide range of qualifications: SGS 
Fimko Oy and VTT Expert Services Oy. (Ståhlberg, 2015)  
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The costs to obtain a CE certification depend on several things: which certification pro-
cedure applies to the product, whether the manufacturer does some or all of the conform-
ity assessments themselves, and the level of support needed to prepare the required com-
pliance documents, Technical File, user manuals, and product labeling. Manufacturers 
can ask and compare quotes from test laboratories, certification bodies, and consultants 
to get an estimated budget for their device. (Zuyderwijk, 2015) 
 Medical devices regulation in the United States 
In the US, laws are developed via legislation, and they are vague mandates interpreted by 
the applicable federal agency, who writes regulations on how the law will be enforced 
(Nolan, 2004). In the medical devices field the applicable federal agency is the FDA, 
who’s legal authority to regulate medical devices is based on the Federal Food, Drug & 
Cosmetic Act (FD&C Act). The FD&C Act contains regulatory requirements defining 
FDA’s level of control. (FDA, 2015) The Medical Device Amendments to the FD&C Act 
were enacted in 1976. These amendments, along with the Food and Drug Administration 
Modernization Act (FDAMA) of 1997 can be viewed as counterparts to the MDD di-
rective in the EU. (van Drongelen et al, 2015)  
To fulfill the regulatory requirements, FDA develops, publishes, and implements regula-
tions. The Federal Register (FR) is the official daily publication for rules, proposed rules, 
notices of Federal agencies and organizations, executive orders, and other presidential 
documents. When rules are final, they are published annually in the Code of Federal Reg-
ulations (CFR), which is a codification of the general and permanent rules. Most of the 
FDA’s medical device regulations are in the Title 21 CFR Parts 800 – 1299. There is also 
a daily updated editorial compilation of the CFR material and FR amendments, the Elec-
tronic Code of Federal Regulations (eCFR), but it is not a legal official edition of the 
CFR. The FDA Safety and Innovation Act (FDASIA) that was signed into law in 2012, 
preserved the general structure of device evaluation, renewing user fees and performance 
targets through 2017. (FDA, 2015) 
Companies who manufacture, repackage, relabel and/or import medical devices sold in 
the US are regulated by the FDA’s Center for Devices and Radiological Health (CDRH) 
(FDA, 2015). The most important offices within the CDRH for manufacturers to know 
about, are the Division of Industry and Consumer Education (guidance), Office of Com-
pliance (market surveillance, Establishment Inspection Reports, recalls), Office of Device 
Evaluation (pre-market notifications 510(k), pre-market approvals, Investigational De-
vice Exemptions), Office of In Vitro Diagnostic (IVD) Device Evaluation and Safety 
(pre-market evaluation of IVD applications, post-market surveillance of IVDs), and Of-
fice of Surveillance and Biometrics (adverse effect reports). In addition to the federal 
authorities, there are local authorities in each state, and procedures between different 
states vary. Many, but not all, international standards are recognized in the US and are 
referred to as Recognized Consensus Standards. Recognized standards can be searched 
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in the database on the FDA’s official webpage. Also national standardization organiza-
tions, for example Clinical and Laboratory Standards Institute, publish standards regard-
ing medical devices. (Ståhlberg, 2015) 
In the US, medical devices are classified into three classes based on the FD&C Act section 
513 that establishes the risk-based classification system. Unlike in the EU, where detailed 
classification rules for medical devices are available, there are no detailed rules in the US, 
but the classification is done by the FDA. The regulatory classes are: Class I, Class II, 
and Class III. The classification is based on the level of control necessary to ensure a 
device’s safety and effectiveness; Class I devices are subject to least regulatory control, 
and Class III devices are subject to the most stringent regulatory control. Table 5 presents 
the idea and descriptions behind the classifications. (FDA, 2015; van Drongelen et al, 
2015)  
Table 5. Classification descriptions for medical devices in the US. (FDA, 2015; van 
Drongelen et al, 2015)  
Class I Devices that are not intended for a use of substantial importance in supporting, sus-
taining, or preventing impairment of human health or life, and the devices do not 
present a potential unreasonable risk of illness or injury 
Class II Devices for which it is necessary to establish a performance standard, in order to 
ensure reasonable assurance of safety and efficacy 
Class III Devices for which there is not sufficient amount of information available to estab-
lish a performance standard. Devices that are intended to be for a use which is of 
substantial importance in supporting, sustaining, or preventing impairment of hu-
man health or life, devices that present a potential unreasonable risk of injury 
The FDA has a database where device types and specific devices are assigned into one of 
these three device classes. A manufacturer can search the classification database, or go to 
one of the 18 medical specialty panels in which over 1700 distinct types of devices are 
described, and look for a predicate device for their product. If a product is completely 
new, the risk class cannot be established from these lists and the manufacturer has to 
contact the FDA for device classification. (van Drongelen et al, 2015) If an exact predi-
cate device for a new product cannot be found, a manufacturer can submit a 513(g) Re-
quest for Information to the FDA. The 513(g) submission should list the characteristics 
of the new device, and the manufacturer’s rationale why it would fall into a specific class. 
The FDA then evaluates the information within 60 days and issues a ruling on the classi-
fication. (US Department of Health and Human Services, 2012) 
The FDA can, on its own initiative or in response to a petition, reclassify a medical device 
based on new information. Reclassification based on new information is applicable to 
existing devices, and the new information must be publicly available valid scientific evi-
dence. For novel devices, reclassification is done by the de novo procedure. By definition, 
a novel device is always classified as Class III device. For low or medium risk devices, 
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the manufacturer can submit a de novo request, which requires the FDA to reconsider the 
risk of the device and decide on its classification. (van Drongelen et al, 2015)  
The classification regulations define the regulatory requirements for a general medical 
device type. The basic regulatory requirements, that manufacturers of medical devices 
sold in the US market must comply with, are presented in table 6. (FDA, 2015)  
Table 6. The basic regulatory requirements for manufactures of medical devices in the 
United States. (FDA, 2015) 
21 CFR Part 807 Establishment Registration 
21 CFR Part 807 Medical Device Listing 
21 CFR Part 807,   
Subpart E 
Premarket Notification 510(k) * 
21 CFR Part 814 Premarket Approval (PMA) * 
21 CFR Part 812 Investigational Device Exemption (IDE) 
21 CFR Part 820 Quality System Regulation (QRS)/Good Manufacturing Practices (GMP) 
21 CFR Part 801 Labeling 
21 CFR Part 803 Medical Device Reporting 
* = Either Premarket Notification 510(k) unless exempt, or PMA, depending on the device. See table 7. 
 
Medical device manufacturers and importers are required to register annually with the 
FDA. This process is called Establishment Registration. As part of the Establishment 
Registration process, foreign manufacturers must designate a US agent to represent them. 
The US agent assists the FDA in communication with the manufacturer, responds to ques-
tions concerning the manufacturer’s devices, assists the FDA in scheduling inspections 
of the manufacturer’s facilities, and receives information or documents from the FDA, in 
case the FDA is unable to contact the manufacturer directly. Manufacturers are also re-
quired to do a Medical Device Listing, in which they list their device with the FDA. Most 
medical devices sold in the US market need either a Premarket Notification 510(k) or a 
Premarket Approval (PMA). This requirement is roughly based on the classification of 
the device, as presented in table 7. (FDA, 2015) 
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Table 7. Premarket Notification 510(k) or Premarket Approval needed, based on the de-
vice class. (FDA, 2015) 
Class I  Most devices are Premarket Notification 510(k) exempt, but manufacturer must register 
device and company 
Class II Most devices require Premarket Notification 510(k) 
Class III Most devices require Premarket Approval 
If a medical device requires a Premarket Notification, it cannot be commercially distrib-
uted before FDA authorization. There is no official form for the 510(k) application, but 
the requirements for a submission are described in 21 CFR Part 807, Subpart E. The 
510(k) must demonstrate that the device is substantially equivalent to another safe and 
effective medical device that is already legally marketed in the US, and does not require 
a PMA. The FDA authorization is based on the information submitted by the applicant, 
and the decision is usually made within 90 days. (FDA, 2015) The differences between 
de novo-process, 513(g) Request for Information, and Premarket notification 510(k) pro-
cesses are highlighted in table 8. 
Table 8. The differences between de novo –process, 513(g) Request for information and 
Premarket notification 510(k). 
De novo-process 513(g) Request for Information  Premarket notification 510(k) 
Completely new device with no  
predicate devices, would auto-
matically be classified as Class 
III: 
For low or medium risk devices, 
a de novo-request requires the 
FDA to reconsider the risk of the 
device and decide on its (re)clas-
sification. 
No exact Class I or Class II pred-
icate device can be found: 
513(G) lists the characteristics of 
the new device, and the manu-
facturer’s argument why it 
would fall into a specific class.  
The FDA evaluates the infor-
mation and issues a ruling on the 
classification. 
A Class I or Class II predicate 
device is found: 
Demonstrates that the new de-
vice is substantially equivalent to 
the predicate device that is al-
ready legally marketed in the 
US, and does not require a PMA.  
The FDA authorization is based 
on the information submitted by 
the applicant. 
Medical devices that require a PMA are Class III high risk devices, or devices that are not 
found substantially equivalent to Class I and II predicate through the 510(k) process. The 
PMA process is the most stringent type of medical device marketing application, and 
includes a submission of technical-, non-clinical-, and clinical data. The PMA approval 
is based on the FDA’s determination of sufficient scientific evidence of the safety and 
efficacy of the device. Formally, the FDA has 180 days to review the PMA and make a 
decision; however, in reality the review time is usually longer. (FDA, 2015) 
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An Investigational Device Exemption (IDE) allows the device to be used in a clinical 
study in order to collect safety and efficacy data. All clinical evaluations must have an 
approved IDE before the study is initiated, unless exempt by the FDA. An approved IDE 
allows the device to be legally shipped for the purpose of conducting investigations of the 
device, even if the device does not comply with other requirements for commercially 
distributed medical devices stated in the FD&C Act. The applicant also does not need to 
submit a PMA or Premarket Notification 510(k), register their establishment, or list their 
device, as long as the device is under investigation. They are also exempt from the quality 
system regulation, except for design controls (21 CFR 820.30). (FDA, 2015) 
Quality System Regulation (QSR) and Good Manufacturing Practice (GMP) regulations 
include requirements for the methods and facilities for designing, purchasing, manufac-
turing, packaging, labeling, storing, installing and servicing of medical devices. Although 
widely recognized, international quality management standards ISO 9000, ISO 14000 and 
ISO 13485 are not recognized by the FDA, and the US definitions and qualifications for 
quality systems regarding medical devices can be found in the Title 21 CFR part 820. 
FDA does not certify quality systems, but it conducts random inspections for compliance 
with the Title 21 CFR part 820. Labeling regulations include the label of the device and 
all the informational material that accompanies the device. Medical Device Reporting 
(MDR) regulation contains mandatory requirements for manufacturers, importers and de-
vice user facilities to report device-related adverse events and problems to the FDA. From 
August 2015, the MDRs are accepted only in electronic format (eMDR). The reporting 
requirement includes death or serious injury caused or contributed by the device, as well 
as malfunctions that would likely to cause or contribute to a death or serious injury if they 
were to recur. (FDA, 2015) The current user fees for different medical devices applica-
tions can be found in the official FDA webpages. Examples of the fees related to the 
different application types in 2016 are presented in table 9.  
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Table 9. Examples of FDA user fees for medical devices application in 2016. (FDA, 
2015b) 
Application type Standard fee (US$) Small business* fee (US$) 
De novo -process No fee No fee 
513(g) 3,529 1,765 
510(k) 5,228 2,614 
PMA 261,388 65,347 
Supplements to PMA 18,297 - 196,041 4,574 - 49,010 
PMA annual report 9,149 2,287 
Annual Establishment Registra-
tion 
3,845 3,845 
* Small businesses with an approved Small Business Deduction and gross sales of 30 million US$ or less 
are eligible to be waived on their first PMA 
The regulatory process for medical devices in the US is illustrated in figure 4. 
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Figure 4. The regulatory process for medical devices in the United States. (Modified from 
Emergo Group, 2015) 
Determine the classification of the device by using the FDA classification database: search “Predicate devices”, or 
if a predicate device is not found, use 513(g) or de novo-process. 
Class I Class II Class III 
Implement Quality Management System (QMS) that complies with the Title 21 CFR 820. 
Innovative Class II and all Class III devices will likely require clinical stud-
ies. Get “Pre-submission” feedback from the FDA. 
If clinical studies are required, apply for an Investigational Device Exemp-
tion (IDE). Develop clinical protocol and conduct studies. 
Random FDA facility inspections 
of all major suppliers involved 
with the device. All parts must 
comply with the Title 21 part 820. 
The FDA listing on their website is the authorization to commercialize the device in the US. The authorization 
does not expire, unless certain types of changes are made (e.g. design, intended use). 
List the device and register company on the FDA website in accordance with the Title 21 part 807. Contract manu-
facturers and sterilizers must also register and list. Specify the appointed US agent. The Establishment Registra-
tion and Device Listing must be renewed every year! 
Appoint an FDA US agent representative as a local point of contact with the FDA. 
Must have full compliance with the Title 21 part 820. FDA does not inspect Class I and Class II device manufac-
turers prior to the device registration, but conducts random inspections for compliance. 
Submit 510(k) Premarket Notifica-
tion application. Pay the 510(k) re-
view fee to the FDA. 
Submit Premarket Approval 
(PMA) application. Pay the PMA 
submission fee to the FDA. 
510(k) clearance letter from the 
FDA, posted online. 
PMA clearance letter from the 
FDA, posted online. 
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4. CELL- AND TISSUE THERAPY PRODUCTS 
Biopharmaceuticals include vaccinations, blood products, allergens, and products utiliz-
ing recombinant DNA techniques, such as insulins and antibodies, and is one of the fastest 
growing group of medicinal products. Recent additions to biopharmaceuticals group are 
the so called advanced therapies; gene-, cellular-, and tissue therapies. Biopharmaceuti-
cals are considered to be the key to the future pharmaceutical treatments, and currently as 
many as half of all medicinal products in development are biopharmaceuticals. (Fimea, 
2014) 
 Cell- and tissue therapy products regulation 
Scientific and technological aspects of stem cell biology and tissue engineering are going 
through rapid developments, and the use of human cells and tissues for the treatment of 
various diseases and injuries has increased. The regulations are in different stages of de-
velopment in different countries and the regulatory requirements are evolving, therefore 
there are no harmonized terminology and technical requirements in this field yet. Cell- 
and Tissue Therapy products (CTTs) are referred to by different terms depending on the 
regulatory agency. In the EU CTTs are regarded as Advanced-Therapy Medicinal Prod-
ucts (ATMPs), and in the US CTTs are referred to as Human Cells, Tissues, and Cellular 
and Tissue-based Products (HCT/Ps). The regulatory agencies across the globe are work-
ing to establish a risk-based system with some common features. Many regulatory con-
trols regarding CTTs have been implemented in the last few years, and most regulatory 
agencies in different countries recognize CTTs as drugs or medicinal products. However, 
in most cases the current drug regulatory framework is not best suited for CTTs, hence 
separate frameworks have been established, or are currently being developed. (Kellathur 
& Lou, 2012)  
 Cell- and tissue therapy products regulation in the Euro-
pean Union 
The EU has proposed a plan of action for the development of new biopharmaceuticals to 
ensure their quality, safety and efficacy. In the plan ATMPs are recognized as new prod-
uct category that has to fulfill the same scientific and regulatory standards defined for 
other medicinal products. (Pacini, 2014) According to the definition in Regulation (EC) 
No 1394/2007, ATMPs contain or consist of engineered cells or tissues, and they are used 
in human for the purpose of regenerating, repairing, or replacing a tissue. ATMPs cannot 
be included in the same category with drugs or transplants because they contain viable 
human cells and their manufacture includes substantial manipulations. Also they may be 
applied for sites where they are not usually present, or to carry out biological functions in 
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which they do not usually participate. The ATMPs can be further divided into four dif-
ferent types of products: Gene Therapy Medicinal Products (GTMPs), Somatic Cell Me-
dicinal Therapy Products (sCTMPs), Tissue Engineered Products (TEPs), and Combined 
Advanced Therapy Products (CATPs). CATPs, TEPs and sCTMPs can be grouped under 
a more general definition: Cell-based Medicinal Products (CBMPs). GTMPs differ from 
CBMPs because they do not contain living cells or tissue, and their medicinal effects are 
based on nucleic acids. (Pacini, 2014)  
GTMPs contain genes that lead to a therapeutic, prophylactic, or diagnostic effect. In 
gene-therapy laboratory fabricated recombinant genes are inserted into the body to treat 
a variety of diseases, including cancer and genetic disorders. sCTMPs consist of cells or 
tissues that have been manipulated to change their original biological characteristics or 
that are intended to be used in different essential functions in the body. Somatic cell-
therapy medicines can be used to cure, diagnose or prevent diseases. TEPs contain mod-
ified cells or tissues that are used to repair, regenerate or replace human tissues. A number 
of ATMPs combine biological materials and one or more medical devices, for example 
cells embedded in a biodegradable polymer scaffold (EMA, 2015). These products are 
called Combined Advanced-Therapy Medicinal Products (CATP) and they lie in the bor-
der of traditional pharmaceutical area and other fields, such as medical devices. Therefore 
they cannot be regulated as conventional drugs or medical devices, but they need adapted 
requirements. New technologies that utilize ATMPs include regenerative medicine, per-
sonalized treatments, and nanomedicines (European Commission, 2015c). Figure 5 pre-
sents a flow chart that helps to define in which category a biological medicinal product 
falls. (Pacini, 2014) 
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Figure 5. Flow chart for the definition of a biological medicinal product. (Modified from 
Pacini, 2014) 
Are there living cells? 
Are cells substantially manipulated? Are there organelles or sub-cellular 
fractions with biological functions? 
BIOLOGICAL MEDICINAL PRODUCTS 
YES NO 
ATMP 
YES 
Are cells administered in non-ho-
mologous sites or to carry out non-
usual functions? 
DRUG 
NO NO 
TRANSPLANT 
NO 
YES 
YES 
Contains or consists of recom-
binant nucleic acids exerting 
the medicinal effects? 
GTMP YES 
Contains or consists of engi-
neered cells or tissues? 
 NO 
sCTMP NO 
Incorporates medical device? 
Directive 93/42/EEC 
TEP NO 
CATP  YES 
   CBMPs 
YES 
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The legislative framework applicable for ATMPs in the EU is formed by the following 
directives and regulations: 
 Regulation (EC) No 1394/2007 
 Directive 2001/83/EC 
 Regulation (EC) No 726/2004 
 Directive 2009/120/EC 
The overall regulation framework for the ATMPs is the regulation (EC) No 1394/2007. 
This regulation document is an amendment to both the directive 2001/83/EC that relates 
to medicinal products for human use, and to the regulation (EC) No 729/2004 that is 
related to the procedures for the authorization and supervision of medicines for human 
and veterinary use, and that also establishes the European Medicines Agency (EMA). The 
Committee for Advanced Therapies (CAT) was also established in accordance with the 
regulation (EC) No 1394/2007. CAT functions under EMA, and it is a multidisciplinary 
committee responsible for assessing the quality, safety and efficacy of ATMPs, as well 
as following the scientific developments in the field.  The directive 2009/120/EC is also 
an amendment to the directive 2001/83/EC, with updated definitions and detailed require-
ments for gene-therapy medicinal products and somatic-therapy medicinal products. The 
directive 2009/120/EC contains detailed scientific and technical requirements for tissue 
engineered products and combined ATMPs. (EMA, 2015) 
In addition to these legislation documents, the rules and regulations concerning the dona-
tion, procurement, testing, processing, storage and distribution of human cells and tissues 
are covered in the directive 2004/23/EC, also known as the European Tissues and Cells 
Directive. Companies developing ATMPs must also be aware of the legislation concern-
ing different stages of the development process, including GMP and good clinical practice 
(GCP) requirements. Directive 2001/20/EC covers the implementation of GCP in the con-
duct of clinical trials. However, this directive is repealed by the regulation EU No 
536/2014, which entered into force in June 2014, but will apply from May 28, 2016. All 
effective scientific guidelines, directives and other relevant information regarding 
ATMPs are published and available on the EMA website. (EMA, 2015) 
As an example in Finland, the preparation of any ATMP based on cell or gene therapy or 
tissue modification, requires a national license from the Finnish Medicines Agency, 
Fimea. If it is uncertain whether the regulations concerning ATMPs are applicable to the 
product in question, the manufacturer must request a Fimea classification before submit-
ting an application. The granting of the license requires that the quality and safety of the 
product meet the requirements, including the GMP requirements when applicable, speci-
fied for the particular product. The manufacturer must have procedures for monitoring 
adverse reactions and incidents, and all the materials used must be traceable. The appli-
cation must also contain a risk assessment of the product based on known risk factors. 
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The information on which the product’s safety assessment has been based (any non-clin-
ical studies and clinical use of the product) must be included in the risk assessment. If the 
product has not been used on human before, additional safety studies may be needed. 
(Fimea, 2014b) 
The first ATMP that successfully completed the entire development track from research 
through clinical testing to European approval, receiving European Marketing Authoriza-
tion in 2009, was ChondroCelect® by TiGenix. ChondroCelect® is a cell-based medici-
nal product that is intended to be used in autologous chondrocyte implantation for the 
repair of single symptomatic cartilage defects in adults. (TiGenix, 2016)  
 Cell- and tissue therapy products regulation in the United 
States 
In the US the regulation for cell- and tissue therapy products intended for human appli-
cations, referred to as HCT/Ps, consists of binding laws and regulations and non-binding 
guidance documents. Laws are passed by the congress and signed by the president, regu-
lations are compiled by the FDA and approved by the executive branch, and guidance is 
the FDA’s interpretation of the regulations, and is written and approved by the FDA. The 
laws concerning HCT/Ps are the FD&C Act and the Public Health Services (PHS) Act, 
and regulations for HCT/Ps are found under the 21 CFR Parts 1270 and 1271. The FDA 
supervises the entire life cycle of a medical product. Cell- and tissue products are regu-
lated by the Office of Cellular, Tissue, and Gene Therapies (OCTGT) that functions under 
the Center for Biologics Evaluation and Research (CBER). (Oh, 2011) As for combina-
tion products that comprise of two or more regulated components, the FDA’s Office of 
Combination Products (OCP) will assign one of the FDA’s centers responsible for drugs, 
medical devices or biologics to act as the lead center, based on the primary mode of action 
of the combination product (van Drongelen et al, 2015). 
The 21 CFR Part 1271.3 defines HCT/Ps to be articles that contain or consist of human 
cells or tissues, and that are intended for implantation, transplantation, infusion, or trans-
fer to a human recipient. The FDA has implemented a risk-based approach to the regula-
tion of HCT/Ps. The low risk products are regulated only under the section 361 of the 
PHS Act and 21 CFR Part 1271, and they do not require a premarket review. According 
to 21 CFR Part 1271.10 a product is of low risk if it fulfills the following criteria (FDA, 
2014): 
(a) It is minimally manipulated 
(b) It is intended for homologous use only 
(c) It does not combine cells or tissues with another article 
(d) It does not have a systematic effect and it is not dependent on metabolic activity 
of living cells for its primary function, or 
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(e) If it has a systematic effect or it is dependent on metabolic activity, it is for autol-
ogous use, allogeneic use in first- or second degree relative, or it is for reproduc-
tive use 
By the definition in 21 CFR Part 1271.3(f) minimal manipulation means such processing 
of structural tissue that does not alter the original relevant characteristics of the tissue, or 
such processing of cells or nonstructural tissues that does not alter the relevant biological 
characteristics of cells or tissues. If a product does not fit in these criteria, and the manu-
facturer does not qualify for any of the exceptions listed in 21 CFR 1271, the product is 
regulated as a drug, device, or biological product. In this case a premarket review is re-
quired, since the 351 of the PHS Act, and/or the FD&C Act, as well as applicable regu-
lations including 21 CFR Part 1271 apply. (FDA, 2014) 
According to Kellathur and Lou, the risk-based HCT/P regulation focuses on preventing 
the use of contaminated tissues with the potential of transmitting infectious deceases, such 
as HIV and hepatitis. On the other hand, the risk-based regulation aims to prevent con-
tamination or damage to tissues caused by improper handling and processing. The regu-
lation also aims to ensure that clinical safety and efficacy of the HCT/Ps are demonstrated. 
The regulatory framework for HCT/Ps is formed by the Good Tissue Practices (GTP) rule 
and GMP requirements. All HCT/Ps have to comply with GTP, and the higher risk 
HCT/Ps regulated under the section 351 of the PHS Act and/or FD&C Act are subjected 
to both GTP and GMP. The GMP requirements focus on the safety, purity and potency 
of the products, thus leading to high level of process control, consistency and product 
characterization. The GTP rule aims to prevent HCT/P contamination with disease agents, 
while ensuring their function and integrity. In addition, all facilities that process tissues 
or cells are required to register and list the establishment with the FDA. (Kellathur & Lou, 
2012) A comparison of general regulatory requirements and marketing pathways for low 
and high risk single entity HCT/Ps, and medical devices are presented in table 10. 
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Table 10. Comparison of general FDA regulatory requirements and marketing pathways 
for single entity HCT/Ps, and medical devices. (Modified from Oh, 2011) 
 Low risk HCT/P High risk HCT/P Medical devices 
Applicable laws 361 PHS Act 361 PHS Act 
351 PHS Act 
FD&C Act 
FD&C Act 
Applicable  
Regulations 
21 CFR 1271 21 CFR 1271 
21 CFR 600 
21 CFR 300 
21 CFR 200 
21 CFR 800 
Marketing pathway No premarket review 
required 
Biologics License Ap-
plication (BLA) 
510(k), PMA 
 
The Biologics License Application (BLA) is regulated under the 21 CRF 600 – 680, and 
it is a permission to introduce, or deliver for introduction, a biologic product. It is an 
equivalent to PMA in medical devices. A BLA can be submitted by any legal person or 
entity who is involved in the manufacturing of the product, or an applicant who takes 
responsibility for compliance with product and establishment standards. The specified 
requirements for the applicant information, product/manufacturing information, pre-clin-
ical studies, and labeling are found in the Form 356h. (FDA, 2010) 
Combination products have become a large and growing segment of the medical device 
market. In 2011 they represented estimated over 30% of all new product submissions to 
the FDA. (Richter, 2011) The FDA defines combination products as products that com-
prise of two or more regulated components, such as: drug/device, biologic/device, 
drug/biologic, or drug/device/biologic, that are physically, chemically, or otherwise com-
bined or mixed and produced as a single entity. Combination products can also be sepa-
rate products that are packaged together in a single package or as a unit, as well as a drug, 
device, or biological product packaged separately but intended for use only with an ap-
proved, individually specified drug, device, or biological product where both are required 
to achieve the intended effect. The constituent parts of a combination product keep their 
regulatory status (for example as a device or drug) after they are combined. Also the 
GMP/QSR requirements that apply to each of the constituent parts continue to apply after 
the parts are combined to make a combination product. (Federal Register, 2013) The man-
ufacturer must define the primary mode of action of the combination product, and submit 
a Request For Designation (RFD) to the FDA’s OCP, which determines the primary mode 
of action. The primary mode of action dictates weather the foundational framework will 
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be medical device QSRs (21 CFR Part 820), drug GMPs (21 CFR Part 210/211), or bio-
logic GMPs (21 CFR Part 600 – 680 and 21 CFR 1271). (Richter, 2011) While the po-
tential of combination products in improving patient care and providing safer and more 
effective treatments has contributed to the rapid market growth, the regulatory framework 
continues to raise a variety challenges to the industry. The diversity in the types of com-
bination products means that there is no general regulatory pathway that would apply to 
all. (Siew, 2014)  
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5. PACKAGING OF MEDICAL DEVICES 
When deciding a suitable package for a medical device, certain questions need to be con-
sidered: What is the shape and mass of the product? What are the sterilization require-
ments? Are there any moisture retention or exclusion requirements? What is the intended 
use of the device and who are the end users? (Turner, 2011) Estimated 10% of all medical 
device recalls are due to packaging failures, and 31% of those are due to a hole in the 
packaging. Therefore, the correct selection of packaging is crucial. (Cleanroom Technol-
ogy, 2014)  
The packaging of a medical device generally has three main functions: protection, utility 
and communication. Protection means protecting the device from the environment and 
vice versa. Protection is necessary for maintaining package integrity for its lifespan from 
sterilization to shipping, storage, handling and use.  (Bix & De La Fuente, 2009)  If a 
device has a shelf life, the packaging has to maintain the device and ensure its function-
ality for the stated period of time. The term shelf life should not be confused with the term 
useful life. According to the FDA, useful life is the duration of actual use, or the number 
and duration of repeat uses of the device, before there is an impact to the device’s ability 
to achieve its intended function. An expiration date means the termination of shelf life, 
after which the device may no longer function as intended. (Teixeira, 2014) Typical pro-
tection wanted from packaging is protection from shock, vibration, crushing, puncturing, 
tearing, bursting, splitting, humidity, and heat. One of the most vital protective functions 
of medical devices packaging is maintaining of the sterile barrier system. For sealed pack-
ages, seal integrity is an equally important characteristic. (Bix & De La Fuente, 2009) 
The packaging material supplier should provide information about materials’ resistance 
to microbial access, mechanical properties, robustness and integrity, suitability for steri-
lization, and biocompatibility (Turner, 2011).  
Utility is related to the usability of the packaging system. It is said that user interactions 
with the packaging of a medical device can be as important as interactions with the device 
itself. (Wiklund et al, 2010) In many cases medical professional base their decision on 
superior medical technology, but in case of two or more equal products, other factors 
emerge – packaging of the device being one of them. For many medical devices quick 
and easy opening and removal of contents without contamination is crucial. Packaging 
design plays the most important role in the opening function. In some cases, the package 
may also have additional functions beside protection, such as a measuring device, dis-
penser, stabilizing stand or a disposal bin. (Bix & De La Fuente, 2009; Crosby, 2008) A 
usability test with packaging and the enclosed materials helps to evaluate how users in-
teract with the packaging and set up the medical device for use. Characteristics that can 
be assessed during a usability test are for example (Wiklund et al, 2010): 
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 Ease of lifting and carrying the package for short and long distances (package 
shape, weight, and handle design) 
 Conspicuousness and comprehension of labels, instructions, warnings, and adver-
tising  
 Ease of opening the package (tearing open cardboard flaps, opening plastic bags, 
uncapping vials, peeling paper liners from plastic trays, removing seals) while 
maintaining sterility of the contents 
 Ease of identifying and distinguishing between package contents 
 Ease of identifying and distinguishing between packaging for similar devices or 
products (e.g. two different concentrations of the same product) 
 Ease of removing package contents without damaging or contaminating them 
 Ease of handling the package and components with one hand (if the other is used 
to perform another task) 
 Package durability (i.e. resistance to damage during handling) 
 Ease of storing the package (e.g. appropriateness of the overall size and shape of 
the package) 
 Acceptance of the amount of material waste 
 Visual appeal of the shape, graphics, and overall visual design of the package 
 Legibility and conspicuousness of printed information, such as warnings and ex-
piry dates, which might be essential to risk mitigation 
 Ease of determining is the contents are damaged 
 Ease of placing components back to the package 
When deciding how to conduct the usability test, the end users of the product must be 
considered (Wiklund et al, 2010). The Institute of Packaging Professionals has conducted 
a survey among the Association of Perioperative Registered Nurses about preferred pack-
aging of medical devices. The results are presented in figure 6. (Crosby, 2008) 
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Figure 6. Preferred packaging of medical devices according to a survey among the As-
sociation of Perioperative Registered Nurses. (Crosby, 2008) 
According to the survey, 84.4% preferred a double-barrier sterile system. Other important 
factors that came up were the ability to read the label, especially the sterility indicator and 
the expiration date, and the ability to quickly open the package during a surgical proce-
dure. (Crosby, 2008)  
A Voice of the Customer –survey and live nurses’ panel was conducted at HealthPack in 
Luisville, KY, US in 2013. The surveyed nurses were from EU and the US. Also in this 
survey double sterile barrier packaging, consisting of a sealed tray within another tray or 
a pouch was a preferred packaging. Clear packaging was thought ideal, and easy opening 
is essential. All surveyed said they check the use before –dates, which should be easily 
observed. Instructions for use provided on CDs was not preferred, since there is often no 
access to a computer in the operating room. Recycling of materials is a growing interest 
also among nurses. (Allen, 2013b) 
Secondary and primary medical device packages are also a means to communicate in-
formation through materials, graphics and shape. The level of packaging communication 
varies depending on the type of the medical device. Typically the communication role 
involves passing important information for the safe and effective use of the device; direc-
tions, warnings and product benefits. It may also include brand differentiation, motivation 
for purchase and so on. A very important function of package communication is product 
identification. This is crucial especially for medical devices that are used in hospital set-
ting, where personnel may have only seconds to identify the correct device. (Bix & De 
La Fuente, 2009) With medical devices the requirement of cleanliness is a key element, 
and has to be reflected in the visual appearance of the device packaging as well (Clean-
room Technology, 2014). 
60,419,3
13,9
6,4
Preferred medical device packaging 
(% of surveyed)
Formed rigid tray with lid
Flexible pouch
Header bag
Formed flexible package
with lid
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The manufacturers of medical devices must provide essential information in several lan-
guages, which can affect the legibility, visibility and accuracy of the information. They 
also have to make sure that components of the package, like adhesives and inks, do not 
interfere with the product’s safety and efficacy. If any of the components of the package 
migrate to the device, it is important that these unintended additives are nontoxic and do 
not affect the performance of the device. (Bix & De La Fuente, 2009) For sterile medical 
devices, the packaging materials also need to be compatible with the chosen method of 
sterilization. (Teixeira, 2014).  
Environmental issues and waste reduction are also important factors to consider. Biode-
gradable and compostable bioplastics, such as PLA, have been used in food packaging 
industry for years. In their current form, however, they have some limitations with impact 
strength and heat deflection properties compared to traditional plastics, thus making them 
unsuitable packaging materials for sterile barrier systems. (Crosby, 2008)  
 Packaging of sterile implantable medical devices 
The ISO 13485 standard defines that an implantable medical device is a device that is 
intended by surgical intervention to be totally or partially introduced into the human body 
or natural orifice, or that is intended to replace an epithelial surface or the surface of the 
eye. An implantable medical device is intended to remain at least 30 days after the pro-
cedure and it can only be removed by medical or surgical intervention. The ISO 13485 
also states that a sterile medical device refers to a category of devices that are intended to 
meet the requirements for sterility. 
Implantable medical devices can be for example prosthetics intended to replace a missing 
body part, or they can be used to deliver medication, monitor body functions, or provide 
support to organs and tissues. Implantable medical devices can be permanent, or they can 
be removed when no longer needed. (FDA, 2015) Implantable medical devices include a 
wide variety of different kinds of devices. Thus when choosing a suitable packaging for 
a sterile implantable medical device, the manufacturer has to consider the critical product 
characteristics, types of protection needed, type of sterilization process, and where, and 
how, the product is going to be dispensed. (Bix & De La Fuente, 2009). Part of this eval-
uation is the defining of environmental factors: characteristics that may have an impact 
on the device or its components during transport, storage, or use. Environmental factors 
include the conditions that can affect the device itself, the user of the device, or the patient 
in the intended use environment. Environmental conditions to be considered can be such 
as: temperature, humidity, moisture, atmospheric gas composition or pressure, energy, 
vibration, motion, lighting, and shock. (Teixeira, 2014) 
Sterility and its maintenance, as well as prevention of cross-infection, are the most critical 
factors in patient care. The packaging around the medical device allows the device to be 
sterilized, provides a microbial barrier, and maintains the sterility of the device. (Sterile 
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Barrier Association, 2006) A sterile barrier system is the minimum packaging configura-
tion that provides a microbial barrier, and allows aseptic presentation of the product at 
the point of use. A sterile barrier system differs from protective packaging, which is de-
signed to prevent damage to the sterile barrier system and its contents. A packaging sys-
tem is the combination of the sterile barrier system and the protective packaging. (Sterile 
Barrier Association, 2006) Inappropriate sealing compromises the package integrity, 
hence sealing of a sterile medical device package is critical. Seals can be weld or peelable. 
Weld seals are not intended to open, and they are produced by heat or ultrasonic. Peelable 
seals are designed to open, and they are achieved either with, or without heat (cold seals). 
Peelable cold seals cannot be resealed when opened, thus they can also be used as tamper 
evidence. (Bix & De La Fuente, 2009) There are over 100 standards and guidance docu-
ments relevant to sterile barrier systems, the full list is presented in appendix B. 
According to the MDD, sterile barrier systems are considered to be accessories to medical 
devices. The MDD defines an accessory as “an article which, whilst not being a device, 
is intended specifically by its manufacturer to be used together with a device to enable it 
to be used in accordance with the use of the device intended by the manufacturer of the 
device”. The directive also states that accessories are treated like medical devices in the 
requirement to comply with the essential requirements, however, according to MEDDEV 
2.1/1 accessories do not usually follow the classification of the medical devices with 
which they are used. (European Commission, 2015) The essential requirements for de-
vices that are delivered in sterile state according to the MDD Annex 1 are: 
(a) Devices delivered in a sterile state must be designed, manufactured and packed  in  a  
non-reusable  pack  and/or  according  to  appropriate procedures to ensure that they 
are sterile when placed on the market, and remain sterile under the storage and 
transport conditions laid down, until the protective packaging is damaged or opened 
(b) Devices delivered in a sterile state must have been manufactured and sterilized by an 
appropriate, validated method 
(c) Devices intended to be sterilized must be manufactured in appropriately controlled (e. 
g. environmental) conditions 
(d) Packaging systems for non-sterile devices must keep the product without deteriora-
tion at the level of cleanliness stipulated and, if the devices are to be sterilized prior 
to use, minimize the risk of microbial contamination; the packaging system must be 
suitable taking account of the method of sterilization indicated by the manufacturer 
The MDD Annex 1 also lists the information the manufacturer has to provide with the 
device. Each device must have with it enough information for safe and proper usage, 
considering the knowledge and training of the intended users. The information also has 
to identify the manufacturer of the device. If possible, the information needed for safe 
usage must be placed directly on the device itself, the packaging of each unit, or on the 
sales packaging. If the devices cannot be packaged individually, a leaflet with proper 
information has to be provided with a package of one or more devices. Class IIb and III 
35 
classified medical devices, and devices which intended purpose is not obvious, must con-
tain instructions for use. The current regulations for the information the manufacturer of 
a medical device must provide in the label of the device and in the instructions for use are 
stated in the MDD Annex 1. The FDA labeling regulations can be found under 21 CFR 
Part 801. The terms label and labeling are similar, but according to the US FD&C Act, 
Section 201(k), there is a difference between them. The Act defines that the term label 
refers to written or printed information on the device or on its packaging, and labeling 
refers to the full collection of device related labels and documentation, including those 
that might not be part of the device or its packaging. 
The MDD Annex 1, section 5, states that the devices must be designed, manufactured and 
packed in such a manner, that their characteristics and performances are not altered or 
adversely affected during their intended use as a result of transport and storage. The An-
nex 1, section 8, specifies the requirements for infection and microbial contamination 
control as it relates to packaging.  
An essential standard to the development and validation of a packaging system for a ster-
ile medical device is the ISO 11607: Packaging for Terminally Sterilized Medical De-
vices. ISO 11607 Part 1 contains the requirements and test methods for materials, pre-
formed sterile barrier systems, sterile barrier systems and packaging systems, and ISO 
11607 Part 2 contains the requirements for development and validation of processes for 
packaging medical devices that are terminally sterilized. (Nolan, 2004). The ISO 11607 
is also an FDA’s Recognized Consensus Standard (FDA, 2015). It is applicable in all 
facilities where medical devices are packaged in sterile barrier systems and sterilized, but 
it does not cover all the requirements concerning sterile barrier systems and packaging 
systems for aseptically packaged medical devices. (ISO 11607, 2006) The informative 
document ISO/TS 16775:2014 provides guidance for the application of the requirements 
in the ISO 11607-1 and ISO 11607-2 standards. Another important standard for termi-
nally sterilized medical devices is the EN-868 Packaging for terminally sterilized medical 
devices. It provides specific requirements for many kinds of medical packaging, for ex-
ample sterilization wraps, paper, paper bags, pouches and reels, paper for low temperature 
sterilization, adhesive coated paper, containers, nonwoven (uncoated) and nonwoven (ad-
hesive-coated).  
 Packaging of sterile biodegradable implantable medical de-
vices 
Problems with traditional permanent implants – such as long term compatibility, possible 
migration, breakage, material reactions, and revision and removal surgeries - has led to 
development of biodegradable implants and devices. Non-permanent, biodegradable im-
plants offer an alternative for patients, as they provide temporary support, and degrade in 
the body at a rate matching new tissue formation, thus removing the need for secondary 
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surgeries. Sutures, orthopedic fixation devices, tissue engineering scaffolds, dental im-
plants, tissue staples, skin covering devices, and drug delivery devices are examples of 
commercially available biodegradable devices. (Amini et al, 2011; Bernkopf, 2007)  
Biodegradable polymers can be of natural origin or synthetic, and they degrade through 
hydrolysis or enzymatic degradation. A variety of biodegradable polymer groups have 
been developed, such as poly(α-esters), polyphosphanezes, and polyurethanes. The most 
studied synthetic biodegradable polymers are poly(α-esters); PGA, PLA, and their copol-
ymer PLGA. Also polydioxanone (PDO), polycaprolactone (PCL), polyhydroxybutyrate 
(PHB), and polyhydroxyvalerate (PHV) have been accepted for use in biodegradable 
medical devices. Also natural biodegradable polymers like chitosan, silk and starch, as 
well as biopolymers like collagen, elastin and hyaluronic acid have been used in devel-
oping biodegradable implants. (Amini et al, 2011)  
Over the last decade, biodegradable metals have also emerged as an alternative to biode-
gradable polymers. Biodegradable metals degrade gradually in the body by corrosion, to 
eventually dissolve completely as the tissue they have been assisting has healed. The cor-
rosion of a biodegradable metallic device generally proceeds by an electrochemical reac-
tion with an electrolyte. Biodegradable metallic devices can be classified as pure metals, 
consisting of only one metallic element; biodegradable alloys, metals with varying mi-
crostructure and at least one alloying element; and biodegradable metal matrix compo-
sites, with all biodegradable components and the major component being a biodegradable 
metal. Metals that have been most investigated for biodegradable applications are mag-
nesium and its alloys, and iron and its alloys. Also other metals, like wolfram, zinc and 
its alloys, and calcium- and strontium based biodegradable metals have been studied. The 
development of biodegradable metallic devices is still in the early stages and they are not 
yet commercially available, but they can potentially be adopted for applications like car-
diovascular stents, bone implants, and wound closing devices in the future. (Zheng et al, 
2014) Since biodegradable metals are only at early research stage, they are not further 
discussed in this thesis.  
In addition to the packaging requirements for sterile implantable devices, discussed in the 
chapter 5.1, biodegradable implantable devices have special features that need to be con-
sidered when designing their package. Biodegradable devices are hydrolytically unstable, 
thus even a small amount of moisture can cause degradation during the storage of the raw 
materials, during the device manufacturing process, and during the storage after the de-
vice fabrication. (Bernkopf, 2007) Therefore, biodegradable devices have to be packaged 
as quickly as possible after fabrication, usually under an inert atmosphere or vacuum. 
Double bagging is generally used, and the bag material must be very resistant to water 
permeability – most often a polymer material or foil. Biodegradable devices are typically 
stored in a freezer to minimize the effect of moisture, but the packaged product should 
always be at room temperature when opened to avoid water condensation. The handling 
of the device at ambient conditions should be kept at minimum; however, studies have 
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shown that biodegradable polymeric devices can remain stable also at room temperature 
for over two years, as indicated by molecular weight retention, when packaged in desic-
cated moisture proof bags. The final packaging solution for a biodegradable implantable 
medical device should be an air-tight moisture proof container. (Middleton & Tipton, 
2000) Biodegradable devices degrade fully in the body, therefore it is necessary that the 
complete product is sterilized before the application. It may sometimes be challenging to 
find a suitable sterilization method, because most biodegradable polymers are also sensi-
tive to high temperatures. (Bernkopf, 2007)   
 Packaging of advanced tissue engineering products 
Advanced tissue engineering products, combination devices, impose new challenges on 
packaging technology by adding complexity to the packaging system, and creating chal-
lenges with self-life stability, solvent loss, moisture and oxygen protection, and package 
testing. Also additional package qualifications may be needed, similar to pharmaceutical 
products. (Crosby, 2008) The practice of aseptic processing of solid combination devices 
has only recently been considered. Thus far, combination products with the device as the 
primary mode of action have most often been sterilized using end sterilization. However, 
the application of end sterilization to combination devices is also limited due to material 
compatibility issues. Therefore, as the combination product market continues to expand 
and evolve, so does the need for new applications of end sterilization solutions. (Lambert 
et al, 2011) 
CTTs typically fall into one of the following categories (Crosby, 2008): 
 Physically or chemically combined into one entity 
 Co-packaged 
 Separately provided cross-labeled products 
 Separate investigational products with proposed cross-labeling 
The key component of packaging of CTTs is the barrier protection. Moisture barrier pro-
tection is found in a few rigid plastic tray packaging applications. The best known tech-
nology is a clear poly-chloro-tri-fluoro-ethylene film, Aclar, laminated on PVC or poly-
ethylene terephthalate (PET). The thickness of the Aclar structure depends on the targeted 
moisture vapor transmission rate, but it is usually between 0.015 – 0.075 millimeters. 
Aclar/PVC structures are common in pharmaceutical industry, whereas Aclar/PET struc-
tures are a growing area in combination products and biologics. Aclar laminate, however, 
has a limited draw depth, thus thermoformed trays with Aclar laminate can be no deeper 
than 2.54 centimeters (one inch). (Crosby, 2008) 
Another moisture barrier option for CTTs is a co-extrusion that utilizes cyclic olefin co-
polymers as a core, covered with either PET or PP, a technology that is developed spe-
cifically for the combination product market. Due to the co-extrusion technology, the 
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draw depth is up to 12.5 centimeters allowing more variation in package size. The cyclic 
olefin copolymer core is typically 0.13 – 1.02 millimeters thick, depending on targeted 
moisture vapor transmission rate. Cyclic olefin copolymer is an amorphous material with 
good clarity properties, and it can be sterilized by irradiation and EtO. (Crosby, 2008) 
Moisture vapor and oxygen transmission rates of various packaging films are presented 
in the next chapter.  
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6. PACKAGING SOLUTIONS FOR STERILE BIO-
DEGRADABLE IMPLANTABLE MEDICAL DE-
VICES 
As discussed in the previous chapter, biodegradable medical devices are hydrolytically 
unstable, thus they need to be packaged in an air-tight, moisture proof container. The 
packaging material in contact with the device, the primary packaging, must be non-toxic. 
Biodegradable implants are delivered sterile; therefore they need to be either terminally 
sterilized or aseptically processed. Packaging has to provide a sterile barrier and protec-
tion of the product to ensure the product’s integrity all the way to the end user. The sec-
ondary packaging that is not in direct contact with the product, offers further protection, 
a way to display the product as desired, as well as functions as a means of communication. 
The compatibility of the product and the packaging materials with the chosen sterilization 
method has to be confirmed. Different sterilization methods and aseptic processing are 
reviewed in chapter 7. Biodegradable devices are often packaged under an inert atmos-
phere or vacuum to remove air-containing moisture, and double packaging is generally 
favored. In this chapter multiple packaging solutions that are, or could be, suitable for 
sterile biodegradable tissue engineering products are presented.  
Typical materials for sterile barrier systems are plastic films, coated or uncoated papers, 
and non-wovens. Key properties for sterile barriers are impermeability for films, or the 
microbial barrier for porous materials, biocompatibility, physical and chemical proper-
ties, compatibility with the manufacturing and sterilization processes, and stability after 
sterilization. Common sterile barrier packaging formats are pre-formed custom trays with 
die-cut lids and premade bags and pouches. (Sterile Barrier Association, 2013b) 
Moisture barrier materials can be selected from plastics, metallized plastics, laminated 
metal foil/plastic composites, or welded metal foils. Plastic materials, however, do not 
usually have good barrier properties for both water and oxygen. Therefore composite 
films are commonly used. (Morgan Advanced Materials GmbH, 2014)  The barrier film 
structure is typically a laminated multilayer. Functional layers enable property tailoring 
such as formability, mechanical strength, oxygen and water vapor barrier properties, as 
well as heat sealing. Multilayers also enable the use of thinner films without compromis-
ing security, thus giving cost benefits. (Cleanroom Technology, 2014) Aluminum foil is 
usually the best option for metal foil barrier packaging due to its ductility, availability, 
and cost. Two properties are typically reported for all barrier materials: Water Vapor 
Transmission Rate (WVTR; g/m2/24h) and Oxygen Transport Rate (OTR; cm3/m2/24h). 
(Morgan Advanced Materials GmbH, 2014) Table 11 presents the OTR and WVTR val-
ues for several flexible packaging films.  
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Table 11. Oxygen and water vapor barrier properties of several flexible packaging films. 
(DuPont Teijin Films, 2001) 
Film type 
Thickness 
(µm) 
Oxygen transmission 
cm3/m2/24h                        
(100% O2, 25 °C, 45% RH) 
Water vapor transmission 
g/m2/24h  
(38 °C, 90% RH) 
Mylar® polyester 12 140 40 
Metallized Mylar® 
(OD3) 
12 0.5 <1 
Polyvinylidene (PVdC) 
coated polyester 
15 6 14 
Cellulose (plain) 22 8-130 (depends on moisture) 3,500 
Nitrocellulose coated 
cellulose 
30 10 12 
PVdC coated cellulose 28 8 5 
LDPE 25 8,000 18 
HDPE 25 3,000 9 
Ethylene vinyl acetate 25 10,000 70 
Propafilm™ C28 28 10 5 
Propafilm™ CR 26 25 4 
Propafilm™ MG 20 2,200 7 
Propafoil™ (metal-
lized) 
25 100 1.5 
Cast PP 25 4,200 12 
Cast nylon 50 140+ (depends on moisture) 35 
Cast nylon 66 30 80+ (depends on moisture) 180 
Oriented nylon 6 15 45 (depends on moisture) 260 
EVAL™ F 20 0.2 (depends on moisture) 75 
EVAL™ E 20 1.8 (dependant) 29 
PVC (plasticized) 20 2,000+ (depends on moisture) 200+ 
PVC (rigid) 20 260 60 
PVdC (extruded) 20 3 5 
PS (oriented) 25 2,500+ 170 
Nitrile barrier resin 20 16 120 
Aluminium foil 9 0+ (depends on pinholes) 0+ 
 
In addition to the films listed in table 11, for example biaxially-oriented polyvinyl alcohol 
(BOPVA) and biaxially-oriented PP (BOPP) have good barrier properties against oxygen 
and moisture, and therefore they are widely used to food- and pharmaceutical packaging 
materials. For both BOPVA and BOPP the transmission rates are dependent on moisture 
and temperature. (Mo et al, 2014) Recently new ultra-high barrier films that utilize nan-
otechnology have emerged. Tera-Barrier Film Pte, Ltd has developed a novel transparent 
micro-pore-plugging film that claims to offer 10 times better moisture barrier than tradi-
tional transparent barrier films. Traditional films commonly have pinholes, cracks and 
grain boundaries that affect their barrier performance. The ultra-high barrier film plugs 
the defects at nanoscale with reactive and non-reactive nanoparticles that also react with 
and retain moisture and oxygen. Traditionally used aluminum foil also has excellent bar-
rier properties, but compared to the ultra-high barrier film it has some disadvantages: it 
has an energy-intensive manufacturing process, it is not transparent, it is not stretchable, 
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and it cannot be use for packaging that has to go through metal detection or radio-fre-
quency identification integration, for instance. (Lingle, 2014) 
 Bags and pouches 
Bags and vented flexible packaging are frequently used for packaging of medical devices, 
primarily due to their low costs and suitability for high profile items (figure 7). 
 
 
Figure 7. Above left: SteriVent® vented bag by SteriPak. Above right: QSEAL® pouches 
by QTS.  Below left: Header bags by SteriPak. Below right: Laminated foil pouch by 
Schott. 
 Vented bags offer a clean, strong packaging. Vented bags are made of film, and they 
have small windows with breathable patches made of paper or Tyvek®, that enable gas 
sterilization. Tyvek® is a thin nonwoven olefin fibre fabric developed by DuPont. It is 
breathable, waterproof, and tear resistant. Header bags are also made of plastic, but in-
stead of breathable patches, there is a peelable paper on Tyvek® strip on top of the bag. 
Header bags are also suitable for aseptic presentation, whereas vented bags are not. Flex-
ible non-formed pouches can be flat or gusset pouches and they are usually used for single 
use items, such as catheters and tubing. Flat pouches are made from two webs and sealed 
along the perimeter. Flat pouches with the right material combination can be sterilized by 
all commercial sterilization methods. If non-permeable materials are used, sterilization 
options are limited to radiation or under controlled conditions, steam. In gusset pouches 
one web is gusseted on the sides or the bottom to make the pouch more suitable for higher 
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profile products. Flexible pouches provide a sterile barrier, the ability to withstand steri-
lization, and when properly designed, easy opening function. Different peel pouches can 
be run on form-fill-seal machines. (Bix & De La Fuente, 2009) The product should be 
immobilized inside the pouch to avoid its free movement and piercing or other damage 
to the pouch material or seal. Pouches are used for packaging of many different kinds of 
items, but due to the lower physical protection qualities, they are generally best suited for 
flat, low bulk products. (Turner, 2011)  
Moisture sensitive items are generally packaged in barrier bags.  There are two primary 
technologies that are used for moisture barrier bags: barriers of aluminum foil, and alu-
minized polymer. Foil/polymer is the oldest barrier technology, where a thin sheet of 
aluminum foil is laminated to nylon or Tyvek®. Aluminized polymer is a newer technol-
ogy in which aluminum vapor is deposited onto polyester. The metal layer is so thin, that 
multiple layers of aluminized polyester can be laminated together, thus voids in one layer 
are covered by another layer. (Beamer, 1997) Examples of moisture barrier pouches are 
presented in figure 8. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8. Above left: Amcor high barrier packaging for medical devices. Above right: 
3M™ Moisture Barrier Bag Dri-Shield 2700 with a humidity indicator card and desic-
cant. Below: Barrier pouches by Oliver-Tolas Healthcare Packaging for packaging of 
sensitive medical, pharmaceutical, biological or combination devices.  
Common film structures for pharmaceutical and biotech packaging are for example: alu-
minum foil – PE (foil thickness ≥ 25 µm); OPA – aluminum foil – PE; Polyesther film – 
aluminum foil – PE; paper – aluminum foil – PE; aluminum foil – heat seal lacquer. 
(Flexifoil Packaging PVT LTD, 2012) Amcor is also offering a metallized heavy gauge 
PP film laminate structure for medical devices and orthopedic devices packaging. The 
metallized PP film laminate provides excellent moisture and UV barrier, yet is more re-
sistant to flex-cracking than aluminum foil laminates and has better chemical resistance 
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due to the film facing sealant. (Amcor Limited, 2016) Also clear plastics without metal 
layers can be used as moisture barrier in some cases, but they offer limited protection and 
are only suitable for very short term dry storage or clean room situations. Even barrier 
bags are not completely moisture proof and over time moisture vapor will leak into the 
bag. Desiccants can be inserted into the bag to reduce the effects of humidity. Also hu-
midity indicator cards with moisture sensitive color-changing chemical spots can be used 
to indicate the relative humidity inside the barrier bag. (Beamer, 1997)  
 Blisters and strip packs 
Blisters are commonly used in pharmaceutical industry for single-dose packaging of tab-
lets and capsules. Blisters packs are also suitable for heavier items, or products with edges 
or corners. Blisters are designed to restrain the product and they have an added advantage 
of presenting the product for the end users in a desired orientation. For example orthope-
dic implants are typically packed in blisters. (Turner, 2011)   
Blister packs compose of a cavity or pocket made from a formable film, commonly a 
thermoformed plastic or cold formed aluminium film, and typically an aluminium foil 
lidding seal. Blister packs can be divided into three types based on the material and prin-
ciple of forming: cold formed aluminium/aluminium blister packs, thermoformed alumin-
ium/plastic blister packs, and aluminium/plastic/aluminium blister packs. Examples of 
the three blister pack types are shown in figure 9. (Jornen Machinery Co., Ltd., 2015) 
 
Figure 9. The three types of blister packs. Left: Cold formed aluminium/aluminium blister 
pack. Middle: Thermoformed aluminium/plastic blister pack. Right: Aluminium/plas-
tic/aluminium blister pack. (Jornen Machinery, Co., Ltd., 2015) 
The three different blister pack types have different protective properties. The general 
advantages and disadvantages of each type are presented in table 12 (Jornen Machinery 
Co., Ltd., 2015). 
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Table 12. Advantages and disadvantages of different types of blister packs. (Jornen Ma-
chinery Co., Ltd., 2015) 
 Advantages Disadvantages 
Aluminium/aluminium 
blister pack 
Nearly complete barrier against 
moisture, gases, and light. Allows 
extended product expiration date. 
Slow speed and high cost production. 
Packaging inspection system compli-
cated due to opaque of the package. 
Higher material costs. 
Aluminium/plastic blis-
ter pack 
Plastic usually PVC; easy to pro-
cess, low cost. Transparent plastic 
enables visual product inspection. 
PVC is a poor barrier against mois-
ture and gases. Not suitable for light 
sensitive items.  
Aluminium/plastic/ alu-
minium blister pack 
Easy and low cost processing. 
Transparent plastic enables visual 
product inspection. Topical alu-
minium foil provides nearly com-
plete barrier against moisture, 
gases, and light.  
The use of topical aluminium foil in-
creases production costs. 
Aluminium/plastic blister packs are generally not suitable for biodegradable applications 
due to the lack of moisture barrier properties. Aluminium/aluminium blister packs and 
aluminium/plastic/aluminium blister packs have excellent barrier properties, and thus 
they are commonly used for packaging of sensitive, hygroscopic pharmaceutical and bi-
opharmaceutical products. Blister pack manufacturers can have a variety of different lid-
ding options available that can provide several opening features for different end-user 
purposes, such as push-thru, peelable, tear-open, and lock-tight. (Winpak, 2014) 
Strip packs differ from blister packs in a way that a strip pack does not have thermoformed 
or cold formed cavities, but the pack is formed around the packaged item. An example of 
a strip pack is presented in figure 10. (Jornen Machinery Co., Ltd., 2015) 
 
 
 
 
 
Figure10. An example of a strip pack. (Jornen Machinery Co., Ltd., 2015) 
Strip packs are usually made of aluminium/PE laminated film, thus they have the same 
moisture, gas, and light barrier properties as cold formed aluminium films. The produc-
tion of strip packs is typically slower than that of thermoformed blister packs. The pack-
aging area of each item is larger in strip packs than in blister packs, because there are no 
pre-formed cavities, thus the strip packs are larger in size than blister packs. (Jornen Ma-
chinery Co., Ltd., 2015) 
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 Tubes and vials 
A dual tube offers an alternative to conventional blister packs and pouches in packaging 
of sterile biodegradable medical devices. For example SoTube™ by Selenium Medical 
has a so called NoTouch configuration, which allows the implant to be presented without 
physical contact. SoTube™ complies with the ISO 11607 and EN 868 standards for sterile 
medical device packaging. The materials used in the tube are biocompatible, and tubes 
are available in different sizes (figure 11). (Selenium Medical, 2016) 
 
 
 
 
 
 
 
 
 
Figure 11. SoTube™ by Selenium Medical in an alternative for blisters and pouches in 
sterile medical device packaging.  
SoTubes™ are transparent, and they have been color coded to make recognition of dif-
ferent implants easier. Also the sleeve of the tube is fully personalizable. SoTubes™ are 
designed to be used in the operating theater. They are also available with the packaging 
service in clean room class ISO 7 and ISO 5, or in separate components. (Selenium Med-
ical, 2016)  
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Vials are available in various sizes and with a broad range of different geometrics, quality 
levels, and controlled surface chemistry. Vials are often made of Type 1 ultra-inert glass. 
Type 1 glass has excellent chemical resistance, neutrality and impermeability. Vials are 
commonly used for packaging of a wide range of injectables, as well as sensitive biotech 
drugs. (Schott AG, 2016) A vial by Schott AG, and a nest and a tub for vials packaging 
are presented in figure 12. Schott vials comply with European, US and Japan standards. 
 
 
Figure 12. Left: A SCHOTT TopLyo® Type 1 glass vial with a hydrophobic coating, de-
signed specifically for a lyophilisation process. Right: Vials can be packaged in a nest, 
which is then placed in a tub. Schott covers the tub with a Tyvek® inlay, and also seals it 
by a Tyvek® seal. The tub is further packed in a header bag and sterilized.  
Cyclic olefin copolymer (COC) is an option for glass, having a transparent glass-like ap-
pearance, but being lighter and more break resistant than glass. COC has also excellent 
barrier properties against moisture, particle level is very low and there is no ion or heavy 
metal release. Schott AG for example uses COC for SCHOTT TopPac® prefillable sy-
ringes. (Schott AG, 2016) 
 Trays and lids 
Thermoformed trays are an ideal packaging choice for irregularly shaped, high-profile 
devices and common for surgical procedure kits. Semi-rigid, structurally self-supporting 
trays provide good physical protection and are suitable for multicomponent kits. Flexible 
trays do not offer the same degree of physical protection as semi-rigid trays, but they are 
appropriate for low-cost devices and simple tray configurations. (Bix & De La Fuente, 
2009) Typical tray styles are a tray with molded lid, a tray with heat sealed lid, and a 
standard tray with undercuts, shown in figure 13. An example of tray for a surgical pro-
cedure kit is presented in figure 14. 
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Figure 13. Typical tray styles. Above left: clear implant tray with molded lid by Brent-
wood Industries Inc. Above right: tray with heat sealed lid by Oliver-Tolas Healthcare 
Packaging. Below: standard long tray with undercuts by Prent Thermoforming. 
 
 
 
 
 
 
 
 
Figure 14. A thermoformed tray for a surgical procedure kit by UFP Technologies.  
A standard tray with undercuts and a tray with molded lid are designed to be used together 
with a pouch that provides a sterile barrier. These tray types do not have molded flanges 
for a heat sealed lid. Standard tray with undercuts and the tray with molded lid are usually 
used for long, narrow items such as catheters. Some kit trays are also designed using these 
styles. A tray with a heat sealed lid has an integral heal-seal flange molded around the 
perimeter of the tray. This type of tray can be used as a single sterile barrier, or it may be 
used with a pouch to provide a double sterile barrier. Typically the lid stock is covered 
with Tyvek®, but also coated papers, nonporous foil laminates and other flexible films 
can be used. (Life Science Outsourcing, 2016b)  
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Common materials used in thermoformed rigid trays are for example PET, polyethylene 
terephthalate glycol (PETG), acrylonitrile butadiene styrene (ABS), and high impact PS 
(HIPS). PET is a clear and rigid polymer and offers excellent gas and moisture barrier 
properties. PET is commonly used in food packaging and soft drink bottles. PETG is also 
clear and tough and easy to process. It is radiation tolerant and withstands many chemical 
sterilization methods without color defects. ABS is light, rigid and moldable, and it is also 
available in conductive and anti-static grades. HIPS is usually used for low cost, high 
volume applications. (UFP Technologies, 2016)   
The use of universal packaging has become more prevalent during the recent years due 
to remarkable cost savings. In universal packaging the goal is to combine as many com-
ponents as possible into one tray. That way, the number of both design and process vali-
dations can be reduced, and fewer sealing tools and lid and carton dies are needed. The 
small clamshell in figure 15 presents an example of a universal packaging that can be 
used in packaging of approximately 300 different implant screws. (Allen, 2013) 
 
 
 
 
 
 
 
 
 
Figure 15. A universal packaging PETG clamshell by Barger that can be used in pack-
aging of approximately 300 different implant screws. The Barger clamshell packaging 
features no sharp edges and is designed to be packaged in a pouch.  
 Applicators 
In case the product is in the form of granules, paste, powder, or a combination of powder 
and liquid, for instance, applicators are an option for packaging. For example BonAlive® 
Biomaterials has applicators for their sterile bioactive glass granules and BonAlive® 
putty, figure 16. 
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Figure 16. Left: Applicator for BonAlive® putty. Right: Applicator for BonAlive® bioac-
tive glass granules on a thermoformed tray. Both by BonAlive® Biomaterials. 
The applicators can be designed in different sizes for different granule and unit sizes. 
BonAlive® applicators are intended to be further packaged in a sterile barrier pouch with 
a thermoformed tray. (BonAlive® Biomaterials, 2015) 
MEDMIX offers unfilled applicators for mixing and delivering multicomponent bio-
materials for various clinical applications, and Nordson MEDICAL has graft delivery 
systems for premixing bone craft materials with intravenous fluids, figure 17. 
 
Figure 17. Right: Applicator system for mixing and delivering biomaterials by MEDMIX. 
Left: OsteoXpress™ Graft delivery device for premixing bone graft materials with intra-
venous fluids by Nordson MEDICAL. 
 Double packaging  
Medical devices for sterile use are often double packaged: the inner package which is 
intended for the sterile field, is placed inside the outer package. Both provide a sterile 
barrier. As mentioned before, operating room nurses generally prefer double packaging 
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because it allows for error and facilitates presentation into the sterile field. (Buntz, 2010) 
Trays are often used in double sterile barrier packaging. Then the inner and outer trays 
are designed to nest together, as seen in figure 18. 
 
 
 
 
 
 
Figure 18. Double trays with an inner and outer tray for double sterile barrier packaging 
of spinal implant products by Orthofix. The material is PETG sealed with coated Tyvek®. 
The product is placed in the inner tray, and the lid is heat sealed in place. The sealed inner 
tray is then placed in the outer tray and the lid is again heat sealed to the outer tray. This 
type of packaging is typically used for orthopedic implants as well as surgical instru-
ments. (Life Science Outsourcing, 2016b) Also double blister packs are commonly used 
in double sterile barrier packaging, as in figure 19. 
 
 
 
 
 
Figure 19. Double Tyvek® peel blister pack for double sterile barrier packaging of sterile 
implants by KLS Martin Group. 
 Cartons and boxes 
Folding cartons and boxes provide secondary protection for individually packaged sterile 
medical devices, as well as multiple unit packs. For multiple unit packs, the carton can be 
designed as a dispenser. The majority of folding cartons used for medical device packag-
ing are custom designed to fit the products, and to enhance the product presentation by 
incorporating the specialized features of the product. The shipping container is a corru-
gated box with a sufficient strength to be used for shipping, sterilization, and storage. The 
inner package has to fit well with the outer box to avoid damage. The most commonly 
used shipping container is the Regular Slotted Container, and it can be used with inner-
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packing materials, such as corrugated inserts, bubble wrap, and rigid or soft foam inserts 
to further protect the product.  (Life Science Outsourcing, 2016) 
The secondary packaging solutions field is also constantly evolving. Manufacturers now 
have a choice of secondary outer packaging from stock medical device packaging options 
(figure 20) to a carton design that is able to play a high-definition video with sound (figure 
21).  
 
 
 
 
 
Figure 20. A turnkey, or “stock” outer carton for medical device packaging by Barger. 
 
 
 
 
 
 
 
 
Figure 21. A carton design with the ability to play a high-definition video with sound by 
Rondo-Pak. 
Stock medical device packaging cartons enable introducing new products to market more 
quickly and with lower costs than custom designed packaging. They will also usually 
require fewer internal resources and lower capital investment from the manufacturer than 
custom packaging. (Barger, 2015) Rondo-Pak’s multimedia carton represents the other 
end of carton designs: Rondo-Pak has introduced a carton that melds print and digital 
content for point-of-use or point-of-purchase messaging. The multimedia carton by 
Rondo-Pak integrates a thin, lightweight, high-definition video screen into a standard or 
custom carton. The video screen can face inwards or outwards. These multi-media cartons 
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can benefit product launches, they can be utilized in physician training kits, patient edu-
cations kits, clinical trials and sales demonstrations, for instance. The video may contain 
instructions for use, additional product information, or for example frequently asked 
questions – in multiple languages. The electronic components are free from lead- , arse-
nic- , and other hazardous materials, and can be removed for disposal. The graphic image 
on the printed carton also contains a digital watermark that enables a consumer to scan it 
with a smartphone to connect directly to web-based digital collateral. (McTigue Pierce, 
2014) 
 Packaging systems 
As defined in chapter 5.1, a packaging system is the combination of a sterile barrier sys-
tem and protective packaging. The configuration of a packaging system depends on the 
product, what kind of protection is needed, the intended end users, the costs, and ecolog-
ical considerations, for instance. Sterile medical device packaging system often consist 
of a double sterile barrier and a protective packaging. Examples of packaging systems are 
presented in figure 22.  
 
 
 
 
 
 
 
 
 
 
 
Figure 22. Top left: Packaging system for stabilization and fracture fixation screw by 
Wright. Top right: Packaging system for a dental implant by Zimmer Dental Inc. Below 
left: Packaging system for Bio-Gide® collagen membrane by Geistlich Biomaterials. Be-
low right: Packaging system for Bio-Oss® bone substitute for regenerative dentistry by 
Geistlich Biomaterials.  
Many medical device companies are nowadays considering how the packaging affects 
the carbon footprint of the product, and for some it has already become part of the design 
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criteria. A double packaging, for instance, can more than double the amount of material 
needed to package the device. Many medical device makers are already using recycled 
PET (rPET) to manufacture secondary packaging in double barrier systems. (Allen, 2013; 
Buntz, 2010) Other ways to reduce the use of packaging materials are down gauging 
(weight reduction), reducing the package density, redesigning the package, or switching 
to another packaging type that requires less use of fossil fuel, produces less CO2 during 
the manufacturing process, and produces less solid waste – such as pouches (Buntz, 
2010). Smaller shipping cartons reduce the need for packaging material, pallet slip sheets 
and shrink wrap, as well as storage space (Gibson, 2011). 
A significant shift towards more sustainable packaging systems in medical device sector 
is yet to happen. Sterilization requirements, safety regulations and biocompatibility are 
all partly to blame. However, the customers’, governments’, and other stakeholders’ in-
creasing interest in the materials and chemicals used in the product and packaging is forc-
ing also the medical device industry rethink its strategy. Sustainability coalition has de-
fined sustainable packaging with eight key criteria (Gibson, 2011): 
A packaging should: 
 Be beneficial, safe, and healthy to individuals and communities through its entire 
life cycle 
 Meet market criteria for performance and cost 
 Be sourced, manufactured, transported, and recycled using renewable energy 
 Optimize the use of renewable or recycled source material 
 Be manufactured using clean production technologies and best practices 
 Be made from materials healthy in all probable end-of-life scenarios 
 Be physically designed to optimize materials and energy 
 Be effectively recovered and utilized in biological or industrial close-loop systems 
 
It is difficult for most manufacturers to meet all the eight key criteria. More important 
would be that manufacturers recognized the whole system perspective; the view of the 
whole lifecycle and entire supply chain. Medical device manufacturers should no longer 
think moving towards more environmentally friendly packaging as a cost, but as an op-
portunity to find cost reductions from reduction in materials used, to lowered transporta-
tion costs. (Gibson, 2011) 
 
 
54 
7. STERILIZATION AND ASEPTIC PROCESSING 
All implantable medical devices must be sterilized prior to their surgical placement (Ath-
anasiou et al, 1996). Sterilization of a product means destroying all microbial life, includ-
ing highly resistant bacterial endospores, by using a physical or chemical procedure. Alt-
hough these procedures are not absolute, a product is considered to be sterile when all the 
parameters of a validated sterilization process have been met. (Patel, 2003) The effective-
ness of a sterilization process is quantified by the probability of a non-sterile unit, and is 
described by the term Sterility Assurance Level (SAL). All implantable medical devices 
are required to be sterilized by a process that achieves a SAL of 10-6, meaning one non-
sterile unit in 1,000,000 units. End sterilization, also known as terminal sterilization, is a 
process where the product is sterilized within its sterile barrier system. End sterilization 
techniques are very efficient, they have a robust process control and they provide a high 
assurance of sterility. (Lambert et al, 2011) The most commonly used end sterilization 
methods for medical devices are based on heat, irradiation, chemicals or a combination 
of these techniques (Athanasiou et al, 1996). These methods, categorized by the means 
of the sterilizing agent, are discussed in the next chapters. 
The FDA has its own system for categorizing sterilization methods in three groups: tra-
ditional, non-traditional and novel non-traditional. According to the FDA, traditional ster-
ilization methods have a long history of safe and effective use demonstrated by validation, 
clearances, and literature. As opposed to the traditional methods, non-traditional sterili-
zation methods do not have a long usage history, and while there is some published data 
and FDA evaluated information on validation of these methods, no FDA-recognized 
standards exist yet. Novel non-traditional sterilization methods category includes newly 
developed methods, which do have neither FDA-recognized standards nor FDA inspec-
tional history, and there is little to no published information on validation. The novel non-
traditional methods have no history of comprehensive FDA evaluation of sterilization 
validation data, and the FDA has not determined the method to be adequate to provide 
assurance of safe and effective use. (Lerouge, 2012) The sterilization methods currently 
placed in these categories are presented in table 13 (FDA, 2008; Lerouge, 2012). 
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Table 13. FDA categories for sterilization methods currently used for medical devices. 
(FDA, 2008) 
Method Sterilization effect based on 
Traditional   
1. Dry heat Heat 
2. Moist heat Heat 
3. Gamma irradiation Radiation 
4. Electron beam (e-beam) Radiation 
5. Ethylene oxide gas (EtO) Chemical 
Non-traditional  
1. Hydrogen peroxide gas plasma Chemical 
2. Ozone Chemical 
Novel non-traditional  
1. Chlorine dioxide Chemical 
2. Ethylene oxide in-a-bag (diffusion or injection   
method) 
Chemical 
3. High intensity – or pulsed light Radiation 
4. Microwave radiation Radiation 
5. Sound waves Radiation 
6. Ultraviolet (UV) light Radiation 
7. Vaporized chemical sterilant systems, e.g. hydrogen 
peroxide and peracetic acid 
Chemical 
Sterilization process can affect the physical and mechanical properties of the device, thus 
affecting its performance in vivo (Athanasiou et al, 1996). Sterilization methods may also 
have an impact on cell proliferation in the sterilized scaffold (Noah et al, 2002). Also the 
integrity of the packaging materials of the device may be affected by sterilization. Some 
packaging materials may not withstand the initial sterilization process, and some are 
known to degrade with time after sterilization, which poses a significant risk to the steril-
ity and integrity of the device. (Simmons, 2012) Due to these facts, it is crucial to select 
a suitable sterilization method (Athanasiou et al, 1996). The AAMI TIR17:2008: Compat-
ibility of materials subject to sterilization - standard provides guidance in the qualification 
of polymers, ceramics, and metals in health care products that are sterilized by irradiation, 
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ethylene oxide (EtO), dry heat, moist heat, hydrogen peroxide (H2O2), and ozone. Besides 
the compatibility and stability of the device and packaging materials, the selection of the 
sterilization method is based on the ability to achieve the desired sterility assurance level. 
Secondary factors to consider are for example costs, availability, and knowledge of use 
and impact on similar products. When selecting a suitable sterilization method, the use of 
standards and guidance documents is recommended, especially if new materials or novel 
sterilization methods are considered. (Lambert et al, 2011) A summary of the sterilization 
methods reviewed in the following chapters is presented in the appendix C. 
 Heat sterilization 
Dry heat sterilization technique use temperatures between 160 – 190 °C for a minimum 
of two hours. The microorganisms are destroyed through heat absorption by conduction. 
(Patel, 2003; Athanasiou et al, 1996) Due to the high temperatures and long sterilization 
time, dry heat sterilization should be used only for materials that might be damaged by 
moist heat, or that are impenetrable by moist heat (McKeen, 2012). Moist heat steriliza-
tion techniques use temperatures between 121 – 148 °C enhanced with high moisture and 
high pressure. The length of the sterilization cycle depends on the temperature and the 
size of the load and ranges between 10 – 60 minutes. Pressure greater than normal atmos-
pheric pressure is needed to increase the temperature of the steam. Microorganisms are 
destroyed by heat and the process is accelerated by moisture; any living organism is killed 
when exposed to saturated steam at 120 °C for over 15 minutes. (Patel, 2003) Moist heat 
sterilization is commonly used whenever possible on all critical and semi-critical heat and 
moisture resistant devices. Steam sterilizers are also used in health care facilities to de-
contaminate biological waste. (McKeen, 2012) Both dry- and moist heat sterilization 
methods are easy to use, cheap, and there are no toxic residues left in the product (Atha-
nasiou et al, 1996).  
Many biodegradable polymers, for example PLA, PGA and PLGA, are susceptible to 
hydrolysis and deformation in high temperatures, thus moist and dry heat sterilization is 
not suitable for this type of materials (Bernkopf, 2007). Also many natural polymers, such 
as collagen, are temperature sensitive, thus heat is not a suitable sterilization method for 
them (Parenteau-Bareil et al, 2010; Noah et al, 2002).The packaging and seal materials 
of the device must also withstand the heat and the high humidity. If moist heat is used for 
sterilization, the packaging materials must be porous for steam to pass through to the 
device. The high temperatures used in this method will deform many plastics, such as 
poly(vinyl chloride) (PVC), polystyrene (PS), polyethylene (PE), and some synthetic fab-
rics. Materials that can tolerate varying temperatures are for example nylon, polypropyl-
ene, oriented polyester, polycarbonate and some grades of high-density PE (HDPE). If 
sterilization temperatures are carefully controlled between 121 °C – 123 °C, also pack-
ages containing Tyvek® may be safely steam sterilized. (Bix & De La Fuente, 2009)  
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Flash sterilization, also called immediate-use sterilization, is used for sterilizing cleaned 
patient care items that cannot be packaged, sterilized and stored before use. Flash sterili-
zation may also be used if there is insufficient time to sterilize an item by the preferred 
packaging method. The sterilization conditions for an unwrapped item are three minutes 
at 132 °C.  The sterilization equipment is often located near operating rooms to handle 
urgent needs. Precautions have to be taken for burn injuries, and the sterilized instruments 
can be cooled by air, or immersing in a sterile liquid. Flash sterilization is not recom-
mended for implantable devices. (McKeen, 2012) 
 Ionizing radiation sterilization 
Irradiation sterilization has become an increasingly popular sterilization method (Lásló, 
2007). The temperature changes in irradiated materials are minimal; therefore irradiation 
may be a suitable sterilization method for many temperature sensitive materials, particu-
larly health care products. Approximately 40 – 50% of disposable medical products are 
radiation sterilized. (Dziedzic-Goclawska et al, 2008) The main sources of ionizing radi-
ation are X-rays, beta particles, gamma rays and high energy electrons (e-beam) (Drobny, 
2012, Patel, 2003). X-rays are mainly used for diagnostic purposes in medicine and in 
certain analytical methods like X-ray microscopy, whereas gamma rays and e-beam are 
commonly used for sterilization (Drobny, 2012). Irradiation can affect some polymers’ 
mechanical and chemical properties, therefore material compatibility has to be consid-
ered. In general, polymers that contain aromatic ring structures are more resistant to radi-
ation effects, compared to aliphatic polymers. Also stabilizers, color correction tints or 
radical scavengers can be used to reduce radiation effects on polymers. (Sastri, 2010) As 
for the sterilization of tissue grafts, the efficacy, and degree of radiation induced damage 
of ionizing radiation is dependent on the sterilization conditions; dose, temperature, pres-
ence or absence of oxygen, as well as the physical state of the samples, such as the pres-
ence or absence of water (Dziedzic-Goclawska et al, 2008).  
Gamma rays are electromagnetic radiation that is emitted from excited atomic nuclei of 
unstable atoms (Drobny, 2012). Figure 23 presents the electromagnetic spectrum and 
gamma rays’ position in it.  
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Figure 23. The electromagnetic spectrum. (Modified from Sastri, 2010) 
Gamma rays penetrate into the matter deeper than beta particles, causing electron disrup-
tion, ionization, on the way. In living cells this ionization causes damage to the DNA and 
other cellular structures, eventually either killing the organism or making it incapable to 
reproduce. The most suitable gamma irradiation sources for medical and industrial appli-
cations are cobalt 60 (60Co), cesium 137 (137Cs) and iridium 192 (192Ir). (Drobny, 2012) 
The radiation dose is usually 25 – 35 kilograys (kGy), depending on the product’s bio-
burden (Hammad, 2008; Dziedzic-Goclawska et al. 2008). Gamma irradiation can be 
used for sterilization of various materials and devices due to its high penetrating power. 
The sterilization process leaves no radioactive residue in the materials. The process itself 
is continuous, fully automated and only one process variable, exposure time or dose, 
needs to be controlled. (Hammad, 2008) 
Ionizing radiation can have a significant effect on polymers, particularly doses above 35 
kGy may induce degradation of the polymer chain, resulting in reduced molecular weight, 
altered mechanical properties, and degradation profile (Bernkopf, 2007). Some polymers 
may also discolor or embrittle due to ionizing radiation. (Athanasiou et al, 1996; Bix & 
De La Fuente, 2009) Even low-dose gamma irradiation may alter molecular structure and 
significantly decrease mechanical and enzymatic resistance of collagen, causing acceler-
ated degradation (Parenteau-Bareil et al, 2010; Noah et al, 2002). Some studies also show 
decrease in cell proliferation in gamma irradiated cells (Noah et al, 2002). To prevent 
heating to the critical temperature during the sterilization process, and thus the effect to 
the molecular weight of the polymer, the product can be cooled to 0 °C or less during 
irradiation by placing commercially available cooling agents in the irradiation container. 
Many biodegradable product manufacturers use gamma irradiation in controlled temper-
atures as the preferred sterilization method. (Bernkopf, 2007)  
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Since radiation sterilization does not require gas porous materials, for example aluminium 
pouches (Bernkopf, 2007) and all-plastic film packaging are suitable for this sterilization 
method. Also Tyvek® is suitable for both gamma and e-beam radiation sterilization due 
to its high-performance properties and radiation resistance. Although radiation steriliza-
tion can affect other packaging materials, for instance some papers may yellow. (Athana-
siou et al, 1996; Bix & De La Fuente, 2009) 
Ultraviolet (UV) radiation is the part of the electromagnetic spectrum between visible 
light and X-rays (figure 23). The specific wavelength area of the UV spectrum between 
240 – 280 nm, also known as UVC irradiation, has a strong germicidal effect, with the 
peak effect at 265 nm. UV irradiation kills microorganisms by penetrating through cell 
membranes and damaging the DNA or RNA, thus making microorganisms unable to re-
produce. The energy dosage of UV radiation needed to kill 99% of the microorganisms 
varies from 2500 µJ/cm2 (Bacillus megaterium species bacteria) to 440 000 µJ/cm2 (To-
bacco mosaic virus). UV sterilization is used in various applications, such as food, water 
and air purification, medical sanitation and sterile work facilities. (McKeen, 2012)  
UV irradiation does not leave toxic residues in sterilized items, and it does not alter the 
chemical composition, taste, odor, or pH of the product. (McKeen, 2012) However, also 
UV radiation has been reported to degrade some polymers, such as PE and polypropylene 
(PP) (Fischbach et al, 2001). Polymers such as polytetrafluoroethylene (PTFE), polyvi-
nylidene fluoride (PVDF), fluorinated ethylene propylene (FEP), and polyether ether ke-
tone (PEEKTM) have a good resistance to UV irradiation. The only plastics with excellent 
resistance are the imides, polyimide (PI) and polyetherimide (PEI). (Cole-Parmer Instru-
ment Company LLC, 2006) Glass containers are essentially UV opaque, but quartz is 
transmissive in both visible and UV light (Xenon Corporation, 2015). 
Fischbach et al. studied the effects of UV irradiation on spin-cast films made of biode-
gradable poly(D,L-lacti acid)-poly(ethylene glycol)-monomethyl ether diblock copoly-
mers (Me.PEG-PLA). They found that after 2 hours’ exposure to UV irradiation - which 
is sufficient for sterilization - cell adhesion to polymer films, polymer film topography, 
and chemical composition were maintained, as compared to non-irradiated films. Fisch-
bach et al. emphasize that the sterilization time must be carefully controlled, however, 
since 5-24 hours’ exposure lead to dramatic changes in polymer properties and biological 
interactions. 
Wekhof et al. (2001) showed that pulsed UV light can provide effective sterilization 
without any UVC component, utilizing only UVA and UVB light. The sterilization effect 
in pulsed UV light is based on a targeted and momentous overheating that ruptures the 
micro-organisms. This method is fast, it has low operating costs, and items can be exposed 
through clear packaging. However, the treated media must be transparent to UV light and 
shadow effects must be avoided. According to Wekhof et al., pulsed UV light can be used 
for sterilization of clear packaging, medical tools, and surfaces, for example. In general, 
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pulsed UV light is suitable for all applications that can utilize continuous UV mercury 
vapor arc lamps. Material compatibility depends on the exposure dose, and generally ma-
terials with known UV transmission characteristics are good candidates for packaging 
materials. The FDA has approved the method for sterilization of food in 1999. (Xenon 
Corporation, 2015) 
Infrared radiation (IR, figure 23) has been used to inactivate bacteria, spores, yeasts and 
molds in liquid and solid food products. IR is also inactivates enzymes. The efficacy of 
IR sterilization depends on various factors: IR power level, sample materials, sample 
depth, moisture content of the sample, temperature of the sample, peak wavelength, band-
width of the IR heating source, and types of microorganisms present. The advantages of 
the IR sterilization are short cycle time, low energy consumption, no toxic residuals in 
the product and it has no environmental effects. IR technology may provide an alternative 
sterilization method for heat resistant devices, but there are no FDA cleared systems yet 
for sterilization of health care products. (McKeen, 2012) 
Microwaves are radio frequency waves that are usually used at the frequency of 2450 
megahertz (MHz) (figure 23). Microwaves produce an alternating electrical field that af-
fects to water molecules and creates friction between them. The intermolecular friction 
generates heat. It has been reported that microwaves are an effective microbicide, but it 
is still debatable whether the sterilizing effect of microwaves is based on the produced 
heat, or on a non-thermal effect. In medicine microwaves are used for disinfecting for 
example contact lenses, dental instruments, urinary catheters, and milk. Due to the pro-
duction of heat during the process, only materials that do not melt are compatible with 
this method. FDA has not cleared the use of microwaves in sterilization of medical de-
vices. (McKeen, 2012)  
Another radiation source is high energy electrons (e-beam). E-beam is created in a vac-
uum by a heated cathode. The electrons are emitted from the cathode and then accelerated 
in an electrostatic field that is applied between the cathode and anode. The energy gain 
of the electrons is expressed in electron volts (eV) and it is proportional to the acceleration 
voltage. When an e-beam enters a material the energy of the accelerated electrons de-
creases significantly due to the large number of interactions between the electrons and 
the material. The accelerated electrons transfer their energy to the material through two 
types of interactions: in collision of electrons which results in material ionization and 
excitation, and in interaction with atomic nuclei that leads to the emission of X-ray pho-
tons. (Drobny, 2012)  
E-beam sterilization has a much faster throughput rates than isotope radiation sources, 
delivery of the same dose of radiation lasts a few hours with gamma rays, but only minutes 
with e-beam. E-beam sterilization is cost effective and it can be integrated into an in-line 
process. The process does not involve volatiles or toxic chemicals, thus irradiated mate-
rials do not need to be aerated after the process. Also the absence of radioactive materials 
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makes the e-beam process often more acceptable within the public. The energy used for 
sterilization is typically 10 MeV which results to penetration of 38 mm in one-sided irra-
diation. (Chmielewski et al, 2008) Due to the poor penetration capability, larger e-beam 
sterilized items have to be irradiated from multiple sides to ensure complete sterilization 
(Massey, 2004). E-beam irradiation, similar to gamma irradiation, induces collagen deg-
radation resulting in loss of mechanical and enzymatic resistance (Parenteau-Bareil et al, 
2010). Cooling cannot be used in e-beam sterilization process. The presence of cooling 
agents in the irradiation container may lead to radiation shading during sterilization with 
accelerated electrons; radiation absorbs because of the high density of the material, thus 
leading to incomplete radiation of the neighboring product. Similar effect has not been 
observed with gamma irradiation. (Bernkopf, 2007)  
A comparison between gamma- and e-beam radiation sources is presented in Table 14. 
Table 14. Comparison of sources of gamma- and e-beam radiation. (Modified from 
Drobny, 2012) 
Characteristics Source of radiation 
 Gamma rays Electron beams 
Power source Radioactive isotope Electricity 
Power activity Half-life 5.27 years Electrical on-off 
Properties Photons (1.25 MeV) 
λ = 1.0 x 10-3 nm 
Electrons 
m = 9.1 x 10-31 kg 
Charge None 1.60 x 10-9 C 
Equipment Easy to operate and maintain Complicate to operate and maintain 
Emission Isotopic, cannot be controlled Unidirectional; can be scanned and 
bent by magnets 
Penetration Exponential attenuation Finite range, depends on energy 
Source  
Attenuation 
Continuous attenuation, requires regu-
lar addition of source 
No attenuation 
Shielding Continuous operation requires more 
shielding 
Can be switched on and off, less de-
manding on shielding 
Dose rate 10 kGy/h 
2.8 x 10-3 kGy/s 
360 000 kGy/h 
100 kGy/s 
 
Beta particles are free electrons that are transmitted from a linear accelerator through a 
high voltage electron beam. These accelerated electrons penetrate into matter until they 
are stopped by collisions with other atoms that are ionized in the impact. The sterilization 
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effect is based on the secondary electrons produced by the collisions and the sterilization 
efficiency depends on the density and thickness of the object, as well as the energy of the 
accelerated electrons. (Patel, 2003) Beta radiation is used in industrial applications, such 
as gauging. For example plastic film thickness or paper thickness can be monitored in 
process with beta particles. Also different types of coating thicknesses can be measured. 
Medical applications include radiotherapy with different beta radiation sources for cancer 
treatment, and treatment of other medical conditions, such as arthritis. (World Nuclear 
Association, 2014)  
Oliveira et al. (2005) have studied the effects of beta radiation on different starch-based 
biomaterials. According to them the advances in electron beam technology has made beta 
radiation a worthy competitor to traditional gamma irradiation. The penetration power of 
beta radiation is lower than in gamma rays, which is less damaging to materials’ mechan-
ical bulk properties for example in biodegradable polymers. With starch-based biomateri-
als, beta radiation was found to increase hydrophilicity in studied polymers, but did not 
significantly affect the mechanical properties. Beta radiation is less damageable to colla-
gen than gamma irradiation, but the applicability finally depends on the type of the col-
lagen based biomaterial produced (Parenteau-Bareil et al, 2010). 
Atmospheric plasma created by electrical discharge of a gas has been investigated during 
recent years as a potential physical agent for sterilization and biological decontamination. 
Low temperature radio frequency (RF) plasma sources at atmospheric pressure have 
been developed for practical applications for industry. As the process occurs in atmos-
pheric pressure, processing and treatments can be implemented continuously, without the 
costly vacuum equipment. Hong et al. (2009) studied inactivation efficiency of low tem-
perature plasma below 70 °C, based on helium gas mixed with different concentrations 
of oxygen. They used electrical power supply with a frequency of 13-56 MHz for the 
generation of low temperature plasma at atmospheric pressure. According to Hong et al., 
low temperature RF plasma method destroys microbes by disrupting cell envelopes, thus 
releasing cellular components and leading to loss of cell viability. They also concluded 
that the method is fast, and it can potentially be used to destroy bacterial cells, including 
spores, on contaminated surfaces. 
 Chemical sterilization 
Ethylene oxide (EtO) gas is a chemical that kills microorganisms and spores. The steri-
lization effect is a combination of humidity, EtO gas, temperature and time. EtO sterili-
zation process does not require very high temperatures, usually in the range of 50 – 60 
°C, but moisture is needed to facilitate microbial kill. Therefore products must be exposed 
to a humid environment before EtO exposure. Humidity and EtO gas are driven into the 
products using vacuum cycles. The process is time consuming, the total sterilization cycle 
times vary from 6 hours to several days. (Lambert et al, 2011) The sterilization effect is 
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temperature dependent and based on a chemical reaction: alkylation of nucleic acid com-
plexes, proteins and enzymes. (Massey, 2004) To reach the effect, EtO gas must be di-
rectly in contact with microorganisms on the items. EtO gas is highly flammable and 
explosive in air, thus explosion proof, environment controlled sterilization chamber is 
needed. (Patel, 2003) Due to its flammability, EtO is often diluted with fluorocarbon 
gases or carbon dioxide (Massey, 2004; Rutala & Weber, 2013). EtO sterilization can 
leave toxic residues to the sterilized items, therefore sterilized items need to be aerated 
after sterilization (Patel, 2003). A complete removal of residual traces of EtO is difficult 
to achieve in products with large surface area, such as meshes, warps, and wovens (Bern-
kopf, 2007). Despite these down sides, EtO sterilization covers about 50% of the indus-
trial end sterilization market (Lambert et al, 2011).  
As EtO is chemically highly reactive, it can act as plasticizer for biodegradable polymers 
causing changes in the polymer structure. In addition, the processing temperature is still 
too high for many biodegradable polymers. (Bernkopf, 2007) However, EtO seems to be 
less damageable to for example collagen than gamma irradiation, and it has been the most 
used method for sterilization of collagen scaffolds (Parenteau-Bareil et al, 2010; Noah et 
al, 2002). EtO sterilization doesn’t seem to have a significant effect on cell proliferation 
(Noah et al, 2002). As for the packaging materials, the higher temperatures, pressures and 
humidity during the EtO sterilization process can cause package stress and loss of seal 
integrity that appears in the form of seal fatigue or sterilizer creep. Packaging materials 
suitable for EtO sterilization should be porous, moisture and EtO tolerant, have hot adhe-
sive strength and be broadly compatible with chemicals and products. (Bix & De La 
Fuente, 2009) 
Ozone sterilization is an alternative to EtO gas sterilization. Ozone gas is a strong oxi-
dizer with a characteristic odor, and it chemically alters and inactivates various chemical 
and microbiological contaminants. Ozone is produced from energized oxygen that splits 
into two monoatomic molecules which then collide with oxygen molecules (O2) to form 
ozone (O3). Ozone can be produced artificially by the action of high-voltage discharge in 
air or oxygen and it has been used for decades to decontaminate water, and to sterilize air 
and food products. Compared to EtO, ozone is safer to use. Human nose can detect very 
low ozone levels, approximately 0.003 parts per million (ppm), so technical staff can be 
aware of the presence of the gas before it poses a hazard. (Lerouge, 2012) Ozone sterili-
zation can be used for moisture and heat sensitive devices. There is no published data yet 
available about material compatibility, penetrability and organic material resistance, and 
only limited data on microbicidal efficacy. The FDA has however cleared the method for 
metal and plastic instruments, including some instruments with lumens. (Rutala & Weber, 
2013)  
Hydrogen peroxide (H2O2) is a known antimicrobial agent that destroys microorganisms 
and inactivates resistant spores by oxidizing key cellular components (Patel, 2003; Sul-
tana, 2007). H2O2 does not have odor, irritation, or disposal issues. It does not have a 
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blood coagulating effect and it does not fix tissues to surfaces. H2O2 may enhance removal 
of organic matter and organisms. There are some functional and cosmetic material com-
patibility issues, mainly with metals like brass, zinc, copper, and nickel/silver plating. 
H2O2 causes serious eye damage with contact, so operators must follow safety precau-
tions. (Rutala & Weber, 2013) H2O2 is also utilized in vaporized H2O2, and H2O2 gas 
plasma systems, as described in the next chapters. 
Vaporized hydrogen peroxide is safe for both the environment and the operator. It 
leaves no toxic residues so aeration of the products after sterilization is not needed. The 
sterilization process is fast; the cycle time is about 55 minutes. (Rutala & Weber, 2013) 
During the process vaporized H2O2 is injected into the sterilization chamber via series of 
pulses. The operating temperature is 30 – 40 °C and the method is suitable for many heat 
and moisture sensitive metal and nonmetal devices. (Patel, 2003; Rutala & Weber, 2013). 
Material compatibility, however, has to be considered; liquids, linen, powders or any cel-
lulose materials are not compatible with this method, and it also requires a synthetic pack-
aging (e.g. PP). There are also restrictions based on the internal diameter and length of 
the sterilized devices. Materials compatibility data for this method is still limited as is the 
data of clinical use and comparative microbicidal efficacy. (Rutala & Weber, 2013) A 
commercially available vaporized H2O2 system by the STERIS Corporation, the Amsco® 
V-PRO® maX Low Temperature Sterilization System, received an FDA approval in 2011 
(Schneider, 2013). 
Hydrogen peroxide gas plasma uses H2O2 that is activated to form a reactive plasma or 
vapor. Plasma is ionized gas consisting of ions and electrons and it can be distinguished 
from solid, liquid and gas, thus often referred to as the fourth state of matter. (Patel, 2003) 
H2O2 plasma sterilization is suitable for heat and moisture sensitive items, since it uses 
operating temperatures below 50 °C and the process happens in a low moisture environ-
ment. The cycle time is from 30 minutes to 4 hours, depending on the size of the system 
(Patel, 2003; Massey, 2004; Rutala & Weber, 2013). The method is non-toxic and it has 
negligible environmental effect; the by-products are water vapor and oxygen, thus there 
is no need for aeration or ventilation of the products after the sterilization process. The 
process is simple to install, operate, and monitor. (Lerouge, 2012; Rutala & Weber, 2013) 
STERRAD® 100NX® Sterilizer in an FDA approved, commercially available sterilizer 
by Advanced Sterilization Products, that uses low temperature H2O2 gas plasma technol-
ogy (Schneider, 2013). 
Due to the limited penetration ability, H2O2 gas plasma sterilization is considered to be a 
surface sterilization method (Bernkopf, 2007). Poor penetration limits the size of each 
sterilization load and impairs the sterilization efficiency for some devices, especially 
those with a small diameter/length ratio. In addition the STERRAD® sterilization systems 
are fairly costly to purchase and the cost of H2O2 ampoules is also quite high. (Lerouge, 
2012) Finally, the STERRAD® sterilization system is incompatible with several materi-
als: it cannot be used for liquids, powders or strong peroxide absorbers. (Patel, 2003; 
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Massey, 2004) Paper, cotton, cellulose and linen absorb H2O2 thus also being incompati-
ble with this method. Polymers, for example polyacetal and nylons, can be damaged by 
oxidative species produced in the sterilization process. Biomedical devices sterilized by 
H2O2 plasma are practically assured to experience some surface modification during the 
process. H2O2 is a strong oxidizer and plasma is known for its ability to modify surfaces 
through etching, deposition, and other surface modification reactions depending on the 
design and plasma parameters. The surface reactions may affect polymeric surface wet-
tability and adhesion properties. (Lerouge, 2012) This method also requires synthetic 
packaging (e.g. polypropylene wraps, polyolefin pouches) and a special container tray 
(Rutala & Weber, 2013).  
Peracetic acid liquid sterilization is a low temperature chemical sterilization system. The 
sterilizing effect of peracetic acid is based on disruption of bonds in proteins and enzymes. 
It may also affect cell walls and oxidize essential enzymes thus interfering cell membrane 
transportation and impairing essential biochemical pathways. Peracetic acid kills also 
spores at low concentrations. Peracetic acid is water soluble, it leaves no residues in the 
sterilized items after rinsing, and it has no harmful health or environmental effects. (Sul-
tana, 2007)  By-products of peracetic acid sterilization are acetic acid, oxygen and water 
(Rutala & Weber, 2013).   
The items sterilized with peracetic acid must be immersible, quite small in size, and able 
to withstand the 55 °C processing temperature. (Sultana, 2007) With The Steris system 1® 
that uses The Steris 20TM  Sterilant Concentrate the sterilization time is 12 minutes, fol-
lowed by repeated rinses with sterile water. The standard cycle is completed in less than 
30 minutes. (Patel, 2003) Immersing in a low concentration peracetic acid is the most 
common method to sterilize acellular collagen (Parenteau-Bareil et al, 2010). Peracetic 
acid may enhance removal of organic material and endotoxin, and it does not cause blood 
coagulation or fix tissues to surfaces. The limitations of this method include potential 
material compatibility issues, and the method being a point-of-use system, which means 
that the sterilized items cannot be stored sterile. Peracetic acid causes serious skin and 
eye damage with contact, so personnel must follow safety precautions. (Rutala & Weber, 
2013)  
Formaldehyde steam is considered to be a low temperature sterilization method, alt-
hough the operation temperature is approximately 70 – 75 °C. Formaldehyde destroys 
microorganisms by coagulation of proteins in cells. In the process formalin is vaporized 
into formaldehyde gas, formaldehyde concentration being 8 – 16 mg/L. The gas is then 
lead into the sterilization chamber. The sterilization cycle has multiple stages, including 
initial vacuum to remove air from the sterilization chamber, steam admission to the cham-
ber, and pulses of formaldehyde gas followed by steam. Formaldehyde is removed from 
the chamber and sterilized items by repeated alternate evacuations and flushing with 
steam and air. Reliable sterilization is achieved when using high concentration of gas, 
temperatures between 60 – 80 °C, and 75 – 100% relative humidity. The cycle time is 
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shorter than in EtO sterilization, for example, and the operating costs are relatively low. 
Formaldehyde steam has some limitations regarding penetration power, and the process 
temperature is still too high especially for many biodegradable polymers. In addition, 
formaldehyde is a mutagen and potential carcinogen. (Rutala et al, 2008) 
Carbon dioxide (CO2) is used for precision cleaning and disinfecting of medical instru-
ments and devices. It can be utilized in cleaning of polymer and silicone surfaces before 
bonding, coating, or assembly for use in cleanrooms, biomedical devices and aerospace 
applications. (Markarian, 2013) CO2 is a well-known bactericide and number of studies 
has demonstrated its effectiveness on various micro-organisms with several different 
treatment parameters, including temperature, time, pressure and use of additives. Super-
critical carbon dioxide (scCO2) is one of the newer sterilization methods that have been 
reported that utilizes CO2. ScCO2 has been found to be compatible with various biological 
materials, as well as biodegradable 3D scaffolds, and it has formed no toxic residues in 
treated materials. (Simmons, 2012; Bernhardt et al, 2015) The sterilizing effect of scCO2 
is believed to be based on the ability of scCO2 to diffuse readily into the cells and alter 
the pH within the cell. In the presence of water, CO2 will react to produce carbonic acid, 
which further reduces the pH within the cell. Thus even a small amount of water enhances 
the sterilizing effect of scCO2. In the studies, the scCO2 sterilization process has been 
found to be sensitive to three factors: 1) the chemical nature of the cell wall, and cell 
shape (the surface-to-volume ratio, for example) 2) efficiency of contact between the 
scCO2 phase and the solid cell phase, and 3) exposure to water. (Dillow et al, 1999) ScCO2 
is non-toxic and non-reactive, it has high penetration ability, and it is easy to remove from 
sterilized items by depressurization. Due to its non-reactive nature, scCO2 does not alter 
the morphology, structure, or mechanical properties of sensitive polymers. (Bernhardt et 
al, 2015)  
Bernhardt et al. (2015) studied scCO2 sterilization at low temperatures on sensitive bio-
materials, such as polysaccharide-based hydrogels and collagen-based scaffolds. They 
showed that the scCO2 procedure under addition of 0.25% water, 0.15% hydrogen perox-
ide, and 0.5% acetic anhydride was effective against a wide variety of microorganisms 
and bacterial spores, and it was less compromising to the mechanical properties of the 
studied biomaterials compared to gamma irradiation, EtO, and steam sterilization. They 
also compared cytocompatibility of the studied hydrogels and scaffolds after scCO2, 
gamma -, EtO -, and steam sterilization, and found that cell viability and proliferation of 
human mesenchymal stem cells were not compromised by the scCO2 treatment. Accord-
ing to Bernhardt et al, scCO2 is a very effective, cytocompatible, and gentle sterilization 
method, and thus a promising alternative especially for biomaterials. The application of 
scCO2 technology, in combination with peracetic acid as additive, for the sterilization of 
various allograft tissues has been successfully commercialized by NovaSterilis. (Bern-
hardt et al, 2015)  
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Nitrogen dioxide (NO2) gas has shown to induce single strand breaks in microbial DNA, 
thus disrupting cellular functions in a wide range of microorganisms and bacterial spores. 
NO2 has lower oxidation potential than H2O2 and O3. Due to that, NO2 is compatible with 
most polymers used in the manufacturing of medical devices, and also with many bio-
molecules that are not compatible with other sterilization methods. Also many common 
packaging materials, such as nonwoven PP wraps, Tyvek/film peel pouches, and 
Tyvek/plastic trays, are compatible with the NO2 sterilization process, however paper and 
other cellulosic materials are not. The sterilization process does not require heat, but it is 
impacted by humidity; increasing humidity enhances spore inactivation, which is thought 
to be related to the hydration of the spore coat (Schneider, 2013) NO2 sterilization process 
operates in room temperature. The low boiling point of NO2, 21 °C, reduces the sterilant 
condensation on surfaces, thus leading to rapid aeration time at the end of sterilization 
cycle. The possible condensed or absorbed NO2 evaporates faster than for example H2O2. 
NO2 sterilization is an emerging low temperature sterilization method. (Markarian, 2013)  
Commercially available RTS Series NO2 Sterilizers by Noxilizer use NO2 gas in room 
temperature process that takes about two to three hours to complete. Noxilizer’s RTS 
series sterilizers can be installed as an in-house system, and integrated in-line with the 
production. They are effective at low humidity levels, which allows processing of most 
moisture sensitive materials. Example applications are sterilization of drug delivery ap-
plications, cartridge delivery systems, orthopedic implants, prostheses, surface steriliza-
tion with no penetration of closure system and sterilization of moisture and heat sensitive 
items. The RTS series sterilizers are CE–marked under the MDD, and they are classified 
as a non-traditional sterilization method by the FDA. (Noxilizer, 2016) 
Another recently developed sterilization method uses reactive species, such as active ox-
ygen species (AOS) or free radicals generated by a cold plasma apparatus. The active 
oxygen species are generated by photochemical reaction from oxygen using UV irradia-
tion. The inactivation effect of atomic oxygen generated in a low-pressure oxygen plasma 
apparatus has been studied, and it has been confirmed that atomic oxygen exposure pro-
motes the inactivation of microorganisms. The use of AOS has several advantages; low 
processing temperature, dry processing, no residual effects, nontoxic, and low initial and 
operational costs. AOS have a very short lifetime, so there will not be high residual con-
centrations of AOS in sterilized items. (Yoshino et al, 2015) 
 Disinfectants 
Disinfection is a chemical procedure that eliminates practically all recognized pathogenic 
microorganisms, but not necessarily all microbial forms, such as bacterial endospores. 
Three levels of disinfection can be distinguished: high, intermediate, and low. High level 
disinfectants eliminate all organisms, except high level of bacterial spores. Intermediate 
level disinfection kills most viruses and bacteria (including mycobacteria), and low level 
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disinfectant only destroys limited spectrum of viruses and bacteria. (McKeen, 2012) Dis-
infection is usually faster and less expensive than sterilization, but whether a product 
should be sterilized or disinfected depends on its intended use. Critical objects, such as 
implanted medical devices, must always be sterilized before use. Less critical objects, 
such as items that touch only non-intact skin or mucous membranes can be disinfected. 
(Patel, 2003) Other aspects that affect the choice of a suitable disinfection method are 
activity spectrum, compatibility with surfaces and disinfected devices, exposure time, 
costs, and harmful effects on the users, patients or the environment. (Gunaydin et al, 
2014) The presence or organic matter may interfere with the antimicrobial activity of 
some disinfectants. The interference occurs either by a chemical reaction between the 
disinfectant and the organic matter, leading to a complex that is less germicidal, or by 
organic matter acting as a physical barrier, protecting microorganisms from the disinfect-
ant. Thus it is important to thoroughly clean the surfaces before disinfection. (Rutala et 
al, 2008) This chapter presents a brief overview of several disinfection methods.  
Alcohol in a health care setting usually refers to either ethyl alcohol or isopropyl alcohol. 
Alcohols destroy bacteria by penetrating the cell wall and denaturizing proteins and en-
zymes. The optimal bactericidal concentration is 60 – 90% alcohol solution in water (vol-
ume/volume), and the effectiveness drops sharply when diluted below 50%. Although 
ethyl alcohol and isopropyl alcohol are rapidly bactericidal against vegetative forms of 
bacteria, fungicidal and virucidal, they do not destroy bacterial spores. That’s why they 
are not recommended for sterilizing medical and surgical materials. Alcohols may also 
damage plastics, elastomers, and coatings. In health care settings alcohols are used mainly 
to disinfect for example thermometers, scissors, stethoscopes, small surfaces, or medica-
tion preparation areas. (McKeen, 2012) Ethanol immersion with the combination of fun-
gicide and antibiotic is used in laboratory to sterilize collagen scaffolds which have been 
physically cross-linked (Parenteau-Bareil et al, 2010). The FDA has not cleared any liquid 
sterilant or high level disinfectant that has alcohol as the main ingredient (McKeen, 2012).  
Chlorine has been used as a disinfectant to treat drinking water since a 100 years. It is by 
far the most used method for disinfecting water, and its antimicrobial effectiveness has 
been widely assessed. Free available chlorine is an effective biocide against a wide variety 
of bacteria, viruses, fungi, and algae. Regardless of the original source of the available 
chlorine, the biocidal effect is based on hypochlorus acid (HOCl).  HOCl is a weak acid, 
which tends to dissociate in water at increasing pH. (Clasen & Edmondson, 2006) The 
dissociated form of HOCl, the hypochlorite ion (ClO-), is less microbicidal than HOCl, 
thus the disinfection activity of chlorine decreases with an increase of pH. In addition to 
chlorine, also many chlorine compounds – hypochlorites, chlorine dioxide, sodium di-
chloroisocyanurate, and Chloramine-T - are commonly used to disinfect drinking water. 
(McKeen, 2012) All chlorine products have some level of toxicity, hence making them 
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effective microbicides. However, when chlorinated water is ingested, the available chlo-
rine is reduced by saliva and stomach fluid into harmless chloride ion salts. (Clasen & 
Edmondson, 2006) 
Hypochlorites are the most widely used chlorine disinfectants, for example as household 
bleaches, and they are available in both liquid and solid form (McKeen, 2012). Hypo-
chlorites have a wide spectrum of antimicrobial activity. They are also able to remove 
biofilms, and dried or fixed organisms from surfaces. Hypochlorites do not leave toxic 
residues to the sterilized products, they affect fast and they are inexpensive. It should be 
noted that hypochlorites release toxic chlorine gas if mixed with ammonia or acids. 
(McKeen, 2012) 
Chlorine dioxide (ClO2) is an oxidizing liquid agent that is effective against bacteria, 
viruses, yeasts, and molds. ClO2 reacts with several cellular structures, including the cell 
membrane. The sterilizing activity is fast even in relatively low concentrations (1 – 30 
mg/L). (McKeen, 2012) In the sterilization process, a compound of dilute chlorine gas is 
converted with sodium chlorite to form chlorine dioxide gas. The sterilized devices are 
exposed to this gas in the sterilization chamber. The processing time with ClO2 is quite 
long; it takes 6 hours of contact time to achieve sterilization. The antimicrobial activity is 
reduced in the presence of organic matter. ClO2 is corrosive, so this sterilization method 
may have some material compatibility issues. ClO2 must also be generated onsite. (Patel, 
2003) ClO2 is used for sterilizing drinking water, as a sanitation agent in food and bever-
age processing, and in health care facilities to decontaminate rooms and isolators, and to 
sterilize products and components. (McKeen, 2012)  
Sodium dichloroisocyanurate is the sodium salt of a chlorinated hydroxytriazine, and 
like other forms of chlorine, it produces hypochlorus acid, a well-known oxidizing agent. 
Whereas hypochlorites release all of their chlorine as free available chlorine, sodium di-
chloroisocyanurate releases approximately 50%, and the balance remains as reservoir 
chlorine in the form of chlorinated isocyanurates, to be released as the equilibrium is 
disturbed. Until recently, isocyanurates were mainly used for disinfection of swimming 
pool water, in the food industry, and in different cleaning and sanitizing applications, such 
as baby bottles and contact lenses. (Clasen & Edmondson, 2006)  Nowadays they are also 
used for disinfecting drinking water – primarily in emergencies, but also in household 
point-of-use water treatment. Studies have shown that sodium dichloroisocyanurate and 
sodium cyanurate have low acute oral toxicity, and sodium cyanurate does not induce any 
carcinogenic, teratogenic, or genotoxic effects. (WHO, 2008) 
Chloramine-T (N-chloro-4-methylbenzenesulfonamide sodium salt) is an organic com-
pound, generated by chlorinating benzene sulfonamide or para-toulene sulfonamide, and 
it is a potential alternative to the use of chlorine (Sanli-Yurudu et al, 2007). Chloramine-
T inhibits bacterial growth by disturbing bacterial metabolism. Its molecular structure is 
similar to para-aminobenzoic acid, which is an intermediate in bacterial metabolism. 
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Chloramine-T is available in tablets and powder, and it has to be dissolved before use. 
Chloramine-T is mainly used for sterilizing surfaces, where it is sprayed on and allowed 
to stand for 15 minutes or more before wiping off. (McKeen, 2012) Chloramine-T is a 
stable solution that is safe for humans, non-cytotoxic, and biodegradable, but it has a 
minor corrosive effect on common industrial materials, such as stainless steel, aluminum, 
and various polymers (Sanli-Yurudu et al, 2007). 
Superoxidized water has become a widely used disinfectant during the recent years. Su-
peroxidized water is generated by applying an electric current on salty water. After elec-
trolysis the water contains hypochlorus acid, hypochlorite ions, dissolved oxygen, ozone, 
and superoxide radicals. Superoxidized water has a broad antimicrobial activity; it is ef-
fective against bacteria, fungi, viruses and parasites. Superoxidized water does not harm 
tissues, and as non-toxic it is safe for the users, as well as the environment. The usage 
costs are low. Although the antimicrobial activity of superoxidized water is very promis-
ing for surfaces and water disinfection systems, there is still lack of information about 
this disinfectant. (Gunaydin, 2014) There may be material compatibility issues, thus the 
user needs to check with the manufacturer for the compatibility with the disinfectant. The 
FDA has cleared superoxidized water as a high level disinfectant. (Rutala et al, 2008)  
Formalin is water-based solution consisting of 37 weight-% of formaldehyde. Formal-
dehyde destroys microorganisms by alkylating the amino- and sulfhydral groups of pro-
teins, and ring nitrogen atoms in purine bases. Formalin is effective against many bacteria, 
viruses, fungi and spores, but requires a long contact time. Due to the irritating fumes and 
pungent odor, the use of formaldehyde is limited especially in health care settings. For-
maldehyde is also a potential carcinogen, so the handling time and employee exposure 
have to be monitored. Formaldehyde is used for example as an embalming agent, to pre-
serve anatomic specimens, and to prepare viral vaccines. (Rutala et al, 2008) 
Glutaraldehyde is a saturated di-aldehyde that is widely used as a high level disinfectant 
and chemical sterilant. Glutaraldehyde’s aqueous solutions are acidic, and generally not 
effective against bacterial spores. For glutaraldehyde solution to become sporicidal it has 
to be activated, that is, made alkaline. The biocidal effectiveness of glutaraldehyde is 
based on the alkylation of sulfhydryl-, hydroxyl-, carboxyl-, and amino groups in micro-
organisms, leading to the alteration of DNA, RNA, and protein synthesis. Glutaraldehyde 
solutions are widely used in health care facilities due to their biocidal properties, activity 
in the presence of organic matter, and non-corrosiveness. Glutaraldehyde is mostly used 
for disinfecting of medical equipment. It is non-corrosive to metal and does not damage 
lenses, rubber, or plastic. Acute or chronic exposure to glutaraldehyde can cause skin 
irritation, mucous membrane irritation, or pulmonary symptoms, for instance. Thus em-
ployees’ glutaraldehyde exposure should be monitored. The FDA has cleared glutaralde-
hyde sterilants that contain 2.4 – 3.4% glutaraldehyde to be used undiluted. A glutaralde-
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hyde-phenol/phenate concentrate that contains 1.12% glutaraldehyde and 1.93% phe-
nol/phenate at its use concentration has been cleared by the FDA as a high level disin-
fectant. (Rutala et al, 2008) 
Iodophors are combinations of iodine and a solubilizing agent or carrier. The formed 
complex acts as a sustained-release reservoir of iodine that releases small amounts of free 
iodine in aqueous solution. The best known iodophor is povidone-iodine, a combination 
of polyvinylpyrrolidone and iodine. Iodine penetrates the cell wall of microorganisms 
rapidly and the microbicidal effect is believed to be based on disruption of protein and 
nucleic acid structure and synthesis. Iodophors are used as antiseptics on skin and tissues, 
and for disinfecting medical equipment. Iodophors formulated as antiseptics contain less 
free iodine than those formulated as disinfectant, therefore antiseptic iodophors should 
not be used for disinfecting hard surfaces. Iodine and iodine-based antiseptics should not 
be used for silicone materials. (Rutala et al, 2008) 
Ortho-Phthalaldehyde (OPA) contains 0.55% 1,2-benzenedicarboxaldehyde. OPA’s 
microbial affect seems to be similar to glutaraldehyde – interaction with amino acids, 
proteins, and microorganisms. OPA has a lipofilic aromatic nature that is likely to assist 
the penetration through the outer layers of mycobacteria and gram-negative bacteria. OPA 
has several advantages over glutaraldehyde: it is not a known irritant and does not require 
exposure monitoring, it has barely perceptible odor, and it does not need activation. OPA 
has also excellent material compatibility. (Rutala et al, 2008) Disadvantages is that OPA 
stains proteins grey, including unprotected skin, as well as clothing, and environmental 
surfaces. Thus it needs to be handled with care. It also has a slow sporicidal activity and 
the use is more expensive than glutaraldehyde. (McKeen, 2012) OPA can be neutralized 
with glycine before disposal through the sanitary sewer system (Rutala et al, 2008). 
Quaternary ammonium compounds are widely used as disinfectants. They are good 
cleaning agents, but high water hardness and some materials, such as cotton and gauge 
pads, can lessen the anti-microbial activity because of insoluble precipitates, or absorp-
tion of active ingredients, respectively. The bactericidal effect is based on inactivation of 
energy-producing enzymes, denaturation of essential cell proteins, and disruption of the 
cell membrane. Quaternary ammonium compounds are used for environmental sanitation 
of non-critical surfaces, such as floors, furniture, and walls. Certain registered quaternary 
ammonium compounds can be used for disinfecting less-critical medical equipment. (Ru-
tala et al, 2008) 
Phenol has long been used in hospital disinfection, but during the last decades the studies 
have concentrated in numerous phenol derivatives, phenolics, and their antimicrobial 
properties. Phenolics are originated when a functional group, alkyl-, phenyl-, benzyl-, or 
halogen group, replaces one of the hydrogen atoms on the aromatic ring. Two most com-
mon phenolics are ortho-phenylphenol and ortho-benzyl-para-chlorophenol. In high con-
centrations phenol acts as a protoplasmic poison; it penetrates and disrupts the cell wall 
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and precipitates the proteins. In low concentrations phenol and higher molecular weight 
phenolics inactivate essential enzyme systems and cause essential metabolites to leak 
from the cell wall. Phenolics are absorbed by porous materials, and residual disinfectant 
can cause irritation. Many phenolics are used as disinfectants for environmental surfaces 
and noncritical medical devices. (Rutala et al, 2008) 
Surfacine is an antimicrobial agent that can be used for animate or inanimate surfaces. 
Surfacine incorporates a water-insoluble antimicrobial drug compound, silver iodide, 
with a surface immobilized coating, a modified polyhexamethylene biguanide. Microbial 
contact with the surface leads to transfer of silver from the coating to the organism, and 
microorganisms contacting the coating accumulate silver until the toxicity threshold is 
exceeded. (McKeen, 2012)  
Photocatalysis offers another alternative to the traditional surface disinfection methods. 
The disinfection abilities of photocatalytic oxidation on titanium coated surfaces are be-
ing studied for use in many different applications. The biocidal activity of titanium thin 
films attached to solid surfaces has been shown in several studies; organic compounds 
can be oxidized to CO2 by hydroxyl radicals generated on titanium dioxide (TiO2) sur-
faces. The bactericidal effect of TiO2 photocatalysis is believed to be a combination of 
cell membrane damage and further oxidative attack of internal cellular components that 
leads to cell death. Photocatalytic reactions do not require high temperatures, and the 
irradiation source can be various types of visible light, UV-light or fluorescent light, de-
pending on the intended use. The method is safe, nontoxic, ecofriendly, and relatively 
inexpensive, as well as applicable to many different applications. Photocatalysis has been 
used in air and water disinfection, and it is studied for use in food industry, laboratory 
applications, and medical applications, such as biomedical implant surfaces. (Nath et al, 
2012) 
Formic acid has shown to be a potential sterilization agent for collagen (Parenteau-Bareil 
et al, 2010). Formic acid is also used in combination with hydrogen peroxide; the combi-
nation forms a fast acting sterilant against spore-forming bacteria. ASP® has developed 
a system that utilizes the combination in their Endoclens systems, which are designed for 
point-of-use sterilization of endoscopes. Endoclens has a fully automated system and 
rapid cycle time, less than 30 minutes. (Rutala & Weber, 2001) 
 Aseptic processing 
If a medical device is not compatible with any end sterilization technique, and the mate-
rials cannot be changed for more compatible ones, the manufacturer of the device may 
have to aseptically process the device (Lambert et al, 2011). Aseptic processing is a gen-
eral term for a group of technologies that enable sterilized components and products to 
be manufactured under conditions that mitigate contamination risk (Agalloco & Agers, 
2010). Aseptic packaging is usually the last option due to the high manufacturing costs 
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and less robust process control. End sterilized products provide superior patient safety 
compared to aseptic processing, therefore the regulatory bodies prefer end sterilization 
whenever possible. (Lambert et al, 2011) Traditionally aseptically processed products 
have been liquids, powders, or suspensions that cannot be terminally sterilized. Nowa-
days, along with the development of different kinds of implantable medical devices, a 
wider variety of devices are aseptically processed. Examples of medical devices and com-
bination products that typically require aseptic processing are: biodegradable implants, 
artificial and/or non-viable biologically based matrixes, hermetically sealed electrome-
chanical devices, and combination products that include viable cells, such as implants 
coated with drug and/or biologically derived substances. (ISO 13408-7, 2012) 
As opposed to end sterilization, aseptic processes are designed to exclude microbial con-
tamination during the manufacturing process. The final sterile product is achieved over 
several process steps, thus process control over all the possible microbial contamination 
sources is much more difficult than in end sterilization. (Lambert et al, 2011) In aseptic 
processing either the entire product is sterilized and then introduced into a sterilized pack-
age, or the product components are sterilized separately, then further processed and as-
sembled, and the final product is packed into a sterilized package. During aseptic pro-
cessing, the handling of sterile containers and devices or their components is performed 
in a controlled environment, in which the air, materials, equipment, and personnel are 
regulated to control microbial and particulate contamination levels. Subsequent sterility 
testing is expected to verify the sterility of the product. (Teixeira, 2014) The ISO 13408: 
Aseptic processing of healthcare products -suite of standards cover the aseptic processing 
of health care products. The standards outline the requirements for aseptic processes, as 
well as validation and routine control of the manufacturing process. The ISO 13408 stand-
ard series is recognized by the FDA (FDA, 2015). The ISO 14644: Cleanrooms and as-
sociated controlled environments contains the classification criteria for cleanrooms, as 
well as specifications for testing and monitoring, test methods, design, construction, and 
operation, and classification of airborne molecular contamination. The ISO 14644 is also 
recognized by the FDA (FDA, 2015)  
In aseptic processing, personnel are the main source of contamination. The most effective 
way to eliminate personnel-borne contamination is to isolate personnel from the product 
by barrier systems, or to eliminate the need for personnel in the process entirely by auto-
mation. These methods are called advanced aseptic processing methods. (Baseman, 1998) 
In advanced aseptic processing direct intervention with open product containers or prod-
uct contact surfaces by operators wearing conventional cleanroom garments is not re-
quired and never permitted. Restricted Access Barrier Systems (RABSs) and isolators are 
used to create a protective physical structure between personnel and the product. The 
terms RABS and isolator are often used interchangeably, but they are slightly different 
systems. (Agalloco & Agers, 2010) A RABS is in most cases “open”, so the air flows 
freely out of the RABS into the surrounding room. An open RABS also permits open 
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door interventions during the process. A RABS is decontaminated manually by asepti-
cally gowned personnel using high-level disinfection with sporicidal materials. (Kania, 
2008) An isolator is either sealed or supplied with High Efficiency Particulate Air 
(HEPA) -filtered air. It is a fully isolated unit that can operate at positive, neutral or neg-
ative pressure with respective to the surrounding environment. An isolator has an auto-
mated decontamination system that uses vaporous or gaseous sporicidal agents. An iso-
lator can be used for aseptic processing as well as containment of potent compounds, or 
simultaneously for both asepsis and containment. (Agalloco & Agers, 2010; Kania, 2008) 
Blow-fill-seal (BFS) and form-fill-seal (FFS) systems have been extensively used in asep-
tic packaging, but the incorporation of RABS and isolators have further improved these 
technologies (Agalloco & Agers, 2010). In the BFS/FFS systems, a polymer container is 
formed, filled and sealed in one continuous automated process. The primary advantage 
of these systems is reducing human intervention. BFS/FFS technologies are very common 
in pharmaceutical industry, where they are used in packaging of liquids in both small 
containers, such as ophthalmic drug ampoules, as well as in larger containers, such as 
saline solutions. Recently, the BFS/FFS technology has expanded into injectables and 
biologics, for example vaccines and monoclonal antibodies. The BFS/FFS systems have 
been successfully used for aseptic processing of heat sensitive materials that cannot with-
stand end sterilization, for more than 30 years. (Markarian, 2014, Patel et al, 2006) With 
newer designs, BFS/FFS technologies can be used for the aseptic filling of small number 
of bags at slower speed, ideal for bulk or clinical subdivision or for niche products (Agal-
loco & Agers, 2010). 
Another approach to improve contamination control in aseptic processing is the use of 
robots and automation that eliminate the use of personnel by replacing manual activities 
with machines. So far, robots and automation have mostly been utilized in secondary 
packaging operations, although there are robots developed for handling activities, such as 
component supply on a routine bases, in isolators or cleanrooms. Also different automated 
bottling and capping systems, as well as aseptic sampling systems are available. 
Healthcare product manufacturers are typically slow to adopt new technologies, thus 
aseptic processes are usually more advanced in other aseptic industries. (Agalloco & Ag-
ers, 2010) 
In cell and tissue processing the sub-culturing for cell expansion is the core process. Dur-
ing the manufacturing, strict control against contamination and human error is mandatory 
due to the un-sterilizable products and the complexity of culture techniques. An auto-
mated processing system would enhance safety, security and cost saving in the processing 
of cells and tissues for therapeutic applications. The criteria for such facility design, how-
ever, has not been clear to date, even though there is a growing need for capable, scalable 
manufacturing technologies. The major challenge in the development of these technolo-
gies has been the transmission from laboratory-scale design to production-scale design of 
biological products that are reproducible, safe, and clinically effective. The products 
75 
would also need to be economically acceptable and competitive in order for the upscaling 
to be successful. For example Kino-oka (2014) has been developing a novel bioreactor 
design as well as a facility design for aseptic cell processing. (Kino-oka, 2014)  
76 
8. CONCLUSIONS 
Packaging of sterile tissue engineering products is a complex issue. Medical devices are 
a highly regulated area, and all manufacturing and packaging activities have to comply 
with the relevant legislation and regulations. Especially in the fairly new field of advanced 
therapy products the regulations in different countries are at different stages of develop-
ment, and globally harmonized terminology and technical requirements are yet to be es-
tablished.  
Advanced tissue engineering products can contain several components, each with differ-
ent properties. This imposes new challenges on packaging technology by adding com-
plexity to the packaging system and creating challenges with self-life stability. The man-
ufacturer of the device has to define what kind of protection from the environmental fac-
tors the product requires. These factors include the conditions that can affect the device 
itself, the user of the device, or the patient in the intended use environment. Environmen-
tal conditions to be considered may be for example: temperature, humidity, moisture, 
atmospheric gas composition or pressure, energy, vibration, motion, lighting, and shock. 
Two common features for all biodegradable tissue engineering products are that they are 
always delivered sterile, and they are susceptible to hydrolytic degradation. Therefore, 
the sterile and moisture barrier properties of packaging materials of biodegradable tissue 
engineering products are of most importance. A sterile barrier maintains the sterility of 
the product all the way to the end user. Typical materials for sterile barrier systems are 
plastic films, coated or uncoated papers and non-wovens, and common packaging formats 
are pre-formed trays and premade bags and pouches. Biodegradable products have to be 
packaged as quickly as possible after fabrication, usually under an inert atmosphere or 
vacuum. A moisture barrier packaging protects the product from hydrolytic degradation 
which would alter the mechanical properties and affect the performance of the product in 
vivo. The packaging material is most often a foil or a laminated polymer film. Recently 
developed ultra-high barrier films that utilize nanotechnology enable extremely thin, 
transparent packaging with superior moisture and oxygen barrier properties.  
Due to the multi-component structures of advanced tissue engineering products, it may 
be challenging to find a suitable end sterilization method. Sterilization may cause imme-
diate or delayed effects to the sterilized products, or it may affect the cell proliferation in 
the sterilized scaffold. Also the packaging materials must be compatible with the chosen 
end sterilization method. Novel, gentler sterilization technologies for sensitive materials 
are being developed, but for the most of them there is still very limited data available 
about material compatibilities and delayed effects. Sterilization methods that use super-
critical carbon dioxide or nitrogen dioxide, however, have shown promising results in 
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compatibility with many moisture and heat sensitive materials. Sterilizers that use nitro-
gen dioxide are also already commercially available. In case these low temperature and 
low moisture sterilization methods are still not compatible with the product, aseptic pro-
cessing might be the only option for fabrication, although it is more costly and less robust 
than end sterilization.   
When designing a packaging of a product, user acceptance is an essential consideration. 
In an often hectic operating room environment it is crucial that the device packaging is 
easy to open and the contents can be removed without contamination. The label must be 
easy to read. A clear packaging is often thought ideal. Healthcare professionals generally 
favor trays and flexible pouches as packaging, and double sterile barrier is highly pre-
ferred. It is apparent, that packaging has an impact on which product will be chosen if 
several similar products are available. 
The major shift towards sustainable packaging systems in the healthcare industry is yet 
to happen, but the interest towards recycling and sustainability is definitely increasing. 
Many manufacturers are starting to recognize the whole life cycle perspective of products, 
and acknowledge the effect of packaging to the carbon footprint of the product. The fa-
vored double packaging more than doubles the amount of material needed for packaging, 
thus significantly increasing the amount of waste. If the double packaging is essential, 
other ways to reduce the use of packaging materials are down gauging, reduction of the 
package density, or redesigning the package. The thin ultra-high barrier nanofilms may 
also help reduce the use of packaging materials. It may also be worth to consider if switch-
ing to another packaging type that produces less waste, requires less use of fossil fuels, 
and produces less CO2 during the manufacturing process is possible. Smaller shipping 
cartons further reduce the need for packaging materials, pallet slip sheets and shrink 
wraps, as well as storage space. While reducing material, transportation and storage costs, 
“green packaging” may potentially be a valuable marketing asset in the future. 
The scope of this thesis was to examine possible packaging solutions for biodegradable 
tissue engineering products. Based on the studied materials, an ideal packaging for a bi-
odegradable tissue engineering product would be a double sterile barrier system consist-
ing of a rigid tray in a flexible, clear pouch that would also serve as a moisture barrier. 
The labeling should be clear and easy to read, and both the pouch and the tray should be 
easy to open quickly in an operating room environment. The outer carton should be as 
small as possible, while still providing sufficient protection and the required information. 
The final materials for the packaging should be chosen based on whether the product will 
be sterilized in the final package or aseptically processed. However, due to the diverse 
nature of biodegradable tissue engineering products, suggesting one universal packaging 
solution suitable for all biodegradable tissue engineering products is impossible. While 
the special features of each product have to be considered, these results can offer some 
general guidelines for which aspects to consider when designing a final package for a 
biodegradable tissue engineering product. 
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APPENDIX A: CLASSIFICATION OF MEDICAL DEVICES ACCORDING TO THE DIRECTIVE 93/42/EEC 
Modified from: Frumento, 2011.  
Device type Class I Class IIa Class IIb Class III 
Category 1: 
Noninvasive devices 
All non-invasive devices unless they are 
listed in any other higher class. 
Devices for channeling or storing blood, 
body liquids or tissues, or liquids or gases 
for infusion, administration or introduc-
tion into the body. Devices for storing or-
gans, parts of organs, or tissues. 
Devices that may be connected to an ac-
tive medical device in Class IIa or a 
higher class. 
Devices for modifying the biological or 
chemical composition of blood through 
filtration, centrifugation or exchanges of 
gas or heat. 
Devices for modifying the biological or 
chemical composition of blood, other 
body liquids or other liquids for infusion 
into the body, that do not use filtration, 
centrifugation, or exchanges of gas or 
heat. 
N/A 
Category 2:  
Non-invasive devices in con-
tact with injured skin 
Devices used as a mechanical barrier, for 
compression or for absorption of exu-
dates. 
Devices for managing the micro-environ-
ment of a wound. 
Devices used principally with wounds 
which have breached the dermis and can 
only heal by secondary intent. 
N/A 
Category 3: 
Invasive devices 
All invasive devices other than surgically 
invasive devices, that are not in connec-
tion to an active medical device and are 
for transient use. 
Devices for short-term use if they are 
used in the oral cavity as far as the phar-
ynx, in an ear canal up to the ear drum, or 
in a nasal cavity. 
Devices for short-term use. 
Devices for long term use in the oral cav-
ity as far as the pharynx, in an ear canal 
up to the ear drum, or in a nasal cavity, 
and are not liable to be absorbed by the 
mucous membrane. 
All invasive devices other than surgically 
invasive devices, intended for connection 
to an active medical device in Class IIa or 
a higher class. 
Devices for long-term use. Devices for transient or short term use for 
diagnosing, monitoring or correcting a 
defect of the heart or of the central circu-
latory system through direct contact with 
these parts of the body. 
Devices for short term use in direct con-
tact with the central nervous system. 
Devices for short-term use to have a bio-
logical effect or to be wholly or mainly 
absorbed. 
Category 4: 
Surgically invasive devices 
Reusable surgical instruments Devices for transient use unless they are 
listed in a higher class. 
Devices for short-term use unless other-
wise specified. 
Devices for transient use or short term 
use to supply energy in the form of ionis-
ing radiation. 
Devices for transient use or short term 
use intended specifically to diagnose, 
monitor or correct a defect of the heart or 
of the central circulatory system through 
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Device type Class I Class IIa Class IIb Class III 
Devices for short-term use to undergo 
chemical change in the body or to admin-
ister medicines, and the devices are 
placed in the teeth. 
 
Devices for transient use to have a bio-
logical effect or to be wholly or mainly 
absorbed. 
Devices for transient use to administer 
medicines by means of a delivery system, 
if this is done in a manner that is poten-
tially hazardous considering the mode of 
application. 
Devices for short-term use to undergo 
chemical change in the body, or to ad-
minister medicines. 
direct contact with these parts of the 
body. 
Devices for short term use in direct con-
tact with the central nervous system. 
Devices for short-term use and to have a 
biological effect or to be wholly or 
mainly absorbed. 
 
Category 5: 
Implantable devices and long 
term surgically invasive de-
vices 
N/A Devices to be placed in the teeth. All implantable devices and long term 
surgically invasive devices are in Class 
IIb unless otherwise specified. 
Devices to undergo chemical change in 
the body or to administer medicines if the 
devices are placed in the teeth. 
Devices used in direct contact with the 
heart, the central circulatory system or the 
central nervous system. 
Devices to have a biological effect or to 
be wholly or mainly absorbed. 
Devices to undergo chemical change in 
the body or to administer medicines. 
Category 6: 
Active devices 
N/A All active therapeutic devices to adminis-
ter or exchange energy are in Class IIa 
unless otherwise specified. 
Active devices for diagnosis if they are 
intended to supply energy which will be 
absorbed by the human body, except for 
devices used to illuminate the patient’s 
body in the visible spectrum. 
Active devices for diagnosis if they are 
intended to image in vivo distribution of 
radiopharmaceuticals. 
Active devices to allow direct diagnosis 
or monitoring of vital physiological pro-
cesses and not specified otherwise. 
All active devices to administer and/or re-
move medicines, body liquids or other 
All active therapeutic devices to adminis-
ter or exchange energy to or from the hu-
man body in a potentially hazardous way, 
considering the nature, the density and 
site of application of the energy. 
Active devices to control or monitor the 
performance of active therapeutic devices 
in Class IIb, or to influence directly the 
performance of such devices. 
Active devices for monitoring of vital 
physiological parameters, where the na-
ture of variations is such that it could re-
sult in immediate danger to the patient, 
such as variations in cardiac performance, 
respiration, activity, or of the central 
nervous system. 
N/A 
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Device type Class I Class IIa Class IIb Class III 
substances to or from the body unless 
otherwise specified. 
 
Active devices to emit ionising radiation 
for diagnostic and therapeutic interven-
tional radiology, including devices which 
control or monitor such devices, or which 
directly influence their performance. 
All active devices to administer and/or re-
move medicines, body liquids, or other 
substances to or from the body in a man-
ner that is potentially hazardous, consid-
ering the nature of the substances in-
volved, the part of the body concerned 
and the mode of application. 
Category 7: 
Special cases 
N/A All devices to be used specifically for dis-
infecting medical devices. 
Non-active devices specifically for re-
cording of X-ray diagnostic images. 
All devices used for contraception or the 
prevention of the transmission of sexually 
transmitted diseases unless otherwise 
specified. 
All devices to be used specifically for dis-
infecting, cleaning, rinsing or hydrating 
contact lenses. 
 
All devices incorporating as an integral 
part a substance which, if used separately, 
can be considered to be a medicinal prod-
uct, as defined in Article 1 of Directive 
65/65/EEC, and which is liable to act on 
the human body with action ancillary to 
that of the devices. 
Devices used for contraception or the pre-
vention of the transmission of sexually 
transmitted diseases that are implantable 
or long term invasive devices. 
All devices manufactured utilising animal 
tissues or derivatives rendered non-via-
ble. 
Breast implants, shoulder, knee and hip 
implants. Active implantable devices 
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APPENDIX B: STANDARDS AND GUIDANCE DOCUMENTS REL-
EVANT TO STERILE BARRIER SYSTEMS 
The list of relevant standards is compiled by Sterile Barrier Association. (Sterile Barrier 
Association, 2013) 
ASTM D4169 Standard Practice for Performance Testing of Shipping Containers 
and Systems. Guidance, testing. 
ASTM D4332 Standard Practice for Conditioning Containers, Packages, or Packag-
ing Components for Testing. Guidance, testing. 
ASTM D7386 Standard Practice for Performance Testing of Packages for single 
parcel Delivery Systems. Guidance, testing. 
ASTM F17 - 13a Standard Terminology Relating to Flexible Barrier Packaging. 
   Guidance, packaging & materials. 
ASTM F1980 Standard Guide for Accelerated Aging of Sterile Barrier Systems for 
Medical Devices. Guidance, testing. 
ASTM F2097 Standard Guide for Design and Evaluation of Primary Flexible Pack-
aging for Medical Products. Guidance, testing. 
ASTM F2475 Standard Guide for Biocompatibility Evaluation of Medical Device 
Packaging Materials. Guidance, biological evaluation. 
ASTM F2559/F2559M Standard Guide for Writing a Specification for sterilizable 
peel pouches. Guidance, packaging & materials 
ASTM F2825 Standard practice for climatic stressing of Packaging systems for Sin-
gle Parcel Delivery. Guidance, testing. 
ASTM F99  Standard Guide for Writing a Specification for flexible barrier roll-
stock materials. Guidance, packaging & materials. 
CEN/TR 13688 Packaging - Material recycling - Report on requirements for sub-
stances and materials to prevent a sustained impediment to recycling.
 Technical report, environment. 
CEN/TR 13695-1 Packaging - Requirements for measuring and verifying the four 
heavy metals and other dangerous substances present in packaging 
and their release into the environment - Part 1: Requirements for 
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measuring and verifying the four heavy metals present in packaging. 
Technical report, environment. 
CEN/TR 13695-2 Packaging - Requirements for measuring and verifying the four 
heavy metals and other dangerous substances present in packaging, 
and their release into the environment - Part 2: Requirements for 
measuring and verifying dangerous substances present in packaging, 
and their release into the environment. Technical report, environ-
ment. 
CEN/TR 13910 Packaging - Report on criteria and methodologies for life cycle anal-
ysis of packaging. Technical report, environment. 
EN 13427  Packaging - Requirements for the use of European Standards in the 
field of packaging and packaging waste. Standard, environment. 
EN 13428  Packaging - Requirements specific to manufacturing and composi-
tion - Prevention by source reduction. Standard, environment. 
EN 13429  Packaging - Reuse. Standard, environment. 
EN 13430  Packaging - Requirements for packaging recoverable by material re-
cycling. Standard, environment. 
EN 13431  Packaging - Requirements for packaging recoverable in the form of 
energy recovery, including specification of minimum inferior calo-
rific value. Standard , environment. 
EN 868-10  Packaging for terminally sterilized medical devices - Part 10: Adhe-
sive coated nonwoven materials of polyolefines - Requirements and 
test methods. Standard, packaging and materials. 
EN 868-2  Packaging for terminally sterilized medical devices - Part 2: Sterili-
zation wrap - Requirements and test methods. Standard, packaging 
and materials. 
EN 868-3  Packaging for terminally sterilized medical devices - Part 3: Paper 
for use in the manufacture of paper bags (specified in EN 868-4) and 
in the manufacture of pouches and reels (specified in EN 868-5) - 
Requirements and test methods. Standard, packaging and mate-
rials. 
EN 868-4  Packaging for terminally sterilized medical devices - Part 4: Paper 
bags - Requirements and test methods. Standard, packaging and ma-
terials. 
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EN 868-5  Packaging for terminally sterilized medical devices - Part 5: Sealable 
pouches and reels of porous materials and plastic film construction 
— Requirements and test methods. Standard, packaging and materi-
als. 
EN 868-6  Packaging for terminally sterilized medical devices - Part 6: Paper 
for low temperature sterilization processes - Requirements and test 
methods. Standard, packaging and materials. 
EN 868-7  Packaging for terminally sterilized medical devices - Part 7: Adhe-
sive coated paper for low temperature sterilization processes - Re-
quirements and test methods. Standard, packaging and materials. 
EN 868-8  Packaging for terminally sterilized medical devices - Part 8: Re-usa-
ble sterilization containers for steam sterilizers conforming to EN 
285 - Requirements and test methods. Standard, packaging and ma-
terials. 
EN 868-9  Packaging for terminally sterilized medical devices - Part 9: Un-
coated nonwoven materials of polyolefines - Requirements and test 
methods. Standard, packaging and materials. 
EN 980  Symbols for use in the labelling of medical devices. Standard, 
   labelling. 
EN ISO 15223-1 Medical devices - Symbols to be used with medical device labels, 
labelling and information to be supplied - Part 1: General require-
ments. Standard, labelling. 
EN ISO 14937 Sterilization of health care products - General requirements for char-
acterization of a sterilizing agent and the development, validation 
and routine control of a sterilization process for medical devices. 
Standard sterilization. 
EN ISO 15225 "Nomenclature - specification for a nomenclature system for medical 
devices for the purpose of regulatory data exchange". Standard,
 nomenclature. 
EN ISO 17025 General requirements for the competence of testing and calibration 
laboratories. Standard, testing. 
ISO 10993-1  Biological evaluation of medical devices - Part 1: Evaluation and 
testing within a risk management process. Standard, biological eval-
uation. 
96 
ISO 10993-10 Biological evaluation of medical devices - Part 10: Tests for irritation 
and skin sensitization. Standard, biological evaluation. 
ISO 10993-11 Biological evaluation of medical devices - Part 11: Tests for systemic 
toxicity. Standard, biological evaluation. 
ISO 10993-12 Biological evaluation of medical devices - Part 12: Sample prepara-
tion and reference materials. Standard, biological evaluation. 
ISO 10993-13 Biological evaluation of medical devices - Part 13: Identification and 
quantification of degradation products from polymeric medical de-
vices. Standard, biological evaluation. 
ISO 10993-16 Biological evaluation of medical devices - Part 16: Toxicokinetic 
study design for degradation products and leachables. Standard,
 biological evaluation. 
ISO 10993-17 Biological evaluation of medical devices - Part 17: Establishment of 
allowable limits for leachable substances. Standard, biological eval-
uation. 
ISO 10993-18 Biological evaluation of medical devices - Part 18: Chemical charac-
terization of materials. Standard, biological evaluation. 
ISO 10993-2  Biological evaluation of medical devices - Part 2: Animal welfare 
requirements. Standard, biological evaluation. 
ISO 10993-3  Biological evaluation of medical devices - Part 3: Tests for genotox-
icity, carcinogenicity and reproductive toxicity. Standard, biological 
evaluation. 
ISO 10993-5  Biological evaluation of medical devices - Part 5: Tests for in vitro 
cytotoxicity. Standard, biological evaluation. 
ISO 10993-6  Biological evaluation of medical devices - Part 6: Tests for local ef-
fects after implantation. Standard, biological evaluation. 
ISO 10993-7  Biological evaluation of medical devices - Part 7: Ethylene oxide 
sterilization residuals. Standard, biological evaluation. 
ISO 10993-9  Biological evaluation of medical devices - Part 9: Framework for 
identification and quantification of potential degradation products. 
Standard, biological evaluation. 
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ISO 11607-1:2006 Packaging for terminally sterilized medical devices - Part 1: Require-
ments for materials, sterile barrier systems and packaging systems. 
Standard, packaging and materials. 
ISO 11607-2:2006 Packaging for terminally sterilized medical devices - Part 2: Valida-
tion requirements for forming, sealing and assembling processes. 
Standard, packaging and materials. 
ISO 11607-1:2006/Amd 1:2014 Packaging for terminally sterilized medical devices -    
Part 1: Requirements for materials, sterile barrier systems and pack-
aging systems. Standard, packaging and materials. 
ISO 11607-2:2006/Amd 1:2014 Packaging for terminally sterilized medical devices - 
 Part 2: Validation requirements for forming, sealing and assembling 
processes. Standard, packaging and materials. 
ISO 14006  Environmental management systems – Guidelines for incorporating 
eco-design. Standard, environment. 
ISO 14971  Medical devices – Application of risk management to medical de-
vices. Standard, risk management. 
ISO 186  Paper and board - sampling to determine average quality. Standard, 
statistics. 
ISO 18601  Packaging and the environment - General requirements for the use of 
ISO standards in the field of packaging and the environment. Stand-
ard, environment. 
ISO 18602  Packaging and the environment – Optimization. Standard, environ-
ment. 
ISO 18603  Packaging and the environment – Reuse. Standard, environment. 
ISO 18604  Packaging and the environment - Material recycling. Standard, envi-
ronment. 
ISO 18605  Packaging and the environment - Energy recovery. Standard, envi-
ronment. 
ISO 18606  Packaging and the environment - Organic recycling. Standard, envi-
ronment. 
ISO 187  Paper, board and pulps - Standard atmosphere for conditioning and 
testing and procedure for monitoring the atmosphere and condition-
ing of samples. Standard, testing. 
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ISO 2233  Packaging - Complete, filled transport packages and unit loads - 
Conditioning for testing. Standard, testing. 
ISO 22442-1  Medical devices utilizing animal tissues and their derivatives - Part 
1: Application of risk management. Standard, risk management. 
ISO 2859-1  Sampling procedures for inspection by attributes - Part 1: Sampling 
schemes indexed by acceptance quality limit (AQL) for lot-by-lot in-
spection. Standard, statistics. 
ISO 4180  Packaging - complete, filled transport packages - general rules for 
the compilation of performance test schedules. Standard, testing. 
ISO 9001  Quality management systems – Requirements. Standard, quality 
management. 
ISO/TR 16218  Chemical recovery. Standard, environment. 
ISO/TR 17098 Report on substances and materials which may impede recycling. 
   Technical report, environment. 
ISO/TS 10993-19 Part 19: Physico-chemical, morphological and topographical charac-
terization of materials. Technical specification, biological evalua-
tion. 
ISO/TS 10993-20 Part 20: Principles and methods for immunotoxicology testing of 
medical devices. Technical specification, biological evaluation. 
ISO/TS 16775:2014 Packaging for terminally sterilized medical devices - Guidance on 
the application of ISO 11607-1 and ISO 11607-2. Technical specifi-
cation, packaging and materials. 
ISO14040  Environmental management - Life cycle assessment - Principles and 
framework. Standard, environment. 
ISO 13485  Medical devices – Quality management systems – Requirements for 
regulatory purposes. Standard, quality management. 
ISO 18472  Sterilization of health care products - Biological and chemical indi-
cators - Test equipment. Standard, indicators. 
ISO 20857  Sterilization of health care products - Dry heat - Requirements for 
the development, validation and routine control of a sterilization pro-
cess for medical devices. Standard, sterilization. 
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ISO 25424  Sterilization of medical devices - Low temperature steam and for-
maldehyde - Requirements for development, validation and routine 
control of a sterilization process for medical devices. Standard, ster-
ilization. 
ISO 11137-1  Sterilization of health care products - Radiation - Part 1: Require-
ments for development, validation and routine control of a steriliza-
tion process for medical devices. Standard, sterilization. 
ISO 11137-2  Sterilization of health care products - Radiation - Part 2: Establishing 
the sterilization dose. Standard, sterilization. 
ISO 11137-3  Sterilization of health care products - Radiation - Part 3: Guidance 
on dosimetric aspects. Standard, sterilization. 
ISO 11138-1  Sterilization of health care products - Biological indicators - Part 1: 
General requirements. Standard, indicators. 
ISO 11138-2  Sterilization of health care products - Biological indicators - Part 2: 
Biological indicators for ethylene oxide sterilization processes. 
Standard, indicators. 
ISO 11138-3  Sterilization of health care products - Biological indicators - Part 3: 
Biological indicators for moist heat sterilization processes. Standard, 
indicators. 
ISO 11138-4  Sterilization of health care products - Biological indicators - Part 4: 
Biological indicators for dry heat sterilization processes. Standard, 
indicators. 
ISO 11138-5  Sterilization of health care products - Biological indicators - Part 5: 
Biological indicators for low-temperature steam and formaldehyde 
sterilization processes. Standard, indicators. 
ISO/TS 11139 Sterilization of health care products – Vocabulary. Technical speci-
fication, vocabulary. 
ISO 11140-1  Sterilization of health care products - Chemical indicators - Part 1: 
General requirements. Standard, indicators. 
ISO 11140-3  Sterilization of health care products - Chemical indicators - Part 3: 
Class 2 indicator systems for use in the Bowie and Dick-type steam 
penetration test. Standard, indicators. 
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ISO 11140-4  Sterilization of health care products - Chemical indicators - Part 4: 
Class 2 indicators as an alternative to the Bowie and Dick-type test 
for detection of steam penetration. Standard, indicators. 
ISO 11140-5  Sterilization of health care products - Chemical indicators - Part 5: 
Class 2 indicators for Bowie and Dick-type air removal tests. 
Standard, indicators. 
ISO 11737-1  Sterilization of medical devices - Microbiological methods - Part 1: 
Determination of a population of microorganisms on products. 
Standard, bioburden. 
ISO 11737-2  Sterilization of medical devices - Microbiological methods - Part 2: 
Tests of sterility performed in the definition, validation and mainte-
nance of a sterilization process. Standard, sterility testing. 
ISO/TS 13004 Sterilization of health care products - Radiation - Substantiation of 
selected sterilization dose: Method VDmaxSD. Technical specifica-
tion, sterilization. 
ISO 13408-1  Aseptic processing of health care products - Part 1: General require-
ments. Standard, aseptic processing. 
ISO 13408-2  Aseptic processing of health care products - Part 2: Filtration. Stand-
ard, aseptic processing. 
ISO 13408-6  Aseptic processing of health care products - Part 6: Isolator systems. 
Standard, aseptic processing. 
ISO 13408-7  Aseptic processing of health care products - Part 7: Alternative pro-
cesses for medical devices and combination products. Standard, 
aseptic processing. 
ISO 14160  Sterilization of health care products - Liquid chemical sterilizing 
agents for single-use medical devices utilizing animal tissues and 
their derivatives - Requirements for characterization, development, 
validation and routine control of a sterilization process for medical 
devices. Standard, sterilization. 
ISO 14161  Sterilization of health care products - Biological indicators - Guid-
ance for the selection, use and interpretation of results. Standard, 
 indicators. 
ISO 14937  Sterilization of health care products - General requirements for char-
acterization of a sterilizing agent and the development, validation 
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and routine control of a sterilization process for medical devices. 
Standard, sterilization. 
ISO 15882  Sterilization of health care products - Chemical indicators - Guidance 
for selection, use and interpretation of results. Standard, indicators. 
ISO 17664  Sterilization of medical devices - Information to be provided by the 
manufacturer for the processing of re-sterilizable medical devices. 
Standard, reprocessing. 
ISO 17665-1  Sterilization of health care products - Moist heat - Part 1: Require-
ments for the development, validation and routine control of a steri-
lization process for medical devices. Standard, sterilization. 
ISO/TS 17665-2 Sterilization of health care products - Moist heat - Part 2: Guidance 
on the application of ISO 17665-1. Technical specification, steriliza-
tion. 
ISO/TS 17665-3 Sterilization of health care products - Moist heat - Part 3: Guidance 
on the designation of a medical device to a product family and pro-
cessing category for steam sterilization. Technical specification, 
 sterilization. 
ISO 11135  Sterilization of health-care products - Ethylene oxide - Requirements 
for the development, validation and routine control of a sterilization 
process for medical devices. Standard, sterilization. 
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APPENDIX C: SUMMARY OF THE STERILIZATION AND DISINFECTION METHODS  
 
Method Advantages  Disadvantages 
Suitability for biodegrable po-
lymers Compatible packaging materials 
Synthetic Natural 
Dry heat  Easy, cheap, no toxic residues 
High temperatures (160 – 190 °C) exceeds the melt-
ing temperature of most biodegradable polymers. 
No No 
Nylon, polypropylene, oriented polyester, poly-
carbonate, some grades of high-density PE 
(HDPE). 
Moist heat Easy, cheap, no toxic residues 
High temperatures (121 – 148 °C) and moisture: Ex-
ceeds the melting temperature of many biodegrada-
ble polymers, causes hydrolytic degradation. 
No No 
Only porous materials, nylon, polypropylene, ori-
ented polyester, polycarbonate, some grades of 
high-density PE (HDPE), Tyvek® (in 121 – 
123 °C), medical grade paper. 
Flash sterilization Easy, cheap, no toxic residues 
On site sterilization method for sterilizing cleaned 
patient care items that cannot be packaged, sterilized 
and stored before use. High temperature (132 °C) ex-
ceeds the melting temperature of most biodegradable 
polymers. 
No No 
On site method, used for items that cannot be 
stored. 
Gamma rays 
High penetrating power, suitable for temper-
ature sensitive materials, no radioactive resi-
dues, no aeration needed, continuous fully 
automated process 
May affect mechanical properties of several poly-
mers, cause discoloring and embrittlement. To pre-
vent heating during sterilization process, the product 
has to be cooled to 0 °C. Requires shielding. 
Limited No 
PE and PE copolymers, radiation tolerant grade 
PP, PS, PC, PET, PU, unplasticized PVC, alumi-
num pouches, Tyvek®. 
UV irradiation 
No toxic residues, does not alter chemical 
composition, taste, odor, or pH of the prod-
uct. 
Degrades some polymers (such as PE and PP). Poor 
penetration power.  
Limited 
Not enough 
data available 
PTFE, PVDF, FEP, PEEKTM, PI, PEI.  
Glass is UV opaque. 
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Method Advantages  Disadvantages 
Suitability for biodegrable po-
lymers Compatible packaging materials 
Synthetic Natural 
Pulsed UV light 
Fast, low operating costs, items can be ex-
posed through clear packaging, no toxic resi-
dues. Suitable for clear packaging, medical 
tools, and surfaces. 
Treated media must be transparent to UV light and 
shadow effects must be avoided. FDA has approved 
the method only for treatment of food.  
Limited 
Not enough 
data available 
Clear packaging materials. Same materials than 
for UV irradiation. 
Infrared radiation 
Short cycle time, low energy consumption, 
no toxic residues, no environmental effects 
Generates heat, method not cleared by FDA, efficacy 
depends on IR power level, sample materials, sample 
depth, moisture content of the sample, temperature of 
the sample, peak wavelength, bandwidth of the IR 
heating source, and types of microorganisms present. 
No 
Not enough 
data available 
Heat resistant materials. 
Microwaves No toxic residues.  Generates heat, method not cleared by FDA No 
Not enough 
data available 
Heat resistant materials. 
E-beam 
Fast, cost effective, can be integrated into an 
in-line process, no volatile or toxic chemi-
cals, no radioactive materials, no aeration 
needed after sterilization. 
Poor penetrating power; larger items have to be irra-
diated from multiple sides. Cooling agents cannot be 
used due to shading effect.  
Limited Limited  
Beta particles 
Might be suitable for natural polymers due to 
lower, less damaging penetration power. 
Lower penetration power not efficient enough for all 
items. Not a lot of research information available.  
Not enough 
data available 
Yes Not enough data available 
Low temperature radio fre-
quency (RF) plasma 
Fast, no toxic residues, atmospheric pressure 
enables continuous processing. 
Surface sterilization method, temperature (70 °C) too 
high for many biodegradable polymers.  
Limited Limited Not enough data available 
EtO gas Low processing temperatures (50 – 60 °C).  
Long process time, must have direct contact with 
sterilized items, requires moisture. Highly flammable 
and explosive in air. Leaves toxic residues, materials 
need to aerated after process. Difficult to remove all 
toxic residuals from porous 3D structures. Acts as a 
plasticizer to many biodegradable polymers.  
Limited Yes 
Porous, moisture and EtO tolerant, hot adhesive 
strength, broadly compatible with chemicals.  
Ozone  
Alternative to EtO gas sterilization, safer to 
use than EtO. Can be used for heat and mois-
ture sensitive items. FDA approved the 
method for metal and plastic instruments. 
Only limited data of the method available.  
Not enough 
data available 
Not enough 
data available 
Not enough data available 
Hydrogen peroxide 
Does not coagulate blood or fix tissues to 
surfaces. No odor, irritation or disposal is-
sues. 
Material compatibility issues with some metals, such 
as brass, zinc, copper, and nickel/silver plating. 
Causes serious eye damage in contact. 
Not enough 
data available 
Not enough 
data available 
Synthetic materials.  
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Suitability for biodegrable po-
lymers Compatible packaging materials 
Synthetic Natural 
Vaporized hydrogen peroxide 
Very fast, low temperature (30 – 40 °C), 
suitable for moisture sensitive materials, safe 
for operator and environment. No toxic resi-
dues. 
Not compatible with liquids, linen, powders, and all 
cellulose materials, restrictions for the diameters of 
the sterilized product. Only limited data available. 
Not enough 
data available 
Not enough 
data available 
Synthetic packaging materials (e.g. polypropyl-
ene) 
Hydrogen peroxide gas 
plasma 
Low temperature (<50 °C), suitable for 
moisture sensitive materials, fast, non-toxic, 
no environmental effects, process simple to 
install, operate and monitor. 
Poor penetration power, restrictions for the diameters 
of the sterilized product. Relatively expensive. Not 
compatible with liquids, powders, strong peroxide 
absorbers (paper, cotton, cellulose), causes surface 
modification 
Not enough 
data available 
Not enough 
data available 
Synthetic packaging materials (e.g. polypropyl-
ene, polyolefin). Requires a special container 
tray. 
Peracetic acid 
Very fast, Low temperature (55 °C), water 
soluble, no toxic residues, no environmental 
effects, does not coagulate blood or fix tis-
sues to surfaces. 
Sterilized items must be immersible, point-of-use 
system; items cannot be stored sterile, peracetic acid 
causes serious skin and eye damage in contact. 
Not enough 
data available 
Yes Not enough data available 
Formaldehyde steam 
Low temperature sterilization method (70-
75 °C), relatively low costs and short process 
time.  
Temperature too high for many biodegradable poly-
mers, requires humidity. Limited penetration power. 
Formaldehyde is a mutagen and a potential carcino-
gen. 
No 
Not enough 
data available 
Not enough data available 
Carbon dioxide  
Non-toxic. Can be utilized in cleaning of 
polymer and silicone surfaces before bond-
ing, coating, or assembly for use in clean-
rooms, biomedical devices and aerospace ap-
plications. 
Surface sterilization method. Yes Yes Not enough data available 
Supercritical carbon dioxide 
Compatible with various biological materi-
als. Low temperature, low pressure method. 
Leaves no toxic residues. Non-reactive, high 
penetration ability. Does not alter the mor-
phology, structure, or mechanical properties 
of sensitive polymers. 
Only limited data of the method available.  Yes Yes Not enough data available 
Nitrogen dioxide 
Compatible with most polymers used in 
medical devices, and with many biomole-
cules that are not compatible with other steri-
lization methods. Low temperature method 
(room temperature), rapid aeration.  
Process requires some humidity.  Limited Yes 
Nonwoven PP wraps, Tyvek/film peel pouches, 
Tyvek/plastic trays. 
Not compatible with paper and other cellulosic 
materials. 
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Suitability for biodegrable po-
lymers Compatible packaging materials 
Synthetic Natural 
Active oxygen species 
Low processing temperature, dry processing, 
no residual effects, nontoxic, low initial and 
operational costs. 
Only limited data of the method available.  
Not enough 
data available 
Not enough 
data available 
Not enough data available 
Alcohols 
Low cost, no harmful environmental effects. 
Effective skin disinfectant.   
Do not destroy bacterial spores, may damage plas-
tics, elastomers and coatings. Not recommended for 
medical and surgical materials. FDA has not cleared 
any liquid sterilant or high level disinfectant that has 
alcohol as the main ingredient. Only limited data of 
the method available. 
Not enough 
data available 
Yes (with 
fungicide and 
antibiotic) 
Not enough data available 
Chlorine Effective water disinfectant.  All chlorine products have some level of toxicity. 
Not enough 
data available 
Not enough 
data available 
Not enough data available 
Hypochlorites 
Wide spectrum of antimicrobial activity, re-
move biofilm, fast, no toxic residues, cost ef-
fective 
Release toxic chlorine gas if mixed with ammonia or 
acids.  
Not enough 
data available 
Not enough 
data available 
Not enough data available 
Chlorine dioxide Effective in low concentrations 
Long processing time (hours), some material compat-
ibility issues due to corrosive nature. Antimicrobial 
activity reduce in presence of organic matter. Point-
of-use system. Corrosive. 
Not enough 
data available 
No  Not enough data available 
Sodium dichloroisocyanurate 
Low acute oral toxicity, and does not induce 
any carcinogenic, teratogenic, or genotoxic 
effects. 
 
Mainly used for water disinfection. 
Not enough 
data available 
Not enough 
data available 
Not enough data available 
Chloramine-T 
Potential alternative to chlorine. Stable solu-
tion, safe for humans, non-cytotoxic, and bi-
odegradable 
Mainly used for surface sterilization. . Has a minor 
corrosive effect on common industrial materials, 
such as stainless steel, aluminum, and various poly-
mers. 
 
Not enough 
data available 
Not enough 
data available 
Not enough data available 
Superoxidized water 
Non-toxic, safe for the users and the envi-
ronment. Low costs. 
Only limited data available, potential material com-
patibility issues. 
Not enough 
data available 
Not enough 
data available 
Not enough data available 
Formalin 
Effective against many bacteria, viruses, 
fungi and spores. 
Requires a long contact time. Irritating fumes and 
pungent odor, thus limited use. Potential carcinogen. 
Employees’ exposure should be monitored.  
Not enough 
data available 
Not enough 
data available 
Not enough data available 
Glutaraldehyde 
Non-corrosive, good biocidal properties and 
activity in the presence of organic matter. 
Generally not effective against spores. Has to be acti-
vated before use. Can cause irritation and pulmonary 
Not enough 
data available 
Not enough 
data available 
Not enough data available 
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Suitability for biodegrable po-
lymers Compatible packaging materials 
Synthetic Natural 
Compatible with metals, glass, rubbers, 
some plastics. 
symptoms. Employees’ exposure should be moni-
tored. 
Iodophors 
Antiseptics on skin and tissues and disinfect-
ant for medical devices.  
Not compatible with silicone materials. 
Not enough 
data available 
Not enough 
data available 
Not enough data available 
Ortho-Phthalaldehyde 
No irritation, no exposure monitoring. Does 
not need activation before use. Excellent ma-
terial compatibility.  
Stains proteins grey. Slow sporicidal activity, use is 
more expensive than glutaraldehyde. 
Not enough 
data available 
Not enough 
data available 
Not enough data available 
Quaternary ammonium com-
pounds 
Good cleaning agents. 
Water hardness and some materials, such as cotton 
and gauge pads, can lessen the anti-microbial activ-
ity.  
Not enough 
data available 
Not enough 
data available 
Not enough data available 
Phenolics 
Disinfectants for environmental surfaces and 
noncritical medical devices. 
Absorbed by porous materials, residual disinfectant 
can cause irritation. 
No  No  Not enough data available 
Surfacine Antimicrobial agent for surface disinfection. Only limited data of the method available. 
Not enough 
data available 
Not enough 
data available 
Not enough data available 
Photocatalysis 
Low temperatures, irradiation source can be 
various types of visible light, UV-light or 
fluorescent light, depending on the intended 
use. Safe, nontoxic, eco-friendly, and rela-
tively inexpensive. Applicable to many dif-
ferent applications. Studied for use in medi-
cal applications. 
Only limited data of the method available. 
Not enough 
data available 
Not enough 
data available 
Not enough data available 
Formic acid 
Potential sterilization agent for collagen. In 
combination with hydrogen peroxide forms a 
fast acting sterilant against spore-forming 
bacteria. 
Only limited data of the method available. 
Not enough 
data available 
Yes Not enough data available 
